<allTrials totalCount="132" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">63412511</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of a three-month course of rosuvastatin in patients with Systemic Lupus Erythematosus</title>
      <scientificTitle/>
      <acronym>Rosuvastatin in SLE</acronym>
      <studyHypothesis>Systemic lupus erythematosus (SLE) is a rheumatologic multi-systemic auto-immune disease particularly affecting joints, skin and kidneys. The aim of this trial was to investigate the effects of rosuvastatin on markers of lipid metabolism and inflammatory parameters in patients with SLE.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured at baseline and after three months of treatment:
1. Total cholesterol 
2. Low density lipoprotein (LDL) cholesterol
3. C-reactive protein (CRP)
4. Tumour necrotising factor (TNF)</primaryOutcome>
      <secondaryOutcome>Measured at baseline and after three months of treatment:
1. Interleukin-6 (IL6), interleukin-10 (IL10), interleukin-8 (IL8)
2. Complement C3 and C4q
3. Anti-double stranded deoxyribonucleic acid (anti-dsDNA)
4. Urine protein</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of the Slotervaart Hospital (The Netherlands) on the 29th November 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63412511</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open-labelled, cross-over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d60ff033-707e-4bb9-a5f6-3d5f440df5ec">
	  <name>Department of Internal Medicine</name>
	  <address/>
	  <city>Maastricht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6229 HX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with chronic, non-acute SLE
2. Greater than 18 years old, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>19</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>19</totalTarget>
      <exclusion>1. Use of statins
2. Pregnancy
3. Raised liver enzymes
4. Recent (less than three months) major surgery or myocardial infarction</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic lupus erythematosus</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic lupus erythematosus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Rosuvastatin 10 mg once daily.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17593-0</funderId>
      <contactId>Contact55560_17593</contactId>
      <sponsorId>Sponsor54139</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55560_17593">
    <title>Prof</title>
    <forename>Hugo</forename>
    <surname>ten Cate</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Internal Medicine
Academisch Ziekenhuis Maastricht</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6229 HX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">H.Tencate@BIOCH.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54139">
    <organisation>AstraZeneca (The Netherlands)</organisation>
    <website>http://www.astrazeneca.nl</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Postbus 599</address>
      <city>Zoetermeer</city>
      <country>Netherlands</country>
      <zip>2700 AN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)79 363 2222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info.nl@astrazeneca.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476086.b</gridId>
    <rorId>https://ror.org/021tmn508</rorId>
  </sponsor>
  <funder id="Funder17593-0">
    <name>AstraZeneca (The Netherlands) - unrestricted research grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">52111135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of three diagnostic tools for latent tuberculosis in haemodialysis patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Latent tuberculosis is hard to diagnose in immunocompromised hosts like haemodialysis patients, and widespread bacille calmette-guerin (BCG) vaccination make it complicated to interpretate Mantoux test results in Korea. Therefore, we need more sensitive and specific diagnostic tools for latent tuberculosis in haemodialysis patients. 

Hypothesis:
T-spot assay or Quantiferon assay is more sensitive and specific than Mantoux test for latent tuberculosis in haemodialysis patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Skin test: positive or negative
2. Quantiferon-gold: positive or negative
3. T-spot test: positive or negative

These outcomes will be measured on the day of testing.</primaryOutcome>
      <secondaryOutcome>1. Skin test: size of induration
2. Quantiferon-gold: concentration
3. T-spot test: number, mean area

These outcomes will be measured on the day of testing.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board (IRB) of Gachon University of Medicine and Science on the 28th February 2008 (ref: 20080228 tuberculosis in haemodialysis).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52111135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, observational, cross-sectional, open trial</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cross-section survey</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7590e94-2e99-4147-96a9-86319001fdd7">
	  <name>Division of Nephrology</name>
	  <address/>
	  <city>Incheon</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>405-760</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chronic maintenance haemodialysis patients who continue to receive haemodialysis for more than three months in the Gil Medical Centre
2. Older than 18 years, and less than 80 years, either sex
3. Agrees to participate in this trial
4. Medical staff in the haemodialysis centre of the Gil Medical Centre</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>162</totalTarget>
      <exclusion>1. Patients who suffer from skin diseases which may interfere with Mantoux test
2. Patients with an active infection, except tuberculosis
3. Patients who cannot make independent decision due to mental disorders</exclusion>
      <patientInfoSheet>Not available in web format, please contact Jaeseok Yang at jcyjs@hanafos.com to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Latent tuberculosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Agreement of three diagnostic tests for latent tuberculosis will be tested in haemodialysis patients. Blood samples are taken for:
1. Quantiferon-gold assay, an enzyme linked immunosorbent assay (ELISA) assay for interferon gamma in response to tuberculosis specific antigens
2. T-spot assay, an enzyme-linked immunosorbent spot (ELISPOT) assay for interferon gamma

After sampling, the Mantoux test will be performed, and the results will be read in two days. Agreement of three test results will be analysed using kappa coefficients, and results will be analysed per each categories of risk groups such as low risk group, casual contact group, latent tuberculosis patients, and active tuberculosis patients. Agreement will be also analysed in medical staff group with normal immunity.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17617-0</funderId>
      <contactId>Contact55587_17617</contactId>
      <sponsorId>Sponsor54163</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55587_17617">
    <title>Prof</title>
    <forename>Jaeseok</forename>
    <surname>Yang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Nephrology
Department of Internal Medicine
Gil Medical Center
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54163">
    <organisation>Gachon University of Medicine and Science (South Korea)</organisation>
    <website>http://home.gachon.ac.kr/icc/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Institutional Review Board (IRB)
Department of Pharmacy
Gil Medical Centre
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.256155.0</gridId>
    <rorId>https://ror.org/03ryywt80</rorId>
  </sponsor>
  <funder id="Funder17617-0">
    <name>Gachon University of Medicine and Science (South Korea) - Division of Nephrology, Department of Internal Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">11431649</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>25- versus 29-gauge Quincke spinal needles</title>
      <scientificTitle>Comparison of 25- versus 29-gauge Quincke spinal needles for minor anorectal surgery as well as abdominal caesarean section in respect of patient satisfaction and handling</scientificTitle>
      <acronym/>
      <studyHypothesis>It is considered, that the incidence of post-puncture dural headache is correlated with the size of the spinal needle. For reason of patients' satisfaction and to minimize complications, a 29-gauge spinal needle is suitable for this purpose, especially in pregnant patients and patients undergoing ambulatory surgery. Though, the handling of this very thin spinal needle is described as difficult and therefore denied by several anaesthesiologists. 

The aim of this study is to evaluate the patients' satisfaction, the incidence of post-puncture dural headache and the handling conditions for the anaesthesiologist. 

Hypothesis:
The performance of a spinal anaesthesia with 29-gauge compared to a 25-gauge Quincke needles has a lower incidence of complications in patients undergoing minor anorectal surgery and abdominal caesarean section.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of post-dural puncture headache and other complications, measured one week after anaesthesia.</primaryOutcome>
      <secondaryOutcome>Time for the performance of spinal anaesthesia and occurring complications, measured one week after anaesthesia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Kommission II: Medizinische Fakultat Mannheim der Ruprecht-Karls-Universitat Heidelberg) on the 19th September 2007 (ref: 2007-236N-MA).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11431649</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="75eefce8-88ad-4c92-8d6b-08065f2f0f55">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with minor anorectal surgery, or 
2. Patients (female) for abdominal caesarean section
3. Age 18 - 80 years
4. American Society of Anaesthesiology (ASA) grade I - III
5. No contraindications for spinal anaesthesia</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Contraindications for spinal anaesthesia
2. Allergy against local anaesthetics</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-puncture dural headache</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Post-puncture dural headache</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients are 1:1 randomised to either a 25-gauge or a 29-gauge spinal needle. Patients receive a questionnaire to obtain information about satisfaction and occurring complications. The time for the performance of the spinal anaesthesia and problems with the handling of the spinal needle are recorded by the anaesthesiologist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17347-0</funderId>
      <contactId>Contact55308_17347</contactId>
      <sponsorId>Sponsor53876</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55308_17347">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53876">
    <organisation>B. Braun Melsungen AG (Germany)</organisation>
    <website>http://www.bbraun.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Carl-Braun-Strasse 1</address>
      <city>Melsungen</city>
      <country>Germany</country>
      <zip>34212</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@bbraun.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.462046.2</gridId>
    <rorId>https://ror.org/04nxj7050</rorId>
  </sponsor>
  <funder id="Funder17347-0">
    <name>B. Braun Melsungen AG (Germany) - provided the spinal needles</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">36101176</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Hospital at home care in chronic obstructive pulmonary disease (COPD): a study on the associated health economy and disease-related quality of life</title>
      <scientificTitle>Hospital at home care in exacerbations of chronic obstructive pulmonary disease (COPD)</scientificTitle>
      <acronym>HBKOLS</acronym>
      <studyHypothesis>Previous studies in other countries indicate that home treatment with nursing support is suitable in selected patients with exacerbations of chronic obstructive pulmonary disease (COPD), presenting to hospital as an emergency. 

Hypothesis: 
Three days of hospital at home care in mild to moderate exacerbations of COPD is cost saving in the Norwegian health care system and implies at least the same level of disease-related quality of life as traditional hospital care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Health economy measures.

Time points: 6 weeks, 6 months and 12 months.</primaryOutcome>
      <secondaryOutcome>1. Level of disease-related quality of life, measured with the St. George Respiratory Questionnaire
2. Mental health (level of anxiety and depression), measured with the Hospital Anxiety and Depression Scale

Time points: 6 weeks, 6 months and 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Regional Ethics Committee for Medical Research of East Norway on the 21st December 2007 (ref: 1.2007.2613).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36101176</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b38f729-f8b1-4940-9305-8d9f5c94fc4e">
	  <name>HØKH</name>
	  <address/>
	  <city>Lørenskog</city>
	  <state/>
	  <country>Norway</country>
	  <zip>1478</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients under 80 years of age, either sex, with exacerbation of COPD
2. Presenting to the hospital as an emergency</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Serious exacerbation including impending or actual respiratory failure
2. Serious comorbidity</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Hospital-at-home group (experimental arm): 
Three days organised by the hospitals with specially trained nurses. In the same period of time the patient can contact the lung department at the hospital by phone for advice. Thereafter, if medical follow up is needed, by the primary care system (primary physician, home nurses).

Hospital group (control arm): 
As long as needed in the hospital. Thereafter, if needed, by the primary care personnel as for the other group. In contrast to the other group, the length of the in-hospital treatment is not specified. 

Follow up for both groups: After 6 weeks, 6 months and 12 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17434-0</funderId>
      <funderId>Funder17434-1</funderId>
      <contactId>Contact55395_17434</contactId>
      <sponsorId>Sponsor53965</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55395_17434">
    <title>Dr</title>
    <forename>Torbjørn </forename>
    <surname>Haugen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>HØKH
Akershus Unversitetssykehus HF
Sykehusveien 27</address>
      <city>Lørenskog</city>
      <country>Norway</country>
      <zip>1478</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53965">
    <organisation>Regional Authorities for Hospital Care, South-East Norway (Helse Sør-Øst Norge RHF) (Norway)</organisation>
    <website>http://www.helse-ost.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>PO Box 404</address>
      <city>Hamar</city>
      <country>Norway</country>
      <zip>2301</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+47 625 85 500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmottak@helse-ost.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.454198.5</gridId>
    <rorId>https://ror.org/02qx2s478</rorId>
  </sponsor>
  <funder id="Funder17434-0">
    <name>Regional Authorities for Hospital Care, South-Eastern Norway (Helse Sør-Øst RHF) (Norway)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17434-1">
    <name>The Norwegian Research Council (Norsk Forskningsråd) (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">75453816</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dietary fibre supplementation to prevent ulcerative colitis relapse: randomised double-blind placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>By taking 60 g of oat bran daily the relapse rate of patients with ulcerative colitis will be lowered from 40% to 20% at six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Colitis relapse at six months.</primaryOutcome>
      <secondaryOutcome>The following will be assessed at six months:
1. General health
2. Bowel symptoms 
3. Faecal butyrate concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ethics committee of Linköping University, Sweden (ref: M 159-04)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75453816</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>v.13</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fa33c085-ab64-4b75-9d53-b0161ff16756">
	  <name>Norrköping Hospital NSÖ stab</name>
	  <address/>
	  <city>Norrköping</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-60182</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults with ulcerative colitis or proctitis in clinical and endoscopic remisson following a colitis relapse within prior 12 months
2. Written consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>130</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>130</totalTarget>
      <exclusion>1. Antibiotics at inclusion
2. Steroids in last two weeks
3. Ongoing treatment with immunosuppressive drugs
4. Pregnancy or planned pregnancy
5. Concomitant serious disorder
6. Inability to comply with study protocol</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (only in Swedish)</patientInfoSheet>
      <recruitmentStart>2006-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ulcerative colitis and proctitis in remission</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Ulcerative colitis and proctitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>60 g of oat bran to the daily diet for six months versus no intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Oat bran</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17486-0</funderId>
      <funderId>Funder17486-1</funderId>
      <contactId>Contact55448_17486</contactId>
      <sponsorId>Sponsor54028</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55448_17486">
    <title>Prof</title>
    <forename>Claes</forename>
    <surname>Hallert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norrköping Hospital NSÖ stab</address>
      <city>Norrköping</city>
      <country>Sweden</country>
      <zip>S-60182 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)70 543 8282 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claes.Hallert@telia.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54028">
    <organisation>Lantmännen Food (Sweden)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Ingmar Börjesson
R&amp;D Department</address>
      <city>Järna</city>
      <country>Sweden</country>
      <zip>153 81</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 519 787 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ingmar.borjesson@lantmannen.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.502516.5</gridId>
  </sponsor>
  <funder id="Funder17486-0">
    <name>Lantmannen Food R&amp;D (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17486-1">
    <name>Medical Research Council of South-East Sweden (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">19821978</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Met-Hb and inflammation markers with tumescence local anaesthesia (TLA)</title>
      <scientificTitle>Met-Hb-concentration and inflammation markers in patients undergoing tumescence local anaesthesia (TLA) with supramaximal dosages of prilocaine</scientificTitle>
      <acronym/>
      <studyHypothesis>Tumescence local anaesthesia (TLA) is an established anaesthesia technique, where large amounts of highly diluted local anaesthetics are used. Due to its low toxicity, prilocaine is used frequently. Though, prilocaine can - dosage-dependant - cause a methemoglobinaemia, leading to a reduced oxygen transport capacity. Furthermore, certain processes of the inflammation cascade are initiated. These effects are important for ambulatory patients and the following healing process. 

The aim of the study is to evaluate the Met-Hb concentration and inflammation markers like  interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), tumour necrotising factor (TNF), C-reactive protein (CRP) in a chronological sequence.

Hypothesis:
TLA in supramaximal dosages of prilocaine has an influence on plasmatic inflammation markers, which will elevate in the first 48 hours. Furthermore, the Met-Hb production will not be finished within this time.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Met-Hb-concentration over the time, measured over 48 hours.</primaryOutcome>
      <secondaryOutcome>Elevation of inflammation markers, measured over 48 hours.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Komission II: Medizinische Fakultat Mannheim der Ruprechts-Karls-Universitat Heidelberg) on the 22nd November 2007 (ref: 2007-258N-MA)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19821978</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study until 48 hours after surgery</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="adaa9697-0634-437a-ad35-cd5ebac75cc4">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with operations which are performed in TLA with prilocaine
2. Age: 18 - 85 years
3. American Society of Anaesthesiologists (ASA) grade I - III
4. No allergy against prilocaine</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Allergy against prilocaine
2. Pregnancy
3. Patient denies operation in TLA</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tumescence local anaesthesia (TLA)/established anaesthesia techniques</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Anaesthesia techniques</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>As a standard procedure in our clinic, patients with dermatological operations will receive a TLA with more than 600 mg prilocaine. Seven blood samples (approximately 8 ml) will be taken 0, 1, 2, 4, 12, 24 and 48 hours after TLA, where the following parameters will be determined from:   
1. Demographic data and vital parameters
2. Met-Hb-concentration
3. Prilocaine-concentration
4. IL-1
5. IL-6
6. IL-8
7. TNF-alpha
8. CRP
9. Procalcitonin (PCT)
10. Creatine kinase (CK)
11. Lactate dehydrogenase (LDH)
12. Reticulocytes
13. Myoglobin
14. Haptoglobin 
15. Complications</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prilocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17346-0</funderId>
      <contactId>Contact55307_17346</contactId>
      <sponsorId>Sponsor53875</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55307_17346">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53875">
    <organisation>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine </organisation>
    <website>http://www.klinikum-mannheim.de/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marc.schmittner@anaes.ma.uni.heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411778.c</gridId>
    <rorId>https://ror.org/05sxbyd35</rorId>
  </sponsor>
  <funder id="Funder17346-0">
    <name>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">01121161</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of lifespan in AN69ST with two different heparinization strategies</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Reduction of heparin dose in acute renal failure treated with hemodiafiltration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Filter lifespan, defined as the time period between patient's connection and filter disconnection due to filter clotting.</primaryOutcome>
      <secondaryOutcome>Adverse events, monitored for up to 24 days of treatment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Local research ethics committee, Göteborg, Sweden. Date of approval: 17/12/2007 (Dnr. 576-07)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01121161</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1446</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Monocentric, open, randomised and controlled study with two parallel groups.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ae69dc32-626c-4977-adfb-92a93462aa2d">
	  <name>Sahlgrenska University Hospital</name>
	  <address/>
	  <city>Gothenburg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE- 413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients requiring continuous renal replacement therapies (CRRT) 
2. Aged 18 and over 
3. Patients weighing 30-120 kg 
4. Patients having signed a written consent to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>1. History of heparin antibodies or heparin-induces thrombocytopenia
2. Known hypertensive to any dialysis membrane
3. Current enrolment in another trial which could impact the successful completion of this study
4. Patients under guardianship
5. Patient anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week .These patients  can eventually be included in a later more stable phase
6. Unconscious patients for whom no relative or person of trust can give consent to treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study
7. Patient requiring anticoagulation for other indications e.g., valvular surgery or extracorporeal ventricular assist devices
8. Patients with active bleeding who does not require heparinization</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Swedish only)</patientInfoSheet>
      <recruitmentStart>2008-02-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute renal failure/  fluid overload</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Acute renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The same dialysis membrane, AN69ST, will be used for both the intervention and control treatment. Two different heparinization strategies will be compared: 

Control group (usual heparin doses): Bolus at start (between 1,000 IU - 2,500 IU) + usual infusion dose (10 IU/kg/h)  
Intervention group (Reduction of heparin dose): No bolus at start + infusion decreased by 50% (5 IU/kg/h)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17516-0</funderId>
      <contactId>Contact55478_17516</contactId>
      <sponsorId>Sponsor54061</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55478_17516">
    <title>Dr</title>
    <forename>Beng-Åke</forename>
    <surname>Henriksson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sahlgrenska University Hospital 
Department of Intensive Care (CIVA) </address>
      <city>Gothenburg</city>
      <country>Sweden</country>
      <zip>SE- 413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54061">
    <organisation>Gambro Lundia AB (Sweden)</organisation>
    <website>http://www.gambro.com/int</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Clinical Trial Function
Clinical Affairs
P.O. Box 10101</address>
      <city>Lund</city>
      <country>Sweden</country>
      <zip>SE -220 10</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420188.7</gridId>
    <rorId>https://ror.org/05mw5ed57</rorId>
  </sponsor>
  <funder id="Funder17516-0">
    <name>Gambro Lundia AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-13T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">09648950</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to compare spinal cord stimulator implantation with laser treatment of the heart in patients with chronic angina</title>
      <scientificTitle>An open label, single-centre, randomized trial of spinal cord stimulation vs percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial</scientificTitle>
      <acronym>SPIRIT</acronym>
      <studyHypothesis>Refractory angina pectoris leads to significant morbidity. There is an increasing group of patients with 'refractory angina pectoris' who are unsuitable for conventional revascularization by coronary artery bypass surgery or percutaneous intervention. This patient group often have significant disability, with limiting symptoms, multiple medications, and frequent hospital admissions. 

Treatment options include percutaneous myocardial laser revascularization (PMR) and spinal cord stimulation (SCS). The primary objective of this study was to compare the effect of SCS vs PMR on treadmill exercise time on a modified Bruce protocol over a period of 12 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total exercise time on a modified Bruce protocol (ETT) at 12 months after SCS compared with PMR. In this study, all tests were terminated by the subject. Both SCS and PMR aim to reduce the frequency and severity of angina, and exercise tolerance is a comparatively objective method of measuring angina-free functional capacity.</primaryOutcome>
      <secondaryOutcome>1. Time to patient-reported angina during exercise test
2. Angina class as measured by the Canadian Cardiovascular Score angina scale
3. Morbidity and mortality
4. Safety profiles of each therapy
5. Health-related quality of life was assessed using questionnaires administered at 3, 12, 24 and 36 month follow-up (disease-specific Seattle Angina Questionnaire, the generic Short Form 36 health survey , and EuroQoL questionnaires)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval was obtained from the Huntingdon Local Research Ethics Committee, UK, prior to study commencement, on 15 August 2000 (ref: H00/557)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09648950</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Version 2.2 dated 5 January 2004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, open, parallel, single-centre, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a4ccb758-67b1-45f8-baeb-33fee1f20445">
	  <name>Papworth Hospital NHS Foundation Trust</name>
	  <address/>
	  <city>Cambridge</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB23 3RE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with limiting angina (Canadian Cardiovascular Society [CCS] III or IV) despite maximally tolerated medical therapy 
2. Documented coronary artery disease (within the last 9 months prior to baseline), which is 
unsuitable for conventional revascularisation techniques
3. Patient has documented reversible ischaemia on nuclear scan (Tc-99 sestamibi) 
4. Patient is limited in daily activities, primarily exercise capability, by their anginal pain 
5. Age 18 or older
6. Patient must understand the therapy and give informed consent
7. Patient must be available for appropriate follow-up times for length of study
8. Non-pregnant women (only women who are post menopausal, surgically sterile or those of 
child bearing potential who are using an acceptable method of contraception) as safety for 
use of SCS during pregnancy or delivery has not been established. Acceptable methods of 
contraception include the following: 
a. Barrier type devices (e.g. female condom, diaphragm and contraceptive sponge) used only in combination with a spermicide 
b. Intrauterine devices (IDUs) 
c. Oral contraceptive agent 
d. Depro-ProveraTM (medroxyprogesterone acetate) 
e. Levonorgestrel implants 
f. Naturally sterile (amenorrheic for at least 1 year) in patients over 50 
Note: Abstinence, the rhythm method or contraception by the partner alone are NOT acceptable methods of contraception</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Patient who is not a candidate for surgical implantation of the spinal cord stimulation system,
and/or not a candidate for a PMR procedure and/or unable to use the SCS device appropriately for treatment
2. Patient who has had one or more major cardiac events within the last 2 months
3. Patient with a myocardial wall thickness &lt;8 mm in the ischaemic area to be treated as verified
by echocardiography
4. Patient with extensive peripheral vascular disease that precludes vascular access required for
PMR
5. Patient on intravenous therapy to control their symptoms
6. Patient who is unlikely to survive for more than 12 months due to non cardiac condition e.g.
malignancy
7. Patient who has other diseases that are considered of greater clinical significance than the
angina pectoris (e.g. inadequately controlled diabetes mellitus, heart failure) that would impact
the ability of the clinician to adequately assess the incremental effects of the trial treatment
8. Patient with ejection fraction of less than 30% as verified by echocardiography
9. Patient with cause of angina other than coronary artery disease (e.g. syndrome "X" patient)
10. Patient who is unable to perform treadmill exercise test per protocol
11. Patient who was previously enrolled in this study, or is currently in another clinical study, which will interfere with this protocol
12. Patient who has had spinal cord stimulation (SCS) therapy, a transmyocardial laser revascularization (TMLR) or PMR procedure in the past
13. Patient with an implanted pacemaker or defibrillator
14. Patient who has medical conditions which may require Magnetic Resonance Imaging (MRI)
15. Patient with a history of dementia or other persisting mental disorders significantly interfering
with ability to cooperate or comply with the requirements of the study or comprehend informed
consent
16. Patient with history of alcohol or drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic angina pectoris</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Angina pectoris</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Trial patients were randomised to either Spinal Cord Stimulation System implant (SCS) or Percutaneous Myocardial Laser Revascularisation (PMR). 

The Spinal Cord Stimulation System used for this trial was a Medtronic fully implantable SCS systems. Either Itrel 3 or Synergy implantable generators were used. The spinal cord stimulation lead was chosen by the investigator from any Medtronic commercially available lead approved for use in refractory angina pectoris. The implant was performed according to the instructions in the technical manuals accompanying the devices. The lead was placed such that adequate/optimal paraesthesia was obtained in the area of angina pain. When adequate paraesthesia coverage was obtained the physician went on to permanent implant of the pulse generator. Proper patient education both pre and post implant of the device is essential. The investigator was responsible for adequately and regularly checking the integrity of the system at 3 months, 12 months and then annually. The stimulator should be used prophylactically by the patient for a minimum of 3 hours per day (for example: 3 times per day for a duration of 1 hour each). However, there is no upper limit and the patient may use the device as much as needed. Parameters for this stimulation vary from patient to patient. Therefore, the physician and patient need to work together to establish an effective and tolerable level. The stimulator should also be used at time of anginal attack to treat the pain. A higher level of stimulation may be used for this acute treatment. The maximum tolerable amplitude should be set for such use. However, it is necessary to assure that this level is not uncomfortable or painful. 

For this trial any commercially available Percutaneous Myocardial Revascularisation could be used. An optical fibre is inserted via the femoral artery under local anaesthesia and passed up into the left ventricle. Energy from a Ho:YAG laser is applied to the endocardial surface of the myocardium to vaporise the myocardial tissue and create channels from the endocardial surface into the myocardium. The co-axial system allows the laser to be manipulated in 3 planes giving access to the whole of the left ventricle. The laser position is monitored by fluoroscopy in orthogonal views. Once the position of the laser has been checked in both views, the laser is fired. Two bursts of the laser are used to create a channel 4-6 mm deep, in the myocardium, except in the apex where only one burst is used. The position is marked in both views on acetate sheets attached to the fluoroscopy monitors. Laser channels are created at a minimum of 1 cm apart, and are placed to cover the target region. Typically 10-15 channels are being made.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16554313 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3ecfb6b5-2300-4e80-b1a6-ab84cb9c90b8" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16554313"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17581-0</funderId>
      <contactId>Contact55543_17581</contactId>
      <sponsorId>Sponsor54127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55543_17581">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Schofield</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Papworth Hospital NHS Foundation Trust
Papworth Everared</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB23 3RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1480 830541</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">peter.schofield@papworth.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54127">
    <organisation>Medtronic Sàrl (Switzerland)</organisation>
    <website>http://www.medtronic.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Route du molliau</address>
      <city>Tolochenaz</city>
      <country>Switzerland</country>
      <zip>CH-1131 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.471158.e</gridId>
    <rorId>https://ror.org/04pf17v09</rorId>
  </sponsor>
  <funder id="Funder17581-0">
    <name>This study was sponsored by Medtronic SA, who were responsible for funding of the trial related investigations such as perfusion scans and treadmill tests, research staff for data collection and travelling expenses for the subjects. The sponsor had no role in study design, data collection and interpretation, or in the decision to submit the above report for publication.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">14206374</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Posture control after lumbar microdiscectomy</title>
      <scientificTitle>Posture control after lumbar microdiscectomy: effect of transmuscular surgical approach and of early postoperative physiotherapy - a randomised clinical trial</scientificTitle>
      <acronym/>
      <studyHypothesis>1. Transmuscular surgical approach causes less damage to postoperative posture control because it does not damage the back muscle insertions
2. Early postoperative physiotherapy improves short and long term posture control</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Muscle control (assessed by postural balance test and sit-to-stand test), assessed in the lab at two weeks, eight weeks and six months post-operatively.</primaryOutcome>
      <secondaryOutcome>Comfort:
1. Back pain
2. Sciatica
3. Functional status
4. Return to work

Secondary outcome measures are assessed by standardised patient questionnaires preoperatively and at two weeks, eight weeks, six months and one year postoperatively.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Commissie Medische Ethiek of Leuven University Hospitals in November 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14206374</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S50782</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, randomised, single centre trial with four arms (two variables: early specific physio versus later non-specific physio; transmuscular versus paramedian surgical approach).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-18T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a8b3dae0-262c-42e2-882b-d1bcbd038e75">
	  <name>Department of Neurosurgery</name>
	  <address/>
	  <city>Leuven</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>3000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. One level disc herniation, either L4-L5 or L5-S1, explaining symptoms and representing operative indication. Purely median disc herniations are excluded.
2. Age: 18 - 60 years, either sex
3. Living within 30 km perimeter of the hospital
4. Informed consent signed</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Emergency operation required
2. Litigation, worker's compensation
3. Clinical suspicion of depression or fibromyalgia (the suffering is not exlusively explained by the disc herniation)
4. Previous lumbar surgery, irrespective of the level
5. Significant neurological deficit (weakness worse than 4/5)
6. Systemic disease significantly affecting patient's functioning (American Society of Anaesthesiologists [ASA] grade greater than 3)
7. Median disc herniation
8. Patient unable to communicate in the Dutch language</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Dutch).</patientInfoSheet>
      <recruitmentStart>2008-02-18T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sciatica caused by a lumbar disc herniation</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Other intervertebral disc disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Transmuscular surgical approach versus classic paramedian approach to the disc herniation at surgery
2. Early postoperative physiotherapy, starting two weeks postoperatively, and consisting of an individualised program with standardised goals versus 'conservative' treatment: no physiotherapy in the first six weeks post-operation and after six weeks only when indicated

Follow up is one year for all four arms.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17533-0</funderId>
      <funderId>Funder17533-1</funderId>
      <funderId>Funder17533-2</funderId>
      <contactId>Contact55495_17533</contactId>
      <sponsorId>Sponsor54079</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55495_17533">
    <title>Prof</title>
    <forename>Bart</forename>
    <surname>Depreitere</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Neurosurgery
University Hospitals Leuven
Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54079">
    <organisation>University Hospitals Leuven (The Netherlands)</organisation>
    <website>http://www.uzleuven.be/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410569.f</gridId>
    <rorId>https://ror.org/0424bsv16</rorId>
  </sponsor>
  <funder id="Funder17533-0">
    <name>Contribution for logistic expenses:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-1">
    <name>Medtronic B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-2">
    <name>Stryker Nederland (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">84003996</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of mesalazine to prevent relapse in paediatric crohn&#146;s disease</title>
      <scientificTitle>Prevention of relapse by mesalazine (Pentasa®) in paediatric crohn's disease: a multicentric double-blind randomised placebo-controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>The trial&#146;s primary objective was to compare the efficacy of mesalazine (Pentasa®, Ferring) versus placebo in maintaining remission in paediatric crohn's disease (CD) patients, when used after the successful treatment of an acute episode with either medication alone or parenteral/enteral nutrition techniques combined or not with medication.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical relapse (HB score greater than or equal to 5, if confirmed within two weeks) 
2. Surgery for an acute complication of CD

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</primaryOutcome>
      <secondaryOutcome>Treatment failure, defined as:
1. Relapse
2. Failure of steroid withdrawal (weaning failure)
3. Side-effects intolerance requiring treatment discontinuation
4. Worsening or aggravation of patient status requiring treatment interruption 
5. Initiation of a new treatment as decided by the clinician

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethcis approval received from the Ethics Committee of Paris VII on the 10th January 1991 (ref: Etude Pentacomp/90/01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84003996</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Etude Pentacomp/90/91</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multicentric, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e3e431c1-1ff0-4c65-9ce5-adb87da73520">
	  <name>Hopital Robert Debré 48 Bd Sérurier</name>
	  <address/>
	  <city>Paris</city>
	  <state/>
	  <country>France</country>
	  <zip>75019</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children less than 18 years old, either sex
2. Diagnosed with crohn&#146;s disease before the age of 16 by means of clinical, radiological, endoscopic and histological data
3. Had to be in an active phase defined by:
3.1. A Harvey Bradshaw score (HB) greater than or equal to 5, and
3.2. An erythrocyte sedimentation rate (ESR) greater than or equal to 25 mm at hour one
4. All lesion localisations, except exclusive anorectal localisation, were included, providing patients&#146; lesion extension had been assessed within two years prior to inclusion

After flare-up treatment, inclusion criteria were as follows: 
1. Patients in clinical remission within six months following flare-up treatment initiation at pre-inclusion
2. An HB score under 5
3. An ESR under 25 mm
4. Normal hepatic and renal functions</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60, extended to 120</totalTarget>
      <exclusion>1. Flare-up had been treated with mesalazine or had required immuno-suppressors
2. Patients with known hypersensitivity to salicylate
3. Patients whose flare-up had occurred at pre-inclusion when on a 5-aminosalicylic acid (5-ASA) dose greater than 50 mg/kg/day for over two months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Paediatric crohn's disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Crohn's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>At inclusion, patients were randomised per stratum, within each centre, using random permuted two to four sized-blocks (each centre did not know the size of their own block), to the following:
1. 50 mg/kg/day mesalazine dose 
2. Placebo (identical tablets) 

This was taken over a one-year period. Patients were monitored every three months over a one-year period or until endpoint. 

The study treatment was initiated either one week after the interruption of parenteral or enteral nutrition, or at the end of a sulfalazine or metronidazole treatment, or if the prednisone dose during the steroid weaning period was below 0.2 mg/kg. After the study treatment began, only antispasmodic and antidiarrhoeal agents, as well as sedatives were to be given as possible additional medications. 

Following the recruitment of 57 children from 1991 to 1993, trial results showed a trend favouring mesalazine. Recruitment was consequently resumed from 1996 to 1999.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mesalazine (Pentasa®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17517-0</funderId>
      <contactId>Contact55479_17517</contactId>
      <sponsorId>Sponsor54062</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55479_17517">
    <title>Prof</title>
    <forename>Jean Pierre</forename>
    <surname>Cezard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hopital Robert Debré 48 Bd Sérurier</address>
      <city>Paris</city>
      <country>France</country>
      <zip>75019</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+33 (0)1 40 03 23 62</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jean-pierre.cezard@rdb.aphp.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54062">
    <organisation>Ferring SA (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>7 rue Jean Baptiste Clément</address>
      <city>Gentilly</city>
      <country>France</country>
      <zip>94250</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487243.e</gridId>
    <rorId>https://ror.org/03vrwsp35</rorId>
  </sponsor>
  <funder id="Funder17517-0">
    <name>Ferring SA (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">45000842</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimisation of incision hernia surgery treatment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Open mesh repair hernia surgery is better than suture repair hernia surgery of incision hernia treatment
2. The recurrence rate using suture hernia repair technique is much higher than mesh repair technique
3. The recovering time to the normal physical activity after surgery is faster, quality of life is better using mesh repair with sublay technique than mesh repair with onlay technique or suture repair technique of the incision hernia treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Recurrence rate, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Quality of life, measured using the 36-item Short Form health survey version 2 (SF-36 v2)at 2 weeks, 1, 3, 6 and 12 months after surgery</primaryOutcome>
      <secondaryOutcome>1. Postoperative complications, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Change of the blood gas and intra-abdominal pressure, measured before and after surgery
3. Recovering time to the normal physical activity after surgery, measured at 2 weeks, 1, 3, 6 and 12 months after surgery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Kaunas Biomedical Research Ethics Committee on the 5th June 2007 (ref: BE-2-41).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45000842</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>73/2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lithuania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dab1e29b-4963-4afa-8cd1-4bd21622092f">
	  <name>Eiveniu str. 2</name>
	  <address/>
	  <city>Kaunas</city>
	  <state/>
	  <country>Lithuania</country>
	  <zip>LT50009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All 18 - 80 years old patients with incision hernia, who will be operated and agree to participate in this clinical trial.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50 patients in each group, 150 patients in all</totalTarget>
      <exclusion>1. Patients older than 80 years
2. Incarcerated incision hernia
3. Mental patients with incision hernia
4. Pregnant women with incision hernia
5. Patients with incision hernia do not agree to participate in this clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hernia</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Hernia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Three groups:
1. Keel technique
2. Onlay technique
3. Sublay technique

The follow up period is 2 weeks, 1, 3, 6 and 12 months after surgery. Surgery, blood gas analysis and intra-abdominal pressure investigation before and after operation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17283-0</funderId>
      <contactId>Contact55244_17283</contactId>
      <sponsorId>Sponsor53812</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55244_17283">
    <title>Dr</title>
    <forename>Linas</forename>
    <surname>Venclauskas</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53812">
    <organisation>Kaunas Medical University Hospital (Lithuania) - Department of Surgery </organisation>
    <website>http://www.kmu.lt/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.45083.3a</gridId>
    <rorId>https://ror.org/0069bkg23</rorId>
  </sponsor>
  <funder id="Funder17283-0">
    <name>Kaunas Medical University Hospital (Lithuania) - Department of Surgery</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">72781592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Short versus long buprenorphine-naloxone treatment in intravenous buprenorphine withdrawal: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>BUNXLOW</acronym>
      <studyHypothesis>1. To investigate the effectiveness of buprenorphine-naloxone compared with treatment as usual (lofexidine) in withdrawal of intravenous buprenorphine dependence
2. To determine whether a longer regime is more effective than a shorter one</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Completion of withdrawal
2. Retention in rehabilitation for one month
3. Abstinence at one month after withdrawal
4. Abstinence at six months after withdrawal</primaryOutcome>
      <secondaryOutcome>1. The extent of withdrawal symptoms experienced, recorded every day during withdrawal
2. The amount of additional medication needed, recorded every day during withdrawal
3. Whether the patient begins naltrexone medication, patients will be offered an opportunity to begin naltrexone three days before finishing withdrawal 
4. Patient satisfaction, measured at the last day of withdrawal, whether at the intended finishing date, or at premature termination of withdrawal. Satisfaction will be measured by a self-made questionnaire of seven questions concerning the satisfaction with the medication, the length of medication, the additional medication, the length of withdrawal, the staff, the opportunity of beginning naltrexone and the overall satisfaction with the withdrawal treatment. Answers will be recorded with a five-grade scale</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. The Ethics Committee for Pediatrics, Adolescent Medicine and Psychiatry/Hospital District of Helsinki and Uusimaa on the 15th May 2007; amendment on the form of informed consent was approved 19th June 2007 (ref: 148/E7/2007)
2. The National Agency for Medicines approval on the 22nd August 2007 (ref: 96/2007)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72781592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HDL07-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, three-arm, parallel group, single centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="587bfde4-7c31-404f-a050-a7361d54ff19">
	  <name>Munkkisaarenkatu 16</name>
	  <address/>
	  <city>Helsinki</city>
	  <state/>
	  <country>Finland</country>
	  <zip>01500</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Opiate dependence (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition [DSM IV])
2. Current misuse of buprenorphine intravenously (mimimun 3 mg/day) (use confirmed by urinalysis)
3. Willingness to participate in withdrawal in the treatment centre and in rehabilitation afterwards
4. Aged between 18 and 50</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="50.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 patients</totalTarget>
      <exclusion>1. Other than buprenorphine as the primary drug of misuse
2. Misuse of other opiates then buprenorphine during the last week (confirmed by urinalysis)
3. Opiate maintenance therapy
4. Psychotic symptoms at recruitment
5. Psychiatric or somatic disease or symptoms that may require hospitalisation at near future
6. Salient increase in alanine aminotransferase (ALAT)
7. Pregnancy
8. Allergy to lofexidine, buprenorphine or naloxone
9. Former participation to the same study
10. Concurrent participation to other intervention studies
11. Native language other than Finnish</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intravenous misuse of buprenorphine</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Opiate dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Short buprenorphine-naloxone (Bu-nx) arm: for 9 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 5: 8 mg
Days 6 - 7: 4 mg 
Days 8 - 9: 2 mg

2. Long buprenorphine-naloxone arm: for 25 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 9: 8 mg
Days 10 - 12: 6 mg 
Days 13 - 16: 4 mg 
Days 17 - 20: 2 mg 
Days 21 - 25: 1 mg

3. Lofexidine arm: lofexidine according to clinical assessment, maximum dose 2.4 mg/d divided into two to three doses, maximum duration 21 days

 In all arms, the intended withdrawal duration (in-patient treatment) is 28 +/- 7 days, and the follow-up period is up to six months after that.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Buprenorphine-naloxone, iofexidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16935-0</funderId>
      <funderId>Funder16935-1</funderId>
      <funderId>Funder16935-2</funderId>
      <contactId>Contact54896_16935</contactId>
      <sponsorId>Sponsor53461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54896_16935">
    <title>Dr</title>
    <forename>Outi</forename>
    <surname>Kuikanmäki</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53461">
    <organisation>Helsinki Deaconess Institute (Finland)</organisation>
    <website>http://www.hdl.fi</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Outi Kuikanmäki
Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487156.9</gridId>
    <rorId>https://ror.org/04zqw9t81</rorId>
  </sponsor>
  <funder id="Funder16935-0">
    <name>Academy of Finland (Finland)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002341</fundRef>
  </funder>
  <funder id="Funder16935-1">
    <name>National Public Health Institute (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16935-2">
    <name>Helsinki Deaconess Institute (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">84133969</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fractional photothermolysis versus triple therapy for the treatment of melasma: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Fractional photothermolysis may be an effective and safe alternative for the treatment of melasma and the effect of the treatment with fractional photothermolysis may last longer than the effect of the triple therapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Observer blinded clinical score (Melasma Area and Severity Index [MASI] score), measured before treatment and during 3, 12 and 24 weeks of follow-up
2. Objective colour measurement by reflectance spectroscopy, measured before treatment and during 3, 12 and 24 weeks of follow-up</primaryOutcome>
      <secondaryOutcome>1. Visual assessment of side effects and quality of life measurements (skindex):
1.1. Fraxel laser group: after laser treatment and during follow-up (3, 12, 24 weeks)
1.2. Triple group: during follow-up (3, 12, 24 weeks)
2. Registration of side effects noticed by the patient: 
2.1. Fraxel group: after laser treatment and during follow-up
2.2. Triple group: after three weeks of treatment by telephone</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Centrale Commissie Mensgebonden Onderzoek (CCMO) on the 19th September 2007 (ref: NL18605.018.07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84133969</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>fraxel-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, observer blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fe24a693-9360-407e-8947-a0ba8e4e612a">
	  <name>Meibergdreef 35</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients with melasma
2. Skin photo type II - V
3. Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders
4. Aged at least 18 years
5. Subject is willing and able to give written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Bleaching cream during the past four weeks
2. Local corticosteroids during the past four weeks
3. Subjects with a history of keloids
4. Subjects with active eczema
5. Subjects with active acne in the face
6. Subjects with a history of facial eczema
7. Suspect allergy to lidocaine or the triple therapy
8. Use of roaccutane in the past six months
9. Subjects not competent to understand what is involved
10. Pregnancy
11. Lesion suspicious for malignancy
12. High exposure to sunlight (vacation in southern countries) or ultraviolet (UV) light (UVA or UVB)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Melasma</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Disorders of pigmentation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects will be randomly allocated to one of two groups who receive either triple therapy (bleaching cream [hydrochinon 5%, tretinoin 0.05% and triamcinolon acetonide 0.1% in cremor lanette II]) or fractional photothermilysis using the fraxel laser. 

Triple therapy: 
The triple therapy will be applied once a day in the evening on all hyperpigmented macules for eight weeks. Follow-up will take 3, 12 and 24 weeks post therapy. 

Fractional photothermolysis: 
Subject will receive a total of four laser treatments, with two week intervals. A topical anaesthetic ointment will be applied to the skin before treatment. The treated area will be less than 3% of the body surface. Follow-up will take place 3, 12 and 24 weeks post therapy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triple therapy bleaching cream (hydrochinon, tretinoin, triamcinolon acetonide)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16718-0</funderId>
      <contactId>Contact54676_16718</contactId>
      <sponsorId>Sponsor53232</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54676_16718">
    <title>Dr</title>
    <forename>Albert</forename>
    <surname>Wolkerstorfer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53232">
    <organisation>Academic Medical Centre (AMC) (The Netherlands) </organisation>
    <website>http://www.amc.uva.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16718-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">14127815</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The SphynX trail: a randomised clinical trial comparing the outcome of endoluminal fundoplication with EsophyX™ to laparoscopic Nissen fundoplication for refractory gastro-esophageal reflux disease (GERD)</title>
      <scientificTitle/>
      <acronym>SphynX</acronym>
      <studyHypothesis>Endoluminal fundoplication with Esophyx™ will not be less effective than laparoscopic Nissen fundoplication, expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effectiveness will be expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery (Visick grading). Visick classification: grade I: No symptoms, resolved; grade II: Mild occasional symptoms easily controlled, improved; grade III: Mild symptoms not controlled, unchanged; grade IV: Not improved, worsened. Success will be defined as grade I or II and failure will be defined as grade III or IV.</primaryOutcome>
      <secondaryOutcome>1. Success expressed as the percentage of patients with normalisation of acid exposure on pH metry, minus the percentage of patients needing reintervention (dilatation or re-operation) for troublesome dysphagia at six months

Definition of objective normalisation of acid exposure: 
The combination of the following:
a. Upright acid exposure &lt;8.4%
b. Supine acid exposure &lt;3.4 % 
c. Total acid exposure &lt;5.8% on post-operative 24-h pH-monitoring
The presence of troublesome dysphagia will render the procedure unsuccessful. 

2. Percentage of patients free from PPIs at three and six months
3. Quality of Life (QoL) assessment: Visual analogue scale [VAS] score, the 36-item Short Form health survey (SF-36) and EuroQol (EQ-5D) at three and six months
4. Impact of reflux symptoms on QoL: The Gastro-Oesophageal Reflux Disease Health-Related Quality-of-Life scale  (GORD-HRQoL) at three and six months
5. Esophageal symptoms: OES18 score at three and six months
6. Prevalence of esophagitis on upper endoscopy at six months
7. Cost-effectiveness expressed as costs per successfully treated patients and incremental costs per Quality Adjusted Life Year gained at six months</secondaryOutcome>
      <trialWebsite>http://www.esophyx.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Independent central medical ethics committee of the University Medical Center Utrecht has approved the study protocol. Date of approval: 08/01/2008 (EC ref: 07-214; CCMO ref: 1795404107)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14127815</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>07-214</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised non-inferiority multicenter trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2009-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="944ca3ea-fb2a-4784-b3d4-d6b483d46e6a">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. GERD patients of eight Dutch hospitals with reflux symptoms persisting for over 6 months despite double dose of Proton Pump Inhibitor (PPI) (&gt;40 mg omeprazole/24 hours or comparable therapy) and/or patients who refuse or do not tolerate to take acid suppressing drugs for life.  
2. Documented temporal relation between pathological reflux and symptoms during 24-hr pH monitoring. 
Pathological reflux is defined as upright acid exposure &gt;8.4%, supine acid exposure &gt;3.4 % and/or total acid exposure &gt;5.8% on 24-hr pH monitoring. A documented relation between reflux and symptoms is reflected by a Symptom Association Probability (SAP) &gt;95%. 
3. Patients without a diaphragmatic hernia or a sliding hernia not exceeding 2 cm (endoscopically measured distance from Z-line and impression of the diaphragm). 
4. Age between 18 and 65 years. 
5. Informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Patients with a diaphragmatic hernia other than of the sliding type and/or larger than 2 cm.
2. Grade C and D esophagitis according to the Los Angeles classification.
3. Histologically proven long-segment Barrett's oesophagus.
4. Patients with severe esophageal or gastric motility disorders. 
5. Patients with a history of esophageal- or gastric surgery. 
6. American Society of Anaesthesiologists classification III and IV patients. 
7. Patients with a psychiatric disease or other conditions making them incapable of filling out the questionnaires or completing the objective esophageal function tests. 
8. Pregnancy.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2009-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastro-esophageal reflux disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Gastro-esophageal reflux disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endoluminal fundoplication with EsophyX™ versus laparoscopic Nissen fundoplication.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17532-0</funderId>
      <funderId>Funder17532-1</funderId>
      <funderId>Funder17532-2</funderId>
      <funderId>Funder17532-3</funderId>
      <funderId>Funder17532-4</funderId>
      <funderId>Funder17532-5</funderId>
      <funderId>Funder17532-6</funderId>
      <funderId>Funder17532-7</funderId>
      <funderId>Funder17532-8</funderId>
      <contactId>Contact55494_17532</contactId>
      <sponsorId>Sponsor54078</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55494_17532">
    <title>Prof</title>
    <forename>H G</forename>
    <surname>Gooszen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht 
P.O. Box 85500 
H.P. G04.228 </address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54078">
    <organisation>University Medical Center Utrecht and seven participating hospitals (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500 
H.P. G04.228</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder17532-0">
    <name>The costs of this trial are internally covered by the eight participating hospitals in the Netherlands:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-1">
    <name>University Medical Center Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-2">
    <name>Meander Medical Center Amersfoort</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-3">
    <name>Lange Land Hospital Zoetermeer</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-4">
    <name>Catharina Hospital Eindhoven</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-5">
    <name>Medical Center Leeuwarden</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-6">
    <name>Antonius-Mesos Hospital Nieuwegein-Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-7">
    <name>Rivierenland Hospital Tiel</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-8">
    <name>Amphia Hospital Breda</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">09659857</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Outpatient chemotherapy protocol using 3 cosolidated drugs (cisplatin, 5 fluoururacil and leucovorin) in a different scheme for the treatment of head and neck and oesophageal cancer, designed for patients without surgical and radiation therapy options</title>
      <scientificTitle>Low cost, outpatient, cisplatinum, 5-fluoururacil and leucovorin chemotherapy regimen for advanced head and neck, and upper oesophageal carcinomas</scientificTitle>
      <acronym/>
      <studyHypothesis>Evaluate the combination of bolus CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL) in patients with advanced (residual, metastatic or recurrent) squamous cell carcinoma (SCC) of head (H)/neck (N) and oesophagus (E), aiming at a feasible and low cost chemotherapy (CHT) regimen to circumvent the need of infusion pumps and/or hospital admission.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Quality of life (QoL) evaluated using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire, previously used in Portuguese, at the beginning of study and before each cycle
2. Toxicities analysed according to National Cancer Institute (NCI) criteria before each cycle together with KPS, clinical reassessment and laboratory evaluation
3. Response, evaluated by computed tomography (CT) scans after 3rd and 6th cycles of chemotherapy and analysed by response evaluation criteria in solid tumours (RECIST)
4. Performance status by measured with Karnofsky Performance Status (KPS)</primaryOutcome>
      <secondaryOutcome>1. Overall survival - time between enrolment and death
2. Progression Free Survival - time between enrolment and disease progression</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ABC Medical School Ethics Committee in December 2004 (ref: 185/2004).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09659857</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II, single arm study conducted at a single Brazilian Institution</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5eb15996-b980-4766-868b-86b9b89146f3">
	  <name>Rua Mere Amedea 833</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>02125-001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Advanced or recurrent, histologically confirmed, head and neck and oesophagus squamous cell carcinoma
2. Patients have to be 18 years of age or older, either sex
3. Normal renal function
4. Measurable disease by the response evaluation criteria in solid tumours (RECIST)
5. Karnofsky performance status (KPS) equal or greater to 50%</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15 patients</totalTarget>
      <exclusion>1. Not meeting the inclusion criteria
2. Concomitant radiation therapy
3. Not a candidate for chemotherapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Head and Neck and Upper oesophageal carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Squamous cell carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Chemotherapy as follows:
Leucovorin 20 mg/m^2/day bolus infusion for four days (D1 - D4), followed by 5-fluoururacil  370 mg/m^2/day bolus infusion for four days (D1 - D4), and Cisplatinum 25 mg/m^2/day in 90 minutes infusion for three days (D1 - D3), every 21 to 28 days, depending upon hematological recovery.

Follow up is until patient death, expected to be less then 24 months for each patient.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17436-0</funderId>
      <funderId>Funder17436-1</funderId>
      <contactId>Contact55397_17436</contactId>
      <sponsorId>Sponsor53967</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55397_17436">
    <title>Dr</title>
    <forename>Vanessa</forename>
    <surname>Fabricio</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Mere Amedea 833</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>02125-001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vcf35@terra.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53967">
    <organisation>Hospital Mario Covas (Brazil) </organisation>
    <website>http://www.hospitalmariocovas.org.br</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Rua Henrique Calderazzo, 321
Bairro Paraíso </address>
      <city>Santo Andre</city>
      <country>Brazil</country>
      <zip>09190-615 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sau@hesa-fuabc.org.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487168.4</gridId>
    <rorId>https://ror.org/00s7ek396</rorId>
  </sponsor>
  <funder id="Funder17436-0">
    <name>ABC Foundation (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17436-1">
    <name>Hospital Mario Covas (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">76047793</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Adhesion prevention with icodextrin</title>
      <scientificTitle>The effect of 4% icodextrin solution vs lactated Ringer's solution on adhesiolysis during Hartmann's reversal: A multi-centre randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Laparotomy almost always causes peritoneal adhesions, which further causes morbidity and even mortality. A regimen to prevent peritoneal adhesions is urgently needed. Icodextrin has been shown to prevent adhesion formation, and our study investigated further the efficacy of icodextrin in colorectal operation. 

Study hypothesis: 
4% icodextrin solution decreases adhesion formation and time needed to divide them after hartmann's procedure compared to lactated Ringer's solution.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Time needed to separate postoperative adhesions, assessed approximately 3 months after hartmann's reversal procedure
2. Total operative time</primaryOutcome>
      <secondaryOutcome>1. Complications and recovery after Hartmann's reversal procedure. Duration of follow-up: 1 month 
2. Safety of icodextrin. Duration of follow-up: 1 month</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>National approval of the study received on 30 April 2003 from the Ethical Committee of Päijät-Häme Hospital District ETL-code Q36. Further approved by every local ethical committee of participating hospitals.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76047793</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, multi-centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="df6e5043-6d70-403e-b683-1823b1916eaf">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Lahti</city>
	  <state/>
	  <country>Finland</country>
	  <zip>15850</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients having rectosigmoid colon obstruction, perforation or diverticulitis (with or without perforation) for which a Hartmann's operation was planned</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Refusal to consent
2. Pregnancy
3. Peritoneal carcinoma
4. Postoperative radiotherapy before restorative surgery
5. Reoperation violating study protocol
6. Severe concomitant disease or other reason that would probably interfere with the restorative surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Laparotomy/ peritoneal adhesions</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Laparotomy/ peritoneal adhesions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study group receives at the end of Hartmann's procedure 1000 ml of 4 % icodextrin instilled into the abdomen. The control group receives same amount of lactated Ringer's solution.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17400-0</funderId>
      <contactId>Contact55361_17400</contactId>
      <sponsorId>Sponsor53931</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55361_17400">
    <title>Dr</title>
    <forename>Jyrki</forename>
    <surname>Kössi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Päijät-Häme Central Hospital
Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53931">
    <organisation>Päijät-Häme Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.440346.1</gridId>
    <rorId>https://ror.org/02v92t976</rorId>
  </sponsor>
  <funder id="Funder17400-0">
    <name>Internally funded by the Päijät-Häme Central Hospital (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">65305620</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is misoprostol a safe alternative to manual vacuum aspiration in women with incomplete abortions in developing countries?</title>
      <scientificTitle>Is misoprostol a safe alternative to manual vacuum aspiration in women with early pregnancy failure in a low resource setting?: a randomized controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Misoprostol is just as effective as Manual Vacuum Aspiration (MVA) in treatment of first trimester pregnancy failure, but is more acceptable to clients in a rural setting in low resource countries.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Ultrasonographic endometrium thickness at day 8</primaryOutcome>
      <secondaryOutcome>The following will be assessed at day 8: 
1. Changes in hemoglobin (Hb) level
2. Side effects including pain 
3. Adverse events 
4. Patients satisfaction and acceptability 

If any problem is observed on day 8, the patient will be reviewed again on day 15 (No review at day 15 if no problem is observed).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The National Institute of Medical Research Dar es Salaam, approved on 18 October 2007 (ref: NIMR/HR/R.8a/Vol. IX/628)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65305620</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Evaluator-blinded, single-centre, randomised controlled non-inferiority trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-02-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e226d8a5-b2b9-4ac5-ba03-7f20cc8cad96">
	  <name>PO box 228</name>
	  <address/>
	  <city>Lindi</city>
	  <state/>
	  <country>Tanzania</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. History of passage of tissue and/or blood and &gt;30 mm endometrial thickness on TransVaginal Sonography (TVS) 
2. On TVS an anembryonic gestation or fetal death with an embryonic crown-rump length between 5 and 62 mm without cardiac activity (in case of a Crown-Rump Length [CRL] of 5-9 mm TVS will be repeated after one week to ensure absence of cardiac activity) or an anembryonic gestational sac of 16-45 mm (TVS will be repeated after one week to ensure growth of the gestational sac is &lt;3 mm and exclude a viable pregnancy)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. On TVS present fetal heart activity, a crown-rump length &gt;62 mm, molar pregnancy or a endometrial thickness less than or equal to 30 mm
2. Fundal height of more than halfway the umbilicus and the symphysis indicating a gestational age &gt;12 weeks
3. Known allergy to prostaglandins
4. Heavy blood loss or a pulse rate of &gt;120/min
5. Axillary temperature of &gt; 38°C or signs of septic abortion such as pus draining from uterus
6. Ectopic pregnancy</exclusion>
      <patientInfoSheet>Patient information form in Kiswahili is available on request. Please use the contact details below to request.</patientInfoSheet>
      <recruitmentStart>2008-02-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-02-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>First trimester pregnancy failure</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>First trimester pregnancy failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Misoprostol 600 microgram 3 doses (one dose every 4 hours) sublingually versus MVA</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>misoprostol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17482-0</funderId>
      <contactId>Contact55444_17482</contactId>
      <sponsorId>Sponsor54024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55444_17482">
    <title>Dr</title>
    <forename>Regine</forename>
    <surname>Unkels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO box 228</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54024">
    <organisation>Tanzanian German Program to Support Health  (TGPSH)  (Tanzania)</organisation>
    <website>http://www.tgpsh.or.tz</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Lindi Office
PO box 97</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17482-0">
    <name>Tanzanian German Program to Support Health (TGPSH) (Tanzania)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-15T00:00:00.000Z">82469428</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</title>
      <scientificTitle>A randomised, double-blind, comparative, multi-centre study of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</scientificTitle>
      <acronym/>
      <studyHypothesis>Is 5 x 200 mg iron sucrose over 3 weeks more effective in the treatment of restless legs than placebo?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>International RLS Study Group Rating Scale at 11 weeks</primaryOutcome>
      <secondaryOutcome>1. Epworth Sleepiness Scale at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months
2. Incidences and severities of adverse events, assessed after 3 , 7 and 11 weeks, 5, 8 and 12 months
3. To assess the ability of the treatments to correct aberrant haematology and iron status at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University Hospital, Uppsala. Date of approval: 13 June 2003 (ref: 03-141)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82469428</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPV-0105</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-22T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbc1ec18-e878-47d5-87a1-f050de824c58">
	  <name>Medical Department</name>
	  <address/>
	  <city>Avesta</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-774 82</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18-70 years
2. RLS defined by four cardinal criteria
3. Ten points or more on the International RLS (IRLS) Study Group Rating Scale 
4. S-ferritin below 45 µg/L, and with folic acid and vitamin B12 within reference values
5. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Treatment with any of the following: 
1.1. Psychopharmacological treatment with antidepressive and dopaminergic agents, sedatives, anticonvulsants and/or pain relievers, i.e. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or stronger, during the preceding 2 weeks. This was changed in study protocol clarification number 2 to "...i.e. with the exception of NSAIDs - during the last 2 weeks". 
1.2. Calcium antagonists, antihistaminic or antiemetic drugs during the preceding 2 weeks. 
1.3. Iron administration during the preceding 2 months 
1.4. Nutritional supplements or natural pharmaceuticals containing iron 
1.5. Antiepileptics 
1.6. Vitamin B12 or folic acid 
2. Presence of clinically significant disease/dysfunction, which in the opinion of the investigator should disqualify the patient from this study, such as asymptomatic intestinal bleeding 
3. Patients suffering from obstructive sleep apnoea syndrome 
4. S-creatinine &gt;130 µmol/L 
5. Positive result of pregnancy test 
6. Breast-feeding women 
7. Contraindications for iron sucrose</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2003-06-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-22T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Restless legs syndrome</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Restless legs syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>200 mg iron sucrose intravenously 5 times over 3 weeks versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>iron sucrose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17503-0</funderId>
      <contactId>Contact55465_17503</contactId>
      <sponsorId>Sponsor54046</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55465_17503">
    <title>Prof</title>
    <forename>Jan</forename>
    <surname>Ulfberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Department
Avesta Hospital</address>
      <city>Avesta</city>
      <country>Sweden</country>
      <zip>SE-774 82 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54046">
    <organisation>Renapharma AB (Sweden)</organisation>
    <website>http://www.renapharma.se</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Box 938</address>
      <city>Uppsala</city>
      <country>Sweden</country>
      <zip>SE-751 09  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476652.4</gridId>
    <rorId>https://ror.org/03x49ea82</rorId>
  </sponsor>
  <funder id="Funder17503-0">
    <name>Renapharma AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">02971192</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of acupuncture in pain relief and functional improvement in ankylosing spondylitis: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy of acupuncture for spinal pain relief in patients diagnosed with Ankylosing Spondylitis (AS).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed before and immediately after the interventions: 
1. Patient's assessment of spinal pain (0-10 cm VAS). 
2. Patient's global assessment of disease-activity and function (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Bath Ankylosing Spondylitis Functional Index [BASFI]). The BASDAI measures the severity of fatigue, spinal and peripheral joint pain, localized tenderness, and morning stiffness, assessed on a 10 cm VAS. The BASFI measures the functional status of AS patients, and is also assessed on a 10 cm VAS.
3. Acute-phase reactants (C-Reactive Protein, Erythrocyte Sedimentation Rate [ESR], Immunoglobulin A [IgA]) 
4. Number of analgesic pills per week</primaryOutcome>
      <secondaryOutcome>Subjective assessment of pain, performed before and immediately after the interventions,  using a 7-point Likert scale, where 1 = much worse, 2 = moderately worse, 3 = slightly worse, 4 = no effect, 5 = small improvement, 6 = moderate improvement, 7 = great improvement.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University Hospital, University of Sao Paulo, School of Medicine, approved on 8 October 2003 (CAPPESQ number: 769-03)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN02971192</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Project number at Institute of Orthopaedics and Traumatology: 371</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, randomised placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f0cfbb5-a458-484b-9006-d99f84058203">
	  <name>Rua Guaramembé, 589</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>01308-050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age range between 20 and 60 years 
2. Painful complaints in the axial line 
3. Patients who have not received any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesics for three months prior to the inclusion into this trial
4. Those who are referred to the Rheumatology Service, University of São Paulo, University Hospital, School of Medicine with diagnosis of ankylosing spondylitis according to the New York 15 and European 16 criteria for spondyloarthropathies
5. A mean baseline Visual Analogue Scale (VAS) score &gt;= 4 for pain</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Severe psychiatric disease
2. Sensory or motor neurological deficits
3. Fibromyalgia
4. Previous treatment with acupuncture 
5. Unable to visit the hospital for treatment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pain relief in patients diagnosed with ankylosing spondylitis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Pain relief in patients diagnosed with ankylosing spondylitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomization was performed using colored balls. Patients rated their pain intensity using VAS, disease activity, and function level at baseline. 

Patients were randomly allocated to one of two treatment groups: 

Group A: Classical acupuncture. Participants received classical acupuncture treatment associated with the use of NSAIDs and analgesics. Disposable, sterilized, stainless steel 0.25 mm x 40 mm length needles were employed. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Group B: Sham acupuncture. Participants received NSAIDs and analgesics together with non-invasive sham electro acupuncture, which was performed using inactive surface electrodes with audiovisual biofeedback reinforcement, touching patient's skin for seven seconds. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Acupuncture points employed in both groups: GV20b, SI3b, BL62b, GB34b and Ex-B2b</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17479-0</funderId>
      <contactId>Contact55441_17479</contactId>
      <sponsorId>Sponsor54021</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55441_17479">
    <title>Dr</title>
    <forename>Liliana</forename>
    <surname>Lourenço Jorge</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Guaramembé, 589 </address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>01308-050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54021">
    <organisation>University of São Paulo (Brazil)</organisation>
    <website>http://www2.usp.br</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>São Carlos
Ribeirão Preto</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11899.38</gridId>
    <rorId>https://ror.org/036rp1748</rorId>
  </sponsor>
  <funder id="Funder17479-0">
    <name>University of São Paulo, University Hospital (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-01T00:00:00.000Z">20442117</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of hemodynamic effects of cascade hemofiltration in septic shock</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of the hemodynamic improvement using cascade hemofiltration in patients treated for septic shock</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of days without catecholamines at the 28th day of randomization</primaryOutcome>
      <secondaryOutcome>1. Rate of decrease of catecholamines during the first 72h 
2. Number of days without mechanical ventilation at the 90th day 
3. Number of days without Renal Replacement Therapy (RRT) at the 90th day 
4. Number of days without ICU requirement at the 90th day 
5. Death or survivor status at the 90th day</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Committee for Protection of Research Subjects (Comité de Protection des Personnes [CPP]) Ile de France VI, approved on 16 July 2007 
2. France's Sanitary Safety in Health Products Agency (AFSSAPS), approved on 30 October 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20442117</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1450</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-center, pilot, prospective, parallel-group, randomised controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9dfb7251-5081-41cd-802c-fb80dbccd2fe">
	  <name>Gambro Industries</name>
	  <address/>
	  <city>Lyon</city>
	  <state/>
	  <country>France</country>
	  <zip>69357</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with a septic shock diagnosed by the medical staff team
2. Patient mechanically ventilated and treated by high doses of catecholamines after adequate fluid administration (superior or equal to 1.0 mg/h of norepinephrine or epinephrine) for more than 120 minutes and &lt;24h
Note: Patients with renal failure (treated or not) can be included</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Age (years) &lt;18 or &gt;85 
2. Weight &gt;120 kg 
3. Thrombocytopenia 50&lt; G/l or Neutrophils &lt;0.5 Giga/l 
4. Contra indication to heparin anticoagulation 
5. Patient requiring catecholamines (epinephrine or norepinephrine superior or equal to 1 mg/h) for &gt;24h 
6. Patient admitted to the Intensive Care Unit (ICU) superior or equal to 7 days before the inclusion criteria 
7. Patient with intercurrent disease limiting his/her self-sufficiency (need of help before septic shock) 
8. Inclusion (&lt;28 days) in another study interfering with the goals of the current investigation 
9. Pregnancy and patient under guardianship 
10. Immune compromised patients (e.g., being treated for cancer, treated by immunosuppressors or steroids, AIDS)</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Septic shock/ hemofiltration</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Septic shock/ hemofiltration</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Either standard hemofiltration or Cascade hemofiltration (2 types of membrane evaluated)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17411-0</funderId>
      <contactId>Contact55372_17411</contactId>
      <sponsorId>Sponsor53942</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55372_17411">
    <title>Mrs</title>
    <forename>Nathalie</forename>
    <surname>Loughraieb</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Gambro Industries
Clinical Affairs Department
61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53942">
    <organisation>Gambro Industries, Clinical Affairs Department (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder17411-0">
    <name>Gambro Industries (International)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-09T00:00:00.000Z">07427212</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of experimental hyperglycemia and AT1 receptor blockade on renal hemodynamics in impaired glucose tolerance</title>
      <scientificTitle/>
      <acronym>IGT-FRA-oo30-I</acronym>
      <studyHypothesis>The study aim is to investigate whether: 
1. Experimental hyperglycemia reduces renal hemodynamics (glomerula filtration rate, renal plasma flow) 
2. Angiotensin II Type 1 (AT1) receptor blocker treatment prevents hyperglycemia induced changes of renal hemodynamics</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured at rest (U1 rest, U2 rest) and during hyperglycemic stress testing (U1 stress, U2 stress) with and without AT1 receptor blocker treatment:
1. Glomerular filtration rate (inulin clearance) 
2. Renal plasma flow (Para-AminoHippurate [PAH] clearance) 

U1: Without AT1 receptor blocker
U2: After a 4-week treatment with valsartan</primaryOutcome>
      <secondaryOutcome>The following were assessed at U1 and U2: 
1. High-sensitivity C-Reactive Protein (CRP) 
2. Adiponectin 
3. HbA1c (blood tests) 

U1: Without AT1 receptor blocker 
U2: After a 4-week treatment with valsartan</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Ethical Committee of the Technical University of Munich.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07427212</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, open, prospective, longitudinal, non-randmoised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="de9d23a8-a9e7-4440-ba4b-1b5baaf9d01a">
	  <name>Nephrology Department</name>
	  <address/>
	  <city>Munich</city>
	  <state/>
	  <country>Germany</country>
	  <zip>81675</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males 
2. 18-70 years old
3. Impaired Glucose Tolerance (for the intervention group [IGT-Group]) (tested by the oral glucose tolerance test according to the World Health Organisation) and normoglycemic patients (for control group [healthy subjects])</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Male</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Renal or liver insufficiency 
2. Micro-or macro-albuminuria 
3. Overt diabetes mellitus</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Impaired glucose tolerance/ renal changes in prediabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Impaired glucose tolerance/ renal changes in prediabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>12 participants were recruited in each of the two groups. Statistical calculation was carried out by the Institute of Statistics, Technical University of Munich. 

Participants of both groups (control and IGT-group) received the following two interventions: 
1. Experimental hyperglycemia (clamp technique) 
2. Valsartan (AT1 receptor blocker)(oral, taken once a day in the morning) treatment for 4 weeks. The initial dose was 80 mg/day, and the dosage was increased after 7 +/- 2 days of administration to 160 mg /day. 

A safety visit was made at 5 +/- 2 days after the beginning of the study for the measurement of serum creatintine, potassium and blood pressure.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>AT1 receptor blocker</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17381-0</funderId>
      <contactId>Contact55342_17381</contactId>
      <sponsorId>Sponsor53912</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55342_17381">
    <title>Dr</title>
    <forename>Helga</forename>
    <surname>Frank</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Nephrology Department
Klinikum rechts der Isar
Ismaninger Strasse 22</address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53912">
    <organisation>Technical University of Munich (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ismaninger Strasse 22 </address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 89 4140 2231</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Helga.Frank@lrz.tum.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6936.a</gridId>
    <rorId>https://ror.org/02kkvpp62</rorId>
  </sponsor>
  <funder id="Funder17381-0">
    <name>Novartis (International)</name>
    <fundRef>http://dx.doi.org/10.13039/100004336</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">25350905</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Topical use of adrenaline in different concentrations for endoscopic sinus surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vasoconstrictors such as cocaine or epinephrine (adrenaline) are routinely applied during functional endoscopic sinus surgery. The goal is to control bleeding because, when surgery is endoscopic, even minor bleeding can be troublesome if it blocks the small end of the endoscope. Nevertheless vasoconstrictors might cause an increase in blood pressure and heart arrhythmias. The ideal adrenaline concentration should be the one to provide optimal operative field with no cardiovascular side effects. Despite its routine use, that concentration is yet to be determined. Concentrations of adrenaline varying from 1:1000 to 1:200,000 have been used both topically and sub-mucosally. Many studies have used both adrenaline and cocaine, which makes it difficult to establish the individual role of each substance on the outcome. We have decided to work with adrenaline solutions applied only topically. 

We study the effects of topical use of adrenaline solution on the nasal mucosa in three different concentrations on systemic absorption of the drug, blood pressure, heart rhythm, operative bleeding and operative time during endoscopic sinus surgery for nasal polyposis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following data were collected during surgery (No assessment was done post-operatively): 
1. Variation of blood pressure during surgery (measured by non-invasive blood pressure measures every 3 minutes)
2. Variation of heart frequency during surgery (measured continuously by 12 lead ECG)
3. Development of heart arrythmias during surgery (measured continuously by 12 lead ECG)
4. Operative bleeding (measured both objectively by the amount of blood aspirated during the procedure and subjectively by visual-analogue scale from 01 = no bleeding to 10 = very high bleeding)
5. Variation of plasma levels of adrenaline measured by three blood samples obtained during each surgery
6. Operative time</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the ethic committee of Federal University of Rio de Janeiro (UFRJ) on 24 November 2004 (ref: 207/04 CEP)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25350905</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind single-centre controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="621fe6be-6b09-4d98-85fb-170c726beeb8">
	  <name>Praia de Botafogo, 422 / 1106</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>+55 22250 040</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Be over 18 years old
2. Need elective endoscopic sinus surgery under general anesthesia for the treatment of nasal polyposis
3. Understand and give written consent to participate in the trial
4. To be classified as grade I or II according to the American Society of Anesthesiology classification of pre-operative assessment</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Patients legally incompetent or unable, for any reason, to read and sign a written consent form 
2. Patients who withdraw their consent in any time during the course of the trial, even if they have signed the consent form 
3. Patients with systemic hypertension, coronary diseases, heart arrythmia, coagulation disorders, collagen disorders, renal or liver insufficiency in any degree, previously diagnosed or detected during pre-operative assessment 
4. Pregnant women 
5. Patients who do not follow the trial protocol for any reason, unless it is related to the use of the adrenaline solution 
6. Patients in use of a number of medications that might interfere with blood pressure or coagulaion, such as anti-inflammatory drugs, oral hypoglicemics, beta agonists, etc</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nasal polyposis</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Nasal polyposis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were submitted to endoscopic sinus surgery under general anesthesia for treatment of nasal polyposis using different concentrations of adrenaline solution applied topically to the nasal mucosa. 

Concentrations: 
1. Adrenaline 1:2000 with lidocaine 1% (4 ml)
2. Adrenaline 1:10,000 with lidocaine 1% (4 ml)
3. Adrenaline 1:50,000 with lidocaine 1% (4 ml)

The control group consisted of patients submitted to tonsillectomies using the same anesthetic protocol as the study groups but without the use of adrenaline solution during surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>adrenaline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17366-0</funderId>
      <contactId>Contact55327_17366</contactId>
      <sponsorId>Sponsor53896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55327_17366">
    <title>Dr</title>
    <forename>Krishnamurti</forename>
    <surname>Sarmento Junior</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Praia de Botafogo, 422 / 1106
Botafogo</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>+55 22250 040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krishnamurti.sarmento@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53896">
    <organisation>Federal University of Rio de Janeiro (UFRJ) (Brazil) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Av. Pedro Calmon, nº 550
Prédio da Reitoria
2º andar
Cidade Universitária </address>
      <city>Rio de Janeiro </city>
      <country>Brazil</country>
      <zip>CEP 21941-901</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8536.8</gridId>
    <rorId>https://ror.org/03490as77</rorId>
  </sponsor>
  <funder id="Funder17366-0">
    <name>Federal University of Rio de Janeiro (UFRJ) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">76293435</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of the effectiveness of endoscopic and microscopic removal of cerumen (wax) from the ear canal</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>What is the best preparation to use for otitis externa in the first instance?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76293435</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0212177259</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="563a1fcd-6767-4778-9b84-bb2997da2fe5">
	  <name>ENT</name>
	  <address/>
	  <city>Bath</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BA1 3NG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with otitis externa</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ear, Nose and Throat: Otitis externa</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Otitis externa</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Dewaxing using microscope
2. Dewaxing using endoscope</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17014445 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3d1cb828-f3d4-4b99-985d-35f98f8f341e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17014445"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17027-0</funderId>
      <contactId>Contact54988_17027</contactId>
      <sponsorId>Sponsor53553</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54988_17027">
    <title>Mr</title>
    <forename>David</forename>
    <surname>Pothier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>ENT
Royal United Hospital
B&amp;NES
</address>
      <city>Bath</city>
      <country>United Kingdom</country>
      <zip>BA1 3NG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">David.Pothier@ruh-bath.swest.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53553">
    <organisation>Record Provided by the NHSTCT Register - 2007 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17027-0">
    <name>Royal United Hospital Bath NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">75155444</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Which intravenous fluid should be given for hospitalized patients?: A prospective randomised study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesize of the study is that in sick children, moderately hypotonic fluids (such as fluids contain 77 mmol/L sodium) are better tolerated (i.e. induce less hyponatraemia without the risk of hypernatraemia) than conventional intravenous fluids that contain 34 mmol/L sodium.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Association between administration of hypotonic fluids and hospital-acquired hyponatraemia, assessed by the following:
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24</primaryOutcome>
      <secondaryOutcome>To determine contributive factors that may increase hyponatraemia risk, assessed by the following: 
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy. 
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24. 
3. Plasma AntiDiuretic Hormone (ADH), measured at T0. Abnormal ADH function was assessed by serum osmolality and serum sodium determinations.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical Board of Istanbul University, Istanbul Faculty of Medicine, approved on 13 June 2005. Ref: 2005/526.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75155444</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Türkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f4d6d98c-6794-4047-a043-44cc3da8e711">
	  <name>Istanbul University</name>
	  <address/>
	  <city>Istanbul</city>
	  <state/>
	  <country>Türkiye</country>
	  <zip>34390</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All children aged between 3 months to 16 years old who received intravenous fluids</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="16.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Dehydration
2. Cerebral oedema
3. Nephrotic syndrome
4. Hepatorenal syndrome
5. Plasma sodium level below 135 mmol/L
6. Congestive heart failure
7. Renal failure
8. Inborn error of metabolism
9. Protein energy malnutrition
10. Patients receiving mannitol or diuretics
11. Patients whose fluid therapy was started before admission</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyponatraemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hyponatraemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients were randomized to one of the three study arms prospectively. Stratified block randomization was performed, with each one-week block featuring a different intravenous solution. Randomization was performed separately for children on the ward and children in the Paediatric Intensive Care Unit (PICU).

Arm 1: 0.2% sodium in 5% dextrose
Arm 2: 0.3% sodium in 3.3% dextrose
Arm 3: 0.45% sodium in 5% dextrose

When hyponatraemia developed in any group during the therapy intravenous fluid sodium composition was increased and fluid therapy was decreased to 80% of the initial volume.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Intravenous Fluid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16511-0</funderId>
      <contactId>Contact54469_16511</contactId>
      <sponsorId>Sponsor53024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54469_16511">
    <title>Prof</title>
    <forename>Metin </forename>
    <surname>Karaböcüoğlu</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Istanbul University
Istanbul Faculty of Medicine 
Department of Paediatric Intensive Care
Millet Cad
Fındıkzade	  </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+01190 5332341818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mkara63@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53024">
    <organisation>Istanbul University, Faculty of Medicine (Turkey)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Paediatric Intensive Care 
Millet Cad
Fındıkzade </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.9601.e</gridId>
    <rorId>https://ror.org/03a5qrr21</rorId>
  </sponsor>
  <funder id="Funder16511-0">
    <name>Mainly investigator-funded with support from Ege Medical Company (Turkey)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-07-10T00:00:00.000Z">99270116</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is laser treatment or surgery the best way of treating varicose veins?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Endovenous laser ablation (EVLA) produces comparable short-term results to surgery (abolition of great saphenous vein [GSV] reflux and improvement in symptoms) for the treatment of primary varicose veins due to sapheno-femoral incompetence with greater saphenous vein reflux.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Abolition of GSV reflux at three months (duplex ultrasound) 
2. Improvement in disease-specific quality of life (Aberdeen Varicose Vein Questionnaire)</primaryOutcome>
      <secondaryOutcome>1. Time to return to work and to normal activity
2. Pain and analgesia use during first week following treatment
3. Overall satisfaction and satisfaction with cosmetic outcome
4. Generic quality of life (36-item Short Form health survey [SF-36]) at 1 and 12 weeks following treatment
5. Complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from Leeds (West) Research Ethics Committee in May 2003 (ref: 03/052).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99270116</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VS03/2281</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Parallel group, non-blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9cfbfbd3-f2c9-4de3-a383-9f1bd0ab14ff">
	  <name>Leeds Vascular Institute</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS1 3EX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Symptomatic varicose veins 
2. Primary sapheno-femoral incompetence with greater saphenous vein reflux</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>342</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>342</totalTarget>
      <exclusion>1. Unable to consent
2. Children (under 18 years)
3. Unfit for general anaesthesia
4. Recurrent varicose veins
5. Patients on long-term anticoagulation
6. Patients with anterior thigh branch of greater saphenous vein arising within 10 cm of groin and competent GSV distal to this</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Varicose veins</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Varicose veins</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endovenous laser treatment (810 nm diode laser, Diomed) versus sapheno-femoral ligation, greater saphenous vein stripping and avulsions (surgery).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18278775 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c53e0951-6902-41b7-baa3-d782cc85afe7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18278775"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16614-0</funderId>
      <funderId>Funder16614-1</funderId>
      <contactId>Contact54572_16614</contactId>
      <sponsorId>Sponsor53127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54572_16614">
    <title>Mr</title>
    <forename>Michael</forename>
    <surname>Gough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53127">
    <organisation>Leeds Teaching Hospitals NHS Trust (UK)</organisation>
    <website>http://www.leedsteachinghospitals.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.415967.8</gridId>
    <rorId>https://ror.org/00v4dac24</rorId>
  </sponsor>
  <funder id="Funder16614-0">
    <name>Leeds Teaching Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16614-1">
    <name>Diomed Ltd (UK) - part of research fellow salary paid (£15,000 pa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-05-02T00:00:00.000Z">48222371</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study on the effects on plasma insulin and glucose after a single meal replacement in patients with type two diabetes mellitus</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A single oral doses of amino acids may play a role as insulin secretagogues.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Insulin and glucose response</primaryOutcome>
      <secondaryOutcome>Hormones involved in glucose homeostasis</secondaryOutcome>
      <trialWebsite>http://www.chdr.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48222371</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9802d8e7-18ec-4b64-9120-d3bab077a0f9">
	  <name>Center for Human Drug Research</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 CL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult Type two Diabetes Mellitus (T2DM) patients</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Insulin use
2. Significant clinical abnormalities</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes, insulin response</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention with single meals with different composition of amino acids in a double-blind placebo controlled trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Plasma insulin, glucose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16479-0</funderId>
      <contactId>Contact54437_16479</contactId>
      <sponsorId>Sponsor52992</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54437_16479">
    <title>Dr</title>
    <forename>J.</forename>
    <surname>Burggraaf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Human Drug Research
Zernikedreef 10</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 CL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52992">
    <organisation>Dutch State Mines (DSM) (The Netherlands)</organisation>
    <website>http://www.dsm.com/en_US/html/about/about_us_home.htm</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 6500</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 JH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10760.30</gridId>
    <rorId>https://ror.org/00k01kt20</rorId>
  </sponsor>
  <funder id="Funder16479-0">
    <name>Dutch State Mines (DSM) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-04-25T00:00:00.000Z">27453314</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical evidence continuous medical education: randomised educational trial of an e-learning program for transferring evidence based information in primary and secondary care</title>
      <scientificTitle/>
      <acronym>ICEKUBE (Italian Clinical Evidence Knowledge Utilisation Behaviour Evaluation)</acronym>
      <studyHypothesis>This trial is designed to test the effectiveness of ECCE (the Italian acronym for Continuing Education Clinical Evidence) e-learning program for transferring evidence based information to medical doctors after three months of ECCE usage and the retention of the transferred information after six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is the basic knowledge of Clinical Evidence contents assessed through the scoring of clinical vignettes selected from ECCE. The test will consist of fixed and multiple choice questions of the selected valid and reliable vignettes and will be administered before (pre-test), immediately after (12 weeks post-test one), and six months after the intervention (post-test two).</primaryOutcome>
      <secondaryOutcome>Satisfaction with the information source and its perceived value for the medical education and clinical practice.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local research ethics committee (Research Ethics Board Azienda Sanitaria Locale &#147;Città di Milano&#148;, Milano) on the 15th December 2007 (ref: 43-06 SO).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27453314</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>43-06 SO</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A before and after pragmatic educational randomised controlled trial utilising a two by two incomplete block design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="595541a4-729a-4656-955e-731234e1778a">
	  <name>Italian Cochrane Centre</name>
	  <address/>
	  <city>Milano</city>
	  <state/>
	  <country>Italy</country>
	  <zip>20156</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All Italian doctors naïve to ECCE who voluntarily adhere to participate. New users to ECCE who connect to ECCE are automatically invited to participate.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>A sample size of 54 practitioners per study arm</totalTarget>
      <exclusion>There are no exclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knowledge of the best available evidence for effective healthcare.</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Healthcare knowledge</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that as of 20/07/2007 the anticipated end date has been extended to 31/09/2007 due to a low recruitment rate. The previous end date of this trial was 31/07/2007. On 18/12/2007 the anticipated end date was extended again to 01/04/2008 due to a continued low recruitment rate. On the 05/03/2008 the anticipated end date was again amended to show the end date as the 29/02/2008 - this is the date this trial was closed to enrolment. 

Sample size/power calculation:
Based on a preliminary examination, we determined that the &#147;minimal&#148; important difference for this intervention to be considered useful was a 20% absolute improvement.

Based on a preliminary test of 300 doctors, we determined that the &#147;mean&#148; improvement due to the intervention, was a 28% absolute improvement. Therefore we calculated our sample size to detect a 0.7 standardised difference in the primary outcome, set the α error rate at 0.05 (two-sided), and the β error at 0.10 (power 90%) &#150; this yielded a sample size of 45 practitioners per study arm. If the accrual period is two months and the maximum follow-up period is six months with a loss during follow-up of 20% at the end of the study, the total number of practitioners to be randomised has been adjusted upwards to 162 (54 per intervention group).

Intervention:
ECCE is an e-learning tool that uses interactive clinical vignettes based on chapters in Clinical Evidence and a predefined sequence of questions. ECCE has four components: 
1. The Clinical Evidence chapter (e.g. headache, chronic tension-type), a clinical vignette derived from the Clinical Evidence chapter gives a plausible medical scenario (e.g. Margaret says to her family doctor: &#147;This time I didn&#146;t come for me, but to talk about Rachel, my 25-year-old daughter&#133;)
2. The lead-in for the clinical vignette and related questions that gives the doctors instructions on what to do (e.g. "more than one answer may be correct&#148;)
3. The questions addressing the recall of Clinical Evidence facts or the application of Clinical Evidence facts to the medical scenario, based on which the doctor is to select the correct answer
4. And finally the potential answers (e.g. a list of potential efficacy descriptors for a therapeutic regimen relevant to the theme) 

Group one access to ECCE for Clinical Evidence chapters and vignettes lot A and provides control data for Clinical Evidence chapters and vignettes lot B.
Group two access to ECCE for lot B and provides control data for lot A. 

To determine the possible Hawthorne effect of this trial, we added to the two-block design arms a third control arm (classical design), in which a minimal intervention was defined. The minimal intervention consisted of one of the elements of the complete intervention, namely the concise printed version of Clinical Evidence and access to the on-line full-text version.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16347-0</funderId>
      <contactId>Contact54304_16347</contactId>
      <sponsorId>Sponsor52857</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54304_16347">
    <title>Dr</title>
    <forename>Lorenzo</forename>
    <surname>Moja</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Italian Cochrane Centre
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52857">
    <organisation>Italian Cochrane Centre (Italy)</organisation>
    <website>http://www.icc.cochrane.org</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o  Dr Lorenzo Moja 
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7548.e</gridId>
    <rorId>https://ror.org/02d4c4y02</rorId>
  </sponsor>
  <funder id="Funder16347-0">
    <name>Italian Drug Agency (AIFA) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-04-11T00:00:00.000Z">54960762</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>LIMIT-1: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose Tolerance and a recent transient ischaemic attack or minor ischaemic stroke: a phase II randomised, controlled trial</title>
      <scientificTitle/>
      <acronym>LIMIT-1</acronym>
      <studyHypothesis>Metformin will be tolerated in patients with Transient Ischaemic Attack (TIA) or minor ischaemic stroke and will result in blood glucose lowering.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Tolerability of metformin treatment (measured as number of patients still on treatment after three months)
2. The safety of metformin treatment (which will be continuously monitored) 
3. The adjusted difference in two-hour post-load glucose levels at three months

Primary outcomes will be measured at three months for feasability (safety will be continuously monitored). Primary outcome on effect on post-load glucose level will be measured at three months, expressed as a for baseline adjusted difference in mean two-hour post-load glucose levels at three months between treatment groups.</primaryOutcome>
      <secondaryOutcome>1. Differences in fasting glucose levels
2. Insulin resistance
3. Body mass index
4. Percentage of patients with a normal glucose tolerance at three months

Secondary outcomes will be measured at three months, as a for baseline adjusted difference between groups.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from the Medical Ethics Committee of Erasmus Medical Centre on the 5th December 2006 (ref: NL15011.078.06 [local METC number MEC-2006-303]).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54960762</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open-label, multicentre, controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b57f755c-57b2-4d06-b9c3-12697e9e00e9">
	  <name>Stroke Research Assistant</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 DR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men or women 18 years and over
2. TIA/minor ischaemic stroke (modified Rankin Score three or less) within six months
3. Impaired fasting glucose (fasting glucose level of 5.6 to 6.9 mmol/L) and/or impaired glucose tolerance (two-hour post-load glucose level of 7.8 to 11.0 mmol/L)
4. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known or newly diagnosed diabetes mellitus
2. Contraindication for metformin:
2.1. Renal impairment (serum creatinine greater than 135 micromol/L for men, and greater than 110 micromol/L for women)
2.2. Hepatic disease (liver enzymes increased twice the upper limit of normal)
2.3. A past history of lactic acidosis
2.4. Cardiac failure requiring pharmacological therapy
2.5. Chronic hypoxic lung disease
2.6. Pregnancy
2.7. Breast feeding
3. Severe comorbidity interfering with follow-up</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Transient ischaemic attack or minor ischaemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Vascular complications</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised for metformin or no oral anti-diabetic drug (open-label) on top of optimal standard treatment, including lifestyle advice aimed at weight reduction and regular physical exercise.

Patients allocated to metformin will be treated with metformin for three months from the day of randomisation until study end. They will start with a daily dose of 500 mg that will be slowly increased in one-month time to a daily dose of 2,000 mg in two gifts. All patients will be followed for three months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Metformin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16389-0</funderId>
      <contactId>Contact54347_16389</contactId>
      <sponsorId>Sponsor52901</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54347_16389">
    <title>Ms</title>
    <forename>Esther</forename>
    <surname>van der Heijden</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Stroke Research Assistant
Erasmus Medical Centre
Room Ee 22.42
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 408 7818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stroke-research@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52901">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Neurology
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16389-0">
    <name>Erasmus Medical Centre (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-03-27T00:00:00.000Z">26123577</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prophylactic Gabapentin for Prevention of Acute Mountain Sickness: a double blind, randomised, placebo controlled, clinical trial</title>
      <scientificTitle/>
      <acronym>GPAMS</acronym>
      <studyHypothesis>Prophylaxis with gabapentin will slow or stop the progression of Acute Mountain Sickness (AMS) compared to those taking a placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. AMS incidence (Lake Louise acute mountain sickness score of equal or more than three with headache and at least one other symptom) 
2. AMS severity (score of five or more)</primaryOutcome>
      <secondaryOutcome>1. Duration of high-altitude headache free phase after prophylaxis initiation
2. Duration of moderate to severe high-altitude headache free phase after prophylaxis</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the institutional review board of the Neurology Research Centre, Imam Hospital, Tehran University of Medical Sciences (Iran) on the 11th Januray 2007 (ref: 85-04-54-4708).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26123577</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>86-01-54-5304</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised, parallel group, two-armed, placebo controlled, participants/outcome assessor blinded, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b362415-80e7-4c6f-b437-4f58e07e8499">
	  <name>No. 15, Shabtab Street</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>19389</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age of 15 to 65 years
2. Ascent to a high altitude of 3500 to 3900 metres above sea level from an altitude of at least 1500 metres using cable cars (within 45 to 90 minutes)
3. Consenting participant
4. May reasonably be expected to complete a 24 hour trial</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>204</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>204</totalTarget>
      <exclusion>1. Severe cardiac, pulmonary, or liver disease
2. Severely impaired kidney function
3. Current history of alcohol or drug abuse
4. Pregnancy
4. Known allergy to gabapentin
5. Treatment with anticonvulsants or tricyclic antidepressants</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute mountain sickness</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Mountain sickness</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group one: gabapentin 600 mg orally; single dose within first two hours of ascent.
Treatment group two: mono-hydrate lactose (same shape and weight to gabapentin capsules); single dose within first two hours of ascent.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Gabapentin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17965148 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="cf867bdb-7c3c-46a4-97ac-03068105e646" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17965148"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16208-0</funderId>
      <funderId>Funder16208-1</funderId>
      <contactId>Contact54163_16208</contactId>
      <sponsorId>Sponsor52717</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54163_16208">
    <title>Dr</title>
    <forename>Sirous</forename>
    <surname>Jafarian</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No. 15, Shabtab Street
Gheytarieh Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)91 2215 6750</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jafarian_s@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52717">
    <organisation>Tehran University of Medical Sciences (Iran)</organisation>
    <website>http://www.tums.ac.ir/index.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Professor Ghaffarpour
Neurology Research Centre
Imam Hospital
Faculty of Medicine 
Keshavarz Blvd</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder16208-0">
    <name>Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16208-1">
    <name>Darou Darman Pars Pharmaceuticals (DDP) (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-08T00:00:00.000Z">45381163</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal haemorrhage admitted in intensive care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Describing the pharmacokinetics of nimodipine, especially the variability of the bio-availability of orally administred nimodipine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pharmacokinetics of nimodipine in this specific group of patients
2. Variability of bio-availability of orally administred nimodipine</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45381163</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, non-randomised, pharmacokinetic study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="559b9792-ab3a-4cf1-bc06-151558b4b2de">
	  <name>VU University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. All patients admitted to the Intensive Care Unit (ICU) with subarachnoidal bleeding/haemorrhage (SAB), treated according to our SAB-protocol
2. Adults aged 18 to 70 years old</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>12</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12</totalTarget>
      <exclusion>1. Pregnancy
2. Expected mortality in less than 24 hours
3. Severe hepatic function disorders
4. Use of medication with known interaction in relation to nimodipine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subarachnoidal haemorrhage</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cerebrovascular diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Blood samples according to strict time protocol during treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nimodipine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16142-0</funderId>
      <contactId>Contact54088_16142</contactId>
      <sponsorId>Sponsor52643</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54088_16142">
    <title>Dr</title>
    <forename>B M</forename>
    <surname>Kors</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Centre 
Afdeling intensive care volwassenen
Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+ 31 (0)20 444 3900</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bm.kors@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52643">
    <organisation>VU University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Intensive Care
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16142-0">
    <name>VU University Medical Centre (VUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-01-22T00:00:00.000Z">43202606</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fatty Acid Absorption Study</title>
      <scientificTitle/>
      <acronym>FAAS</acronym>
      <studyHypothesis>The biochemical importance of dietary lipids to human physiology and nutrition is now firmly established and research continues to show potential health benefits of polyunsaturated fatty acids (PUFAs) and in particular the omega 3 fatty acids from fish and precursors of the same family found in many plant oils. Current UK recommendations advise the public to eat at least two portions of fish every week including one of oily fish, which is rich in omega-3 PUFAs, or take more than 200 mg/day of omega-3 PUFAs.  According to the World Health Organization (WHO), one portion should provide an equivalent of 200-500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In fact most people in the UK consume considerably less than one portion per week indicating that the recommended levels are not being achieved leaving fish oil supplementation as the most convenient route to augment dietary intake.  However, reaching recommended intake levels may require taking several capsules of fish oil per day. An alternative is to use a more palatable version of liquid fish oils presented as a flavoured emulsion, which may offer a more flexible route to achieve the required level of intake.

Approximately 95% of dietary lipids ingested from foods consist of triacylglycerols (TAGs) and lipid digestion is initiated by the action of lingual/gastric lipases which, together with the physical mixing action of the stomach, produces small partially emulsified droplets containing mainly TAGs but also free fatty acids (FFA) and diacylglycerols. Further emulsification together with the action of pancreatic lipase results in the production of 2-monoacylglycerols (sn2-MAG) and free fatty acids and these are incorporated into mixed micelles before passive diffusion into the enterocyte. Once inside the enterocyte the fatty acids with less than 12 carbon atoms pass directly into the hepatic portal vein. However, most dietary fatty acids have a chain length greater than 12 and these are re-synthesised into TAG and incorporated into the chylomicron (CM) family of lipoproteins which are secreted into the lymphatic system and transported to the thoracic lymphatic duct where they enter the circulation. The fatty acid composition of the core of the CM - TAG generally reflects the dietary fatty acid profile, particularly in the first four to six hours postprandial period. The CM-TAG are rapidly hydrolysed by lipoprotein lipase (LPL) releasing between 70 and 90% of the total TAG and leaving CM remnants which are removed from the plasma via low density lipoprotein (LDL) receptors in the liver. There have been conflicting observations that the use of emulsified forms of fish oils in some studies has led to improved digestion and absorption of EPA and DHA with other studies showing no differences in absorption.

Preliminary research in our laboratory has indicated that both the rate and extent of absorption of the fatty acids EPA and DHA improve if the oil is pre-emulsified prior to ingestion. This cross over absorption study was designed to establish whether pre-emulsification of an oil mixture leads to improved absorption of fatty acids, particularly DHA and EPA, compared with the non-emulsified form of the oil mixture.

The hypothesis of this trial is that absorption of fatty acids occurs more rapidly and extensively in a pre-emulsified form than in the straight oil.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Plasma fatty acid concentrations.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received by the local research ethics committee (Lechyd Morgannwg Health) on the 2nd October 2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43202606</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2002.112</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised cross-over study with oral ingestion of a fatty acid mixture in the form of an oil mixture or a water miscible oil emulsion.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b6f1d0e-2985-46e1-9b80-bf8d7e9d0fed">
	  <name>Obsidian Research Limited</name>
	  <address/>
	  <city>Port Talbot</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SA12 7BZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. Healthy volunteers, male or female
2. Body mass index (BMI) less than 30
3. Capable of providing written informed consent
4. Not pregnant or subject to medication</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Involved in dietary control
2. Obese/very low body weight
3. Hypercholesterolemic
4. Taking dietary fatty acid supplements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Absorption of fatty acids as part of a healthy dietary lifestyle</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Absorption of fatty acids</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In a cross-over study, participants were randomly assigned to receive either the oil mixture or oil emulsion mixture, with thirteen subjects receiving oil and eleven subjects receiving oil emulsion in the first stage. The mixtures of oils (comprising concentrated fish oil 43%, borage oil 31% and flaxseed oil 26%) in both the natural form and in the emulsified form were supplied by Cultech Ltd., Port Talbot, United Kingdom.

The participants fasted for 12 hours prior to the study. Subjects consumed 30 ml of oil as part of a meal comprising fat free cereal (37.5 g), skimmed milk (230 ml), sugar (4 g) and apple juice (150 ml). For the remainder of the nine hour collection period the participants ate only boiled rice (100 g), boiled pasta (100 g) and fresh fruit (large apple). Apple juice or water was available to drink throughout the day. The average energy intake was 3596 kJ (859 kcal) comprising 147 g carbohydrate, 23 g protein and 32 g total fat. Twenty days later (washout period), the procedure was repeated with the assignments reversed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17254329 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d6f0da26-8a35-4162-b098-b2b16676b090" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-01-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17254329"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16035-0</funderId>
      <contactId>Contact53981_16035</contactId>
      <sponsorId>Sponsor52530</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53981_16035">
    <title>Dr</title>
    <forename>Sue</forename>
    <surname>Plummer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Obsidian Research Limited
Unit 2 Christchurch Road
Baglan Industrial Park</address>
      <city>Port Talbot</city>
      <country>United Kingdom</country>
      <zip>SA12 7BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52530">
    <organisation>Obsidian Research Limited (UK)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Unit 2 Christchurch Road
Baglan Industrial Park</address>
      <city>Port Talbot</city>
      <country>United Kingdom</country>
      <zip>SA12 7BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16035-0">
    <name>Funded in-house by Cultech Limited with financial support from Welsh Development Agency as part of Technology Exploitation Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">85744812</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Alternative Intra Osseous Devices: randomised controlled trial comparing three intraosseous methods</title>
      <scientificTitle/>
      <acronym>AIOD</acronym>
      <studyHypothesis>The aim of this study is to analyse whether or not it is possible to created a fast, reliable intraosseous entrance using the BIG and/or FAST bone needles, with less complications compared with the traditional bone needle Jamshidi.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Primary endpoint: aspiration of bone marrow upon successful placement of a bone needle.
2. Primary parameter is time required for successful placement.</primaryOutcome>
      <secondaryOutcome>Secondary endpoint: Complications encoured using an intraosseous device
Secondary parameters:
1. Adverse events
2. Success rate (%)
3. User friendliness (Visual Analogue Scale [VAS])
4. Pain scored by the patient (VAS)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Medical Ethical review board, Erasmus Medical Centre, Rotterdam, The Netherlands. The approval was completed at 15th June 2006 with reference number MEC-2006-109.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85744812</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, single blinded study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="54f620ec-a652-4038-8812-36c07c8132fb">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients in acute life threatening situations, requiring assistance of a mobile medical team
2. Intravascular medical or fluid resuscitation is necessary and intravascular access cannot be obtained after two attempts</inclusion>
      <ageRange>Other</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Children under the age of one year
2. Patients with suspected sternumanomaly (only FAST1)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe injury, life threatening</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Severe injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consists of the application of a randomised instraosseous needle:
1. In people over 14 years: BIG versus FAST versus conventional bone needle
2. In children more than one and less than 14 years: BIG versus conventional bone needle</description>
	<interventionType>Device</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15956-0</funderId>
      <contactId>Contact53902_15956</contactId>
      <sponsorId>Sponsor52451</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53902_15956">
    <title>Dr</title>
    <forename>I B</forename>
    <surname>Schipper</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
Trauma Center ZWN
Room Z-9.15
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 5034</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.schipper@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52451">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Trauma Center ZWN
P.O. Box 2040</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15956-0">
    <name>Medirisk (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">32882895</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The variations in small vascular function and arterial compliance during the menstrual cycle in young healthy women (De cyclus afhankelijke variatie in de microcirculatie bij jonge gezonde ovulerende vrouwen)</title>
      <scientificTitle/>
      <acronym>MCycle</acronym>
      <studyHypothesis>It has been suggested in literature that insulin sensitivity and determinants of the blood pressure vary according to the past ovulation cycle. Since microcirculation plays a large role in the transport and supply of insulin to the muscle fibres, it can be assumed that the microcirculatory function cycle will be dependent on the ovulation cycle. Indeed from literature it has been suggested that this is true, however another group of researchers found no cycle dependent pattern. Moreover in the Vrije University the most unique method has been developed to measure the microcirculation (capillary microscope) and this measuring has never been examined in women in their ovulation cycle. The results of this research are very important for the interpretation of cardiovascular events in women during their ovulation cycle.

Hypothesis:
Microcirculatory function is cycle dependent in healthy ovulating women.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Microcirculatory function measured in three phases of the cycle (early and late follicular, and luteal).</primaryOutcome>
      <secondaryOutcome>Blood pressure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32882895</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bee72f5b-9219-42b2-b062-41b5aa6db158">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy as judged by history and physical examination
2. Regular ovulatory menstrual cycles between 21 - 35 days (proven by biphasic basal temperature curve [BTC] or midluteal progesterone more than 10 nmol/l)
3. Aged 18 to 35 years
4. No medication including oral conceptive or hormonal intra-uterine device (IUD) for at least three months
5. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>16</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16</totalTarget>
      <exclusion>1. Cardiovascular disease (hypertension [more than 160/90 mmHg], stroke, coronary artery disease, peripheral vascular disease, heart failure)
2. Diabetes mellitus (according to American Diabetes Association [ADA] criteria)
3. Smoking for the last three months
4. Alcohol use more than 4 units/day
5. Pregnancy
6. Diseases that influence reproductive hormone status</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Small vascular function, arterial compliance</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Small vascular function, arterial compliance</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Microcirculation measured by means of:
1. Microscopic examination of the nail bed (assessment of the refill after temporary occlusion of the finger) 
2. Ionthophoresis with acetylcholine (ACH) (endothelium dependent) and sodiumnitroprusside (SNP) (endothelium independent vasodilatation)
3. Blood pressure</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15970-0</funderId>
      <contactId>Contact53916_15970</contactId>
      <sponsorId>Sponsor52465</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53916_15970">
    <title>Dr</title>
    <forename>I J G</forename>
    <surname>Ketel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Department of Reproductive Medicine (Poli H)
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 0041</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ijg.ketel@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52465">
    <organisation>VU University Medical Center (The Netherlands)</organisation>
    <website>http://www.vumc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Reproductive Medicine
Postbus 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder15970-0">
    <name>Institute for Cardiovascular Research of the Vrije University of Amsterdam (ICaR-VU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">92152389</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical feasibility study to evaluate the effectiveness and safety of VivescOs™ as bone graft for reconstruction of intra-oral osseous defects</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Cultured mesenchymal stem cells differentiated into osteoblasts and seeded on scaffolds can induce bone formation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety of VivescOs™ has been confirmed.</primaryOutcome>
      <secondaryOutcome>Efficacy of VivescOs™ is doubted.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92152389</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Clinical feasability study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Other</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-11-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="249a2c1c-6aff-411c-bfab-83163d6a43b2">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Repair of the intra-oral defect was indicated as preparation for dental implant placement in a secondary stage.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Presence of local or systemic disease;
2. Pregnancy, cancertherapy; 
3. Previous participation in another trial within 30 days; 
4. Known hypersensitivity for penicillin, streptomycin.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-11-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intra-oral bone defects, loss of teeth/molars</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Intra-oral bone defects, loss of teeth/molars</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>VivescOs™ versus tissue engineered bone.

Preoperatively, four weeks before the implantation procedure, a aspiration biopsy will be taken.

Post-operatively patients will be evaluated using radiographic analysis by OphtoPantomoGrams (OPG), histological analysis by biopsy specimens and clinical evaluation of functionality at three months, six months, nine months, 12 months and 15 months after surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>VivescOs™</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15415-0</funderId>
      <contactId>Contact53348_15415</contactId>
      <sponsorId>Sponsor51895</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53348_15415">
    <title>Dr</title>
    <forename>Gert</forename>
    <surname>Meijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU)
AZU
Department of Oral Maxillofacial Surgery
Heidelberglaan 100
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gmeijer@azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51895">
    <organisation>IsoTis NV (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Prof. Bronkhorstlaan 10-D</address>
      <city>Bilthoven</city>
      <country>Netherlands</country>
      <zip>3723 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.422884.0</gridId>
    <rorId>https://ror.org/04qce9v53</rorId>
  </sponsor>
  <funder id="Funder15415-0">
    <name>IsoTis NV (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">47031769</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study of the efficacy of topically applied cyclosporin solution on psoriatic nails</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the study is to establish and evaluate the affectivity of topical application of cyclosporin in psoriasis of the fingernails.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Nail Psoriasis Severity Index (NAPSI) scores.</primaryOutcome>
      <secondaryOutcome>1. Prevention 
2. Does the NAPSI correlate with patient satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47031769</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32d5c572-1626-42ff-b9bc-25aa0fe29742">
	  <name>Postbus 2040</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinical diagnosis of  psoriasis of fingernails in both hands
2. In cases of oral treatment with  methotrexate, prednisone or fumarates, the dose of medication before the start  has to be constant for eight weeks and it may be reasonably expected that the dose shall not be altered during the treatment phase of the study
3. A minimum of at least two affected nails on the left hand and the right hand, and the number of affected nails may differ by one nail at the maximum on the left hand compared with those on the right hand</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Systemic treatment with cyclosporine or a biological agent (efaluzimab, etanercept or related medication)
2. Change of oral medication eight weeks before the start of the trial
3. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Psoriatic nails</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Psoriatic nails</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>On left and right fingernails either placebo, or 100 mg/ml cyclosporin application, twice daily.
The duration of the treatment is till complete cure or for a maximum of 16 weeks.
Control group maximal 28 weeks</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cyclosporin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15416-0</funderId>
      <contactId>Contact53349_15416</contactId>
      <sponsorId>Sponsor51896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53349_15416">
    <title>Dr</title>
    <forename>Annik</forename>
    <surname>van Rengen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Postbus 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4634569</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.vanrengen@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51896">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15416-0">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">07851536</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Information processing, neuropsychological, and neurobiological processes in pediatric obsessive-compulsive disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Information-processing:
1. Changes in measures of severity of Obsessive-Compulsive Disorder (OCD) are explained (partially) by changes in measures of meta-cognitions (explicit and/or implicit)
2. Changes in measures of meta-cognitions (explicit and implicit) precede changes in measures of severity of OCD

Neuropsychological processes:
1. Changes in measures of severity of OCD are explained (partially) by changes in measures of inhibition of attentional processes
2. Changes in measures of inhibition precede changes in measures of severity of OCD

Neurobiological processes:
1. Volumes of prefrontal cortex and striatum, activity of anterior cingulate, orbitofrontal region and striatum differ from healthy controls and change during treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Severity of OCD (CY-BOCS, measured at the start of the waitlist condition, directly before start of the CBT, session eight, 16 and follow up after 16 weeks)
2. Anxiety/Depression (Revised Child and Anxiety Depression Scale [RCADS]) measured at the start of the waitlist, directly before start of the CBT, at the end of the therapy (session 16) and follow up after 16 weeks)</primaryOutcome>
      <secondaryOutcome>1. Information-processing (explicit: Revised 44 item version of the Obsessive-Beliefs Questionnaire scale [OBQ-44 R], Meta-Cognitions Questionnaire for Adolescents [MCQ-A], Implicit: Implicit Association Procedure [IAP]) (measured at the start of the waitlist, directly before start of the CBT, session eight and 16 and follow up after 16 weeks)
2. Inhibition/selective attention (dot-probe, measured at the start of the waitlist, directly before start of the CBT, session eight and 16 and follow up after 16 weeks)
3. Neuroimaging data: volumes grey and white matter, activity on planning (tower of London), selective attention (Flanker) and inhibition (dot-probe) task in fMRI</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07851536</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="47cb03c5-9dc2-4d84-a711-40c4219c4e85">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children and adolescents eight to 18 years
2. Primary diagnosis: Obsessive Compulsive Disorder (OCD)
3. OCD symptoms for more than six months
4. Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) total score more than 16
5. IQ (Intelligence Quotient) more than 80
6. Informed consent of parents and child</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>45</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>45</totalTarget>
      <exclusion>Use of the following medication: 
1. Selective Serotonin Reuptake Inhibitor (SSRI)
2. Tricyclic Antidepressant (TCA)
3. Anti-psychotic medication

For neurobiological measures (functional Magnetic Resonance Imaging [fMRI]): 
1. Claustrophobia
2. Metal on body</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obsessive-Compulsive Disorder  (OCD)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Obsessive Compulsive Disorder (OCD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 16 weekly sessions Cognitive Behavioral Therapy (CBT)
2. Waitlist (eight weeks) followed by 16 weekly sessions CBT</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15417-0</funderId>
      <contactId>Contact53350_15417</contactId>
      <sponsorId>Sponsor51897</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53350_15417">
    <title>Ms</title>
    <forename>L H</forename>
    <surname>Wolters</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
Department of Child and Adolescent Psychiatry
Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5662242</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.h.wolters@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51897">
    <organisation>Academic Medical Center (AMC) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder15417-0">
    <name>Academic Medical Center (AMC) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003180</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-25T00:00:00.000Z">67906788</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Proof of principle study of the effect of individual and team drill on the ability of labour ward staff to manage acute obstetric emergencies</title>
      <scientificTitle/>
      <acronym>SaFE study</acronym>
      <studyHypothesis>The use of mock drills in simulation centres and labour wards (fire drills) has increased in response to issues of patient safety and the Clinical Negligence Scheme for Trusts (CNST) requirements. These provide opportunities for staff to practise emergency obstetric scenarios. However, there has been little evaluation of the effects of such training on individuals or obstetric teams. The Department of Health has funded this work, to establish proof of principle of the effect of individual and team drill training on the ability of labour ward staff to manage acute obstetric emergencies. The study evaluates training involving simulation centre and local in-house labour ward drills, so that future policies and studies can be based on the most promising methods.

The aim of this study is to evaluate the effect of individual and team drill for the management of acute obstetric emergencies. The specific research questions are:

1. Primary questions
a. Does the use of a high fidelity setting improve clinical skills in obstetric emergencies?
b. Does including team training in emergency drills improve clinical skills in dealing with obstetrics emergencies?

2. Secondary questions
a. Does team training in obstetric emergency drills improve team working?
b. Does the use of a high fidelity setting improve team working in obstetric emergencies?
c. Does team training in emergency drills improve knowledge in obstetric emergencies?
d. Does the use of a high fidelity setting improve knowledge in obstetric emergencies?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Global rating scores of individual clinical skills
2. Time taken to execute procedures
3. Number of actions, omissions and inappropriate actions</primaryOutcome>
      <secondaryOutcome>1. Knowledge assessed by a multiple choice questionnaire
2. Applied delivery force in shoulder dystocia skill station
3. Communication - as assessed by a content analysis of a sub sample of skill stations
4. Global rating scores of teamwork behaviours on a sub sample of skill stations</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Southwest Devon Medical Research Ethics Committee (reference number: 04/Q2103/68), approval gained on September 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67906788</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>0270030</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II exploratory trial within the format of a factorial 2 x 2 randomised trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="02475b0e-a8ee-48fa-8886-2be2b2b2a996">
	  <name>St Michael's Hospital</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS2 8UG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All hospital and community midwives and obstetric medical staff (junior and senior) who provide care to mothers and babies are eligible to enter the study.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>144</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>144</totalTarget>
      <exclusion>Staff who have attended addition accredited training course in the management of obstetric emergencies (Advanced Life Support in Obstetrics [ALSO], Managing Obstetric Emergencies and Trauma [MOET], South West Obstetric Emergency Course) within the past 12 months will be excluded from the study, and also:
1. Staff who have taken part in the Simulation and Fire drill Evaluation study (SaFE) pilot study
2. Staff involved in the delivery of the training interventions
3. Local staff involved in assisting the research team
4. Staff currently on maternity leave or long term sick leave</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute obstetric emergencies</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Acute obstetric emergencies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Phase II exploratory trial of two aspects of the training intervention, high versus low fidelity and team training versus no team training, will be assessed within the format of a factorial 2 x 2 randomised trial.

The participants will be randomly allocated to one of the four training interventions.
Group A1: One day obstetric emergency training course. This will be within the low fidelity setting in the local participating hospitals and will exclude specific team training.
Group B1: One day obstetric emergency training course. This will be within the high fidelity setting of the Bristol Medical Simulation Centre and will exclude specific team training.
Group A2: Two day obstetric emergency training course. This will be within the low fidelity setting of the local participating hospitals and will include specific team training.
Group B2: Two day obstetric emergency training course. This will be within the high fidelity setting of the Bristol Medical Simulation Centre and will include specific team training.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18310377 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="54cc7507-8c93-4ddc-9e33-ac2aea462f73" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18310377"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15346-0</funderId>
      <contactId>Contact53274_15346</contactId>
      <sponsorId>Sponsor51823</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53274_15346">
    <title>Dr</title>
    <forename>Bryony</forename>
    <surname>Strachan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St Michael's Hospital
Southwell Street</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS2 8UG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 117 9285594</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bryony.strachan@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51823">
    <organisation>United Bristol Healthcare Trust (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Research and Effectiveness Department
Marlborough Street</address>
      <city>Bristol</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>BS1 3NU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 117  923 0000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">maria.palmer@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410421.2</gridId>
    <rorId>https://ror.org/04nm1cv11</rorId>
  </sponsor>
  <funder id="Funder15346-0">
    <name>The trial is funded by Policy Research Programme of the Department of Health as part of the Patient Safety Research Portfolio (PSRP) (reference number: 0270030).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-13T00:00:00.000Z">25825250</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy</title>
      <scientificTitle/>
      <acronym>IM-VIT100</acronym>
      <studyHypothesis>To determine the safety and efficacy of VIT100 (VitrenAse), a proliferating cell nuclear antigen (PCNA) ribozyme (Immusol, Inc. San Diego, CA), in preventing recurrent proliferative vitreoretinopathy (PVR) in patients with established PVR who undergo vitrectomy for retinal reattachment repair.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Efficacy variables included:
1. Failure rate of retina repair surgery secondary to PVR
2. All cause of failure rate of retina repair surgery
3. Retinal status</primaryOutcome>
      <secondaryOutcome>Safety variables included:
1. ETDRS best corrected visual acuity
2. Lens status
3. Intraocular pressure
4. Biomicroscopy findings
5. Adverse effects
6. Serum Blood Urea Nitrogen (BUN) and creatinine</secondaryOutcome>
      <trialWebsite>http://www.immusol.com/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Columbia University Institutional Review Board reviewed and approved research on the 31st July 2003 (reference number: AAA8110).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25825250</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>IM-VIT 100-01 (IND # 63,756)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, double-masked, placebo controlled, randomised clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c1699ea0-d135-46c6-bcf7-3a21f1b87b8b">
	  <name>635 West 165th Street</name>
	  <address/>
	  <city>New York</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>10032</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with retinal detachment with Grade C or worse PVR who undergo vitrectomy for retinal reattachment:
1. Retinal detachment
2. Proliferative vitreoretinopathy (PVR) grade C or worse under direct visualisation
3. Visual acuity greater than no light perception
4. Aged at least 18 years
5. Patient willing and able to sign informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>170</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>170</totalTarget>
      <exclusion>1. Vision of no light perception
2. Presence of any uncontrolled, sight threatening concomitant eye disease
3. Severe non proliferative diabetic retinopathy or proliferative diabetic retinopathy according to Early Treatment Diabetic Retinopathy Study (ETDRS) criteria
4. Other pre-existing vaso-proliferative retinopathy
5. History of intraocular inflammatory disease
6. Retinoschisis detachment
7. Heredity vitreoretinopathies
8. Best corrected visual acuity less than 20/200 prior to onset of retinal detachment due to permanent pre-existing condition
9. Vision less than 5/200 or visual field less than 20 degrees in the fellow eye
10. Pregnant or nursing women or women of childbearing potential not using a reliable form of contraception
11. Concurrent participation in any other research study within 30 days of entry into the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Proliferative Vitreoretinopathy</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Proliferative Vitreoretinopathy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients undergo retinal reattachment surgery with pars plana vitrectomy. Additional intraoperative procedures including scleral buckle placement or revision, pars plana lensectomy or limbal cataract extraction, Intraocular Lens (IOL) implantation or removal, temporary keratoprosthesis and penetrating keratoplasty, retinotomy, and/or gas or silicone oil tamponade could be performed at the discretion of the operating surgeon and required the assistance of an anterior segment specialist in certain cases.

All patients were to be randomly assigned to one of the three treatment groups: 0.75 mg or 0.15 mg VitrenAse and placebo (ratio 1:1:1). A single intravenous administration of VitrenAse or placebo was administered after the completion of the vitrectomy procedure.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>VitrenAse (VIT100)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17846353 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c03cc984-b5ff-4406-a8da-44814ec9bb93" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17846353"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15341-0</funderId>
      <contactId>Contact53268_15341</contactId>
      <sponsorId>Sponsor51817</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53268_15341">
    <title>Dr</title>
    <forename>William</forename>
    <surname>Schiff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>635 West 165th Street</address>
      <city>New York</city>
      <country>United States of America</country>
      <zip>10032</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 212 305 5922</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wms13@columbia.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51817">
    <organisation>Immusol, Inc. (USA)</organisation>
    <website>http://www.immusol.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>10790 Roselle Street</address>
      <city>San Diego, CA</city>
      <country>United States of America</country>
      <zip>92121</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 858 824 1100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bsimon@immusol.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420473.6</gridId>
    <rorId>https://ror.org/03q43d318</rorId>
  </sponsor>
  <funder id="Funder15341-0">
    <name>Immusol, Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-07-14T00:00:00.000Z">33728802</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Labour support and evidence  based medicine: a randomised controlled trial of implementation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Providing women with evidence based maternity care, with provision of labour support as a focus, will improve the care of women during childbirth.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Whether women had a labour support person with them during labour.</primaryOutcome>
      <secondaryOutcome>Whether women during labour were:
1. Offered food or fluids
2. Left alone for long periods of time
3. Allowed to move during labour and delivery
4. Given an episiotomy
5. Given an enema
6. Shouted at
7. Struck or slapped
8. Unhappy with their care or percieved their care was bad</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Committee for Research on Human Subjects (Medical), University of the Witwatersrand on the 1st August 1998 (ref: M960512).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33728802</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>M960512</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="74bc46ec-6ffe-49b4-8cef-1f618d01ea0a">
	  <name>Effective Care Research Unit</name>
	  <address/>
	  <city>East London</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>5201</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Maternity units within Gauteng Province, South Africa, that delivered a minimum of 150 women per month.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10 maternity units</totalTarget>
      <exclusion>Maternity units within Gauteng Province, South Africa, that were directly linked to a university teaching scheme.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Support during labour and evidence based medicine</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Labour</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two educational interventions for maternity staff: one focused on provision of labour support and the other on accessing evidence based maternity care information.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17470267 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ddbdea08-bf7d-404f-b55b-396859ea2d88" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-04-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17470267"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15217-0</funderId>
      <funderId>Funder15217-1</funderId>
      <funderId>Funder15217-2</funderId>
      <funderId>Funder15217-3</funderId>
      <contactId>Contact53115_15217</contactId>
      <sponsorId>Sponsor51657</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53115_15217">
    <title>Prof</title>
    <forename>Justus</forename>
    <surname>Hofmeyr</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Effective Care Research Unit
University of the Witwatersrand/University of Fort Hare/East London Hospital Complex
P Bag X9047</address>
      <city>East London </city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51657">
    <organisation>Effective Care Research Unit (South Africa)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>University of the Witwatersrand/University of Fort Hare/East London Hospital Complex
P Bag X9047</address>
      <city>East London</city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11951.3d</gridId>
    <rorId>https://ror.org/03rp50x72</rorId>
  </sponsor>
  <funder id="Funder15217-0">
    <name>Department for International Development (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15217-1">
    <name>Medical Research Council (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
  <funder id="Funder15217-2">
    <name>International Childbirth Educators Association (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15217-3">
    <name>Johnson and Johnson (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-29T00:00:00.000Z">29920470</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Patients with chronic idiopathic axonal polyneuropathy: relationships in the disablement process</title>
      <scientificTitle/>
      <acronym>EXAMPLE part II</acronym>
      <studyHypothesis>1. A specific set of variables of impairments are related or predictive of functional limitations and disabilities
2. A specific set of variables of functional limitations are related or predictive of disabilities
3. Psychological variables (defined by theory of planned behaviour [TPB], anxiety and depression) add to impairment variables in the prediction of functional limitation (in self-report and performance measures)
4. These psychological variables mediate the relationship between impairment and functional limitations</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Parameters of four domains of the disablement process will be measured:
1. Impairment: muscle strength (hand-held dynamometry), balance (Berg balance scale), sensory function (sensory modality score), pain (McGill pain questionnaire), fatigue (fatigue severity scale)
2. Functional limitations: walking (modified shuttle walk test), physical functioning (physical functioning performance 10 test), hand functioning (button test and disabilities of the arm, shoulder, and hand questionnaire), physical activity (DigiWalker stepcounter), problematic activities (McMaster-Toronto arthritis patient function preference questionnaire)
3. Disability: autonomy and participation (impact on participation and  autonomy questionnaire and Rankin score)
4. Intra-individual risk factor: cognitions; intentions and perceptions of control (TPB questionnaire), emotions (hospital anxiety and depression scale)</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN29920470</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Longitudinal study; one patient group with CIAP in which the health status will be monitored</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e586c4d4-6226-4dc0-94b7-ee0545d7b078">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with chronic idiopathic axonal polyneuropathy (CIAP), diagnosed on established criteria
2. Patients who write and speak the Dutch language well
3. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Relevant co-morbidity, expected to influence the test results
2. Anticipated health risks during performance-based testing</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic idiopathic axonal polyneuropathy (CIAP)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Chronic idiopathic axonal polyneuropathy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>None: this is a longitudinal study with one patient group with chronic idiopathic axonal polyneuropathy (CIAP), in which the health status will be monitored</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15193-0</funderId>
      <contactId>Contact53075_15193</contactId>
      <sponsorId>Sponsor51625</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53075_15193">
    <title>Dr</title>
    <forename>N.L.U.</forename>
    <surname>van Meeteren</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht
Department of Neurology and Neurosurgery
Rudolf Magnus Institute of Neuroscience
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">n.vanmeeteren@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51625">
    <organisation>University Medical Center Utrecht (UMCU) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Rehabilitation
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15193-0">
    <name>University Medical Center Utrecht (UMCU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-06-26T00:00:00.000Z">12814243</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Self-help parent-training for conduct problems in children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Children in the treatment group will show significantly fewer behavioural problems than children in the control group at post-treatment and six-month follow-up as measured by parent and teacher report.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Child behaviour problems as measured by parent's report and teacher's report post-treatment and at six-month follow-up</primaryOutcome>
      <secondaryOutcome>1. Utilisation of mental health services after treatment
2. Parental mental health
3. Parents' sense of competence in parenting
4. Parent's self-report of parenting practices
5. Families' satisfaction with treatment
6. Parent report of parental relationship quality</secondaryOutcome>
      <trialWebsite>http://www.apsoc.ox.ac.uk/EBIG.html</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by National Health Service (NHS) Oxfordshire Research Ethics Committee C, reference number 05/Q1606/57.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12814243</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00299442</clinicalTrialsGovNumber>
      <protocolSerialNumber>05/Q1606/57</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="315a2ae3-3e7f-4560-8ce1-4229eaa35653">
	  <name>University of Oxford</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX1 2ER</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Families with children aged 2-5, on the waiting lists of child and adolescent mental health service clinics, and scores in the clinical range on the standardised measure of child behavioural problems. At least one parent in each family must be literate and a fluent English speaker to participate because the self-administered intervention will primarily consist of written instructions and information in English.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="2.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70 (100 subjects will be recruited to allow for dropout)</totalTarget>
      <exclusion>1. Clients whose children score below a clinical cut-off score on a standardised measure of child behaviour problems. This is to ensure that participants are appropriate for an intervention aiming to reduce behaviour problems.
2. Non-English speakers or those who are unable to read cannot be included because reading English is required to complete the self-administered intervention
3. Children or parents with severe disabilities and children with a developmental disorder (e.g. autism) will be excluded because the version of the parent-training programme that will be implemented is not designed for families with these types of problems
4. Children who live with a temporary carer will be excluded because the intervention is designed for full-time parents and follow-up will be after one year
5. Children or parents who are currently receiving treatment for psychological problems will be excluded because outcomes may be influenced by interventions not affiliated with this project</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Behavioural problems in children</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Behavioural problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that, as of 18/03/2008, the anticipated end date was updated from 01/10/2007 to 31/08/2008. 

This project will introduce a self-help parent-training programme for families on NHS waiting lists for child mental health services. It will examine whether access to treatment can be increased by providing an intervention that requires fewer resources and by releasing clinician time for more serious cases. This intervention will be tested in a randomised, controlled trial in which 35 subjects will receive treatment and 35 will not. All families will also complete questionnaires before and after treatment in order to measure changes in child behaviour, parenting, and parental-mental health. Cost-effectiveness of this programme will also be analysed. Intention-to-treat analyses will be conducted. 

The control group will receive the self-help intervention after the intervention group completes their post-treatment outcome assessments. The treatment intervention is a self-help version of the Triple P parenting programme and will consist of six parent-training videos and a workbook that will be divided into 10 weeks of treatment, to be completed at home by the families. This intervention is based on social learning theory and provides information about preschoolers' development, promoting acceptable behaviour and responding to unacceptable behaviour in effective ways, promoting children's self-esteem and coping with stress. The control group will receive no treatment during this period. 

Both groups will remain on the waiting list for treatment in a clinic and will commence that treatment if they still wish to do so when they reach the end of the waiting list, regardless of their position in the trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16437442&amp;query_hl=1&amp;itool=pubmed_docsum Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="565431c3-5d83-4364-8fbd-065ddc6533bd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-01-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16437442&amp;query_hl=1&amp;itool=pubmed_docsum"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12882-0</funderId>
      <contactId>Contact50388_12882</contactId>
      <sponsorId>Sponsor48757</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50388_12882">
    <title>Ms</title>
    <forename>Gretchen</forename>
    <surname>Bjornstad</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Oxford
Department of Social Policy and Social Work
Barnett House
32 Wellington Square</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX1 2ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 270342</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gretchen.bjornstad@socres.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48757">
    <organisation>University of Oxford (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Paul Montgomery
Deparment of Social Policy and Social Work
Barnett House
32 Wellington Square</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX1 2ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 280325</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.montgomery@socres.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder12882-0">
    <name>University of Oxford Research Development Fund and Oxfordshire Health Services Research Committee (OHSRC) Grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-22T00:00:00.000Z">25438351</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind, active-controlled, randomized, parallel group multicentric study to investigate the safety, tolerability and efficacy of reparagen - a dietary supplement compared to glucosamine sulphate in patients with moderate osteoarthritis of the knee</title>
      <scientificTitle/>
      <acronym>REPVGLUOA</acronym>
      <studyHypothesis>That reparagen is safe and effective in patients with moderate osteoarthritis, and compared to glucosamine sulphate, reparagen has a faster onset of action with an overall greater response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain visual analogue score
2. Modified Western Ontario and McMaster University osteoarthritis index (WOMAC)</primaryOutcome>
      <secondaryOutcome>1. Serum insulin-like growth factor-1 (IGF-1)
2. Global assessment of therapy
3. Patient's opinion
4. Consumption of rescue medication</secondaryOutcome>
      <trialWebsite>http://www.santerra-pharma.com</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Ethics Committee of KJ Somaiya Medical College and Hospital, Mumbai, India, submitted on 30/12/2005, approved on 08/02/2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25438351</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VL/050421/SP</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, active-controlled, randomized, parallel group multicentric study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1b347a48-8896-4a84-a6cc-ef500b11b40f">
	  <name>Vedic Lifesciences</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400 053</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ambulatory adult patients of either sex &gt;20 years of age
2. Patients with moderate osteoarthritis of the knee, clinically detected and/or diagnosed as per radiological examination and American Rhematology Association (ARA) functional classification
3. ARA functional class II or III
4. Kellgren Lawrence for knee osteoarthritis grade II, grade III
5. Patient's assessment of overall pain score between 40 and 100 mm on a pain-visual analogue scale after washout period</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Arthritis other than osteoarthritis
2. Arthroscopy of either knee in the past year
3. Administration of intraarticular steroids within the past three months or hyaluronic acid in the last nine months
4. Known adverse responses to non-steroidal anti-inflammatory drugs (NSAIDs), suspected hypersensitivity, allergy or other contraindication to any compounds present in the study medication
5. Significant gastrointestinal (GI) diseases or previous GI upset to NSAID administration
6. Pregnant or lactating women or woman of child-bearing age not following adequate contraception
7. Evidence of severe renal, hematopoetic disease or severe cardiac insufficiency as revealed by laboratory investigations and other tests
8. Moderate to severe peripheral neuropathy or other neurological disorders
9. Unwilling or unable to come to regular follow-up studies
10. Any condition which in the opinion of the investigator does not justify patient inclusion in the study
11. Inability to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Moderate osteoarthritis of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Reparagen, a combination of a cat's claw extract (Uncaria guianensis), a herbal medicine from the Amazon, and RNI 249, an extract of maca (Lepidium meyenii) a vegetable native to the Andes compared to glucosamine sulphate</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Reparagen, glucosamine sulphate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17974032 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="30d4c240-17ba-4dba-b961-4a907f196053" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-31T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17974032"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15074-0</funderId>
      <contactId>Contact52911_15074</contactId>
      <sponsorId>Sponsor51461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52911_15074">
    <title>Mr</title>
    <forename>Jayesh</forename>
    <surname>Chaudhary</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vedic Lifesciences
118 Morya House
Off Link Road
Andheri (West)</address>
      <city> Mumbai</city>
      <country>India</country>
      <zip>400 053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)22 5693 9757</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jayesh@ayuherbal.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51461">
    <organisation>Santerra Pharmaceuticals LLC (USA)</organisation>
    <website>http://www.santerra-pharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Santerra Pharmaceuticals LLC
12721 Strickland Road</address>
      <city>Raleigh</city>
      <country>United States of America</country>
      <zip>27613</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 919 847 2221</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pbobrowski@santerra-pharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15074-0">
    <name>Santerra Pharmaceuticals LLC (USA)  - contracted by Rainforest Nutritionals, Inc.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-06-19T00:00:00.000Z">34091554</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind, randomised, crossover study to investigate the difference in frequency of episodes of hypoglycaemia during treatment with Biphasic Insulin Aspart 30 (NovoMix®30) compared to Biphasic Human Insulin 30 (Mixtard® 30) in patients with well-controlled, type 2 diabetes</title>
      <scientificTitle/>
      <acronym>REACH</acronym>
      <studyHypothesis>The trial is a double-blind, two-period cross-over, randomised, multicentre trial in insulin-treated subjects with type-2 diabetes comparing the efficacy and safety of NovoMix® 30 and Mixtard® 30.
Patients will first complete a screening and run-in period lasting eight weeks during which their current insulin dose will be adjusted to achieve pre-breakfast and pre-evening meal blood glucose levels of 5-7 mmol/l.
Patients who achieve an HbA1c of 6.5-8.5% at the end of the run-in period will be randomly allocated to treatment with either NovoMix® 30 or Mixtard® 30 for a 16-week treatment period.
At the end of this period patients will be crossed over to the alternative treatment. The second crossover period will also last for 16 weeks. Both insulin regimens will involve administration just before meals. Total duration of the trial will be 40 weeks. Patients will self-check blood-glucose levels daily. Insulin total dosage will be adjusted by a maximum of either plus or minus 10% using the following algorithm in order to improve blood-glucose profiles, based on the targets stated above. The primary assessment variable will be the number of glucose readings below 3.5 mmol/l as measured by continuous glucose monitoring system overview (CGMS) during two 72-hour periods mid-way through and at the end of each treatment period.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Frequency of hypoglycaemic episodes measured by CGMS for three days.</primaryOutcome>
      <secondaryOutcome>1. Frequency of reported severe hypoglycaemic episodes, minor hypoglycaemic events and nocturnal hypoglycaemia, during the last 12 weeks of each treatment period
2. HbA1c
3. Diabetes treatment satisfaction questionnaire 
4. Adverse event recording</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by South East Multicentre Research Ethics Committee (MREC) on 03/05/2002 reference number: MREC 01/1/67</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34091554</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BIAsp-1466</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, randomised, crossover study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-11-07T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8cd93d74-89eb-4534-b89b-af8e7b8fae7f">
	  <name>Department of Diabetes and Endocrinology</name>
	  <address/>
	  <city>Leicester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LE1 5WW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 160 male or female, adult subjects, with type 2 diabetes and treated with 1 - 3 injections of insulin daily for at least six months
2. HbA1c less than 9.5% at screening and 6.5 - 8.5 at randomisation
3. Judged by the investigator to be eligible for a twice a day (BID) mixed-insulin treatment regimen</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Impaired hepatic, renal or cardiac function
2. Concomitant oral hypoglycaemic agents
3. History of frequent severe hypoglycaemic episodes requiring external assistance within the last six months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-11-07T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 2 diabetes requiring insulin</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Crossover trial comparing the glucose control of using NovoMix® 30 to Mixtard® 30.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Biphasic Insulin Aspart 30 (NovoMix® 30), Biphasic Human Insulin 30 (Mixtard® 30)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17277042 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a2c8e56c-dc35-46ff-9406-1f39445eb270" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17277042"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15110-0</funderId>
      <contactId>Contact52963_15110</contactId>
      <sponsorId>Sponsor51512</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52963_15110">
    <title>Prof</title>
    <forename>Paul</forename>
    <surname>McNally</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Diabetes and Endocrinology
Leicester Infirmary Close</address>
      <city>Leicester</city>
      <country>United Kingdom</country>
      <zip>LE1 5WW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51512">
    <organisation>Novo Nordisk Ltd (UK)</organisation>
    <website>http://www.novonordisk.co.uk</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Broadfield Park
Brighton Road</address>
      <city>Crawley</city>
      <country>United Kingdom</country>
      <zip>RH11 9RT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1293 613555</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gcom@novonordisk.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.436696.8</gridId>
    <rorId>https://ror.org/0415cr103</rorId>
  </sponsor>
  <funder id="Funder15110-0">
    <name>Novo Nordisk Ltd (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-03-30T00:00:00.000Z">42445141</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective, randomised trial comparing fluids and dobutamine optimisation of oxygen delivery in high-risk surgical patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We aimed to investigate the effect of oxygen delivery index (DO2I) optimisation with fluids versus with fluids and dobutamine on 60-day hospital mortality and incidence of complications.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the effect of both DO2I optimisation with fluids compared to with fluids and dobutamine on 60-day mortality in high-risk general surgery patients.</primaryOutcome>
      <secondaryOutcome>The incidence of complications, particularly adverse cardiovascular events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics board on the 13th May 2002 (ref: 2611/2002).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42445141</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2611/2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbb7f3b6-21e3-4b48-ac00-f0a97c44c9fc">
	  <name>Av Faria Lima 5416</name>
	  <address/>
	  <city>São Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>15091/000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients older than 18 years old undergoing elective surgeries with greater than or equal to three points according to a risk scoring system adapted from the American College of Cardiology (ACC) or the American Heart Association (AHA) guidelines</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>98</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>98</totalTarget>
      <exclusion>1. Refusal of consent
2. Haemodynamic instability prior to surgery
3. Congestive heart failure
4. Presence of infection
5. Acute myocardial ischaemia prior to enrolment
6. Life expectancy lower than 60 days
7. Disseminated malignancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>High-risk patients undergoing prolonged surgery</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>High-risk surgical patients</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Therapy consisted of pulmonary artery catheter (PAC)-guided haemodynamic optimisation during the operation and 24 hours postoperatively, using either fluids alone or fluids and dobutamine with the aim of achieving supranormal values (oxygen delivery index [DO2I] greater than 600 ml/min/m^2).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dobutamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16696864 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eb6370aa-1d7b-4662-90b8-caa7272906cf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16696864"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14940-0</funderId>
      <contactId>Contact52739_14940</contactId>
      <sponsorId>Sponsor51278</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52739_14940">
    <title>Prof</title>
    <forename>Suzana</forename>
    <surname>Lobo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av Faria Lima 5416
Jardim Universitário
São José do Rio Preto</address>
      <city>São Paulo</city>
      <country>Brazil</country>
      <zip>15091/000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51278">
    <organisation>Faculty of Medicine of São José do Rio Preto (FAMERP) Foundation (Brazil)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Av. Brigadeiro Faria Lima, 5416
Vila São Pedro</address>
      <city>São Paulo</city>
      <country>Brazil</country>
      <zip>15091/000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419029.7</gridId>
    <rorId>https://ror.org/052e6h087</rorId>
  </sponsor>
  <funder id="Funder14940-0">
    <name>Faculty of Medicine of Sao Jose do Rio Preto Foundation (Fundacao Faculdade de Medicina de Sao Jose do Rio Preto [FAMERP] - Hospital de Base) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-03-08T00:00:00.000Z">10791836</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of an educational program on the prevention of complicated infections in patients with diabetes</title>
      <scientificTitle/>
      <acronym>DELPHI</acronym>
      <studyHypothesis>A health education program for both patients and general practitioners will change behaviour by 15%.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Self-reported behaviour with regard to the uptake of measures relevant to patients and healthcare providers on the basis of the developed educational program.</primaryOutcome>
      <secondaryOutcome>The following outcomes are assessed both in persons with diabetes and in primary health care providers:
1. Awareness of the possibility of an abnormal course and a specific treatment of common infections in persons with diabetes
2. Knowledge about infections and prevention of an abnormal course in persons with diabetes
3. Attitude towards infections in persons with diabetes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10791836</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>U03/175-P230</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2625d266-a6f4-4008-b0d2-df93244c5e27">
	  <name>University Medical Center Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 AB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with type 2 diabetes
2. Aged 45 years or older 
3. Able to attend a meeting and without a Dutch language barrier</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>2400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2400</totalTarget>
      <exclusion>Patients greater than or equal to 85 years.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urinary tract infections, lower respiratory tract infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention group of patients and general practitioners participates in an educational program on urinary tract and lower respiratory tract infections. The control group doesn&#146;t receive any intervention, but is managed according to usual care. The intervention period is five months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18056887 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fa0830ac-401a-409d-b432-d78f58664a36" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18056887"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14883-0</funderId>
      <funderId>Funder14883-1</funderId>
      <contactId>Contact52663_14883</contactId>
      <sponsorId>Sponsor51196</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52663_14883">
    <title>Ms</title>
    <forename>Leonie M.A.J.</forename>
    <surname>Muller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht (UMCU)
Julius Center for Health Sciences and Primary Care
Str. HP. 6.131
P.O. Box 85060</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2538181</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.m.a.muller@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51196">
    <organisation>University Medical Center Utrecht (The Netherlands)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder14883-0">
    <name>Public Health Fund (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14883-1">
    <name>Diabetes Fund (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-03-07T00:00:00.000Z">87656977</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intravenous and oral administration of amiodarone for the management of recent onset atrial fibrillation (AF): a randomized, digoxin and disopyramide controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To confirm if oral amiodarone is as effective as intravenous amiodarone in restoring sinus rhythm in patients with recent AF.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Restoration of sinus rhythm</primaryOutcome>
      <secondaryOutcome>Blood pressure monitoring</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Provided by the Ethics Committee of the Medical School of the University of Athens on 12/03/1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87656977</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-04-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1ed34b82-020f-43a4-95e1-fd3dc499ec3e">
	  <name>15B Agiou Thoma street</name>
	  <address/>
	  <city>Athens</city>
	  <state/>
	  <country>Greece</country>
	  <zip>11527</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with recent onset atrial fibrillation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>223</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>223</totalTarget>
      <exclusion>1.  Age &lt;18 years
2.  Baseline systolic blood pressure &lt;100 mmHg
3.  Known thyroid disease
4.  Serum potassium &lt;3.5 mmol/l
5.  Pre-treatment with any antiarrhythmic drug
6.  Documented permanent AF
7.  Atrial flutter and corrected heart rate (QTc) interval &gt;440 msec
8.  The duration of tachyarrhythmia estimated by medical history
9.  The current guidelines regarding prevention of thromboembolism are also followed</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-04-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Atrial fibrillation</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Atrial fibrillation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients, a total number of 338 received digoxin and disopyramide and if this restored sinus rhythm within two hours, they were excluded from the study.
Patients were randomized into two groups. One group received intravenous amiodarone
and the other group received oral amiodarone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>amiodarone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17434635 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="234302d4-4145-4ce1-aaad-b2823cf9c6ad" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17434635"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14738-0</funderId>
      <contactId>Contact52503_14738</contactId>
      <sponsorId>Sponsor51018</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52503_14738">
    <title>Dr</title>
    <forename>Theodoros</forename>
    <surname>Xanthos</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>15B Agiou Thoma street</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 (0)2107462550</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">theodorosxanthos@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51018">
    <organisation>Greek National Health Service (Greece)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>15B Agiou Thoma street</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 (0) 2107462501</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dperrea@med.uoa.gr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14738-0">
    <name>Greek National Health Service</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-01-30T00:00:00.000Z">07286796</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness and cost-effectiveness of public access defibrillation in urban and rural populations in Northern Ireland</title>
      <scientificTitle/>
      <acronym>Northern Ireland Public Access Defibrillation (NIPAD)</acronym>
      <studyHypothesis>Training laypersons such as first responders and police officers to carry and use automated external defibrillators to attend the scene of out-of-hospital sudden cardiac arrests will result in the resuscitation of additional patients by a reduction in the response time compared to the existing emergency medical service response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Survival after hospital discharge following out-of-hospital sudden cardiac arrest
2. Cost-effectiveness of public access defibrillation in the study areas</primaryOutcome>
      <secondaryOutcome>1. Reduction in response time compared to existing emergency medical services
2. Return of spontaneous circulation
3. The modelling of the results to Northern Ireland as a whole using a spatial modelling approach
4. The modelling of the effectiveness and cost-effectiveness of public access defibrillation across Northern Ireland</secondaryOutcome>
      <trialWebsite>http://www.med.qub.ac.uk/nipad</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Northern Ireland Research Ethics Committee on the 26th March 2003 (ref: 47/03).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07286796</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>COM/2371/03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An observational study for one year followed by an intervention using public access defibrillation on the cohort</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-03T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Northern Ireland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7a4040e6-3a07-41bf-b4c3-62c61018cd42">
	  <name>QUB Centre For Clinical and Population Science</name>
	  <address/>
	  <city>Belfast</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BT12 6BA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients with a presumed out-of-hospital sudden cardiac arrest over the age of 14 in Antrim, Ballymena, Magherafelt and North and West Belfast district council areas of Northern Ireland.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300,000 people in study area, expected 300 cardiac arrests</totalTarget>
      <exclusion>Out-of-hospital sudden deaths due to non-cardiac causes including trauma, drowning, overdose, poisoning and fire.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-03T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Out-of-hospital sudden cardiac arrest</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cardiac arrest</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Training lay cardiac first responders and police officers to carry and use automated external defibrillators in response to sudden out-of-hospital cardiac arrest in fixed and mobile locations.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17540690 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7836ea51-5d18-48ca-bc90-e78be31b0a25" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17540690"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14619-0</funderId>
      <contactId>Contact52375_14619</contactId>
      <sponsorId>Sponsor50885</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52375_14619">
    <title>Prof</title>
    <forename>Frank</forename>
    <surname>Kee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>QUB Centre For Clinical and Population Science
1st Floor Mulhouse building
Royal Victoria Hospital
Grosvenor road</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)28 90632746</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.kee@qub.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50885">
    <organisation>The Research and Development Office for Health and Personal Social Services in Northern Ireland (UK)</organisation>
    <website>http://www.centralservicesagency.n-i.nhs.uk/display</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>R&amp;D Office
12-22 Linenhall street</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT2 8BS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)28 90553617</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joanne.O'Neill@rdo.n-i.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412915.a</gridId>
    <rorId>https://ror.org/02tdmfk69</rorId>
  </sponsor>
  <funder id="Funder14619-0">
    <name>The Research and Development Office for Health and Personal Social Services in Northern Ireland (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-01-13T00:00:00.000Z">91576704</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Intranasal calcitonin can be effective in the treatment of acute Charcot foot.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Effect on bone remodeling markers
2. Markers of disease activity - skin temperature</primaryOutcome>
      <secondaryOutcome>1. Prevention of deformities
2. Shortening of the treatment
3. Recurrence of Charcot foot</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local ethics committee, and all participants gave written informed consent.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91576704</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MZO00023001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Czech Republic</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cde2359c-64fb-4dc1-8ee7-7196d95f4bff">
	  <name>Videnska 1958/9</name>
	  <address/>
	  <city>Prague 4</city>
	  <state/>
	  <country>Czech Republic</country>
	  <zip>14021</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute Charcot foot
2. Type 1 or Type 2 Diabetes</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Foot ulcer
2. Acute osteomyelitis</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetic Foot</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Acute charcot foot</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intranasal Calcitonin 200 IU + Calcium 1000 mg per day or Calcium 1000 mg per day in monotherapy; two years follow-up period.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Calcitonin, calcium</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14563-0</funderId>
      <contactId>Contact52297_14563</contactId>
      <sponsorId>Sponsor50784</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52297_14563">
    <title>Dr</title>
    <forename>Robert</forename>
    <surname>Bem</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Videnska 1958/9</address>
      <city>Prague 4</city>
      <country>Czech Republic</country>
      <zip>14021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50784">
    <organisation>Institute for Clinical and Experimental Medicine (Czech Republic)</organisation>
    <website>http://www.ikem.cz</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Videnska 1958/9</address>
      <city>Prague 4</city>
      <country>Czech Republic</country>
      <zip>14021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418930.7</gridId>
    <rorId>https://ror.org/036zr1b90</rorId>
  </sponsor>
  <funder id="Funder14563-0">
    <name>Institute for Clinical and Experimental Medicine MZO00023001 (Czech Republic)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">28577651</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intervention project Osteogenesis Imperfecta (OI) type I and IV: home based training program to increase exercise capacity, muscle strength and aspects of quality of life in children with Osteogenesis Imperfecta</title>
      <scientificTitle/>
      <acronym>ETOI</acronym>
      <studyHypothesis>Children with Osteogenesis Imperfecta type I and IV would benefit from a gradual training program. Increased exercise capacity and muscle strength could increase quality of life.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Exercise capacity and muscle strength.</primaryOutcome>
      <secondaryOutcome>Health related quality of life.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28577651</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>04/331-k (METC UMCU)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, single-blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-08-02T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b35c6d21-d68c-4848-9a7d-b032e2897b40">
	  <name>KB 02.056.0, 3508 AB</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 EA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Osteogenesis Imperfecta Type I and IV
2. Between 8 and 18 years of age 
3. Ambulatory</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Osteogenesis Imperfecta type II and III
2. Retardation
3. Non-walking</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-08-02T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteogenesis Imperfecta</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteogenesis imperfecta</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Training program for 12 weeks (two times/week).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18154911 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ba9bc6ae-da99-44b1-b5e0-d2d6835aa3bf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18154911"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14339-0</funderId>
      <funderId>Funder14339-1</funderId>
      <contactId>Contact52225_14339</contactId>
      <sponsorId>Sponsor50753</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52225_14339">
    <title>Dr</title>
    <forename>R.H.H.</forename>
    <surname>Engelbert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>KB 02.056.0, 3508 AB
P.O. Box 85090</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 EA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2504030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.engelbert@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50753">
    <organisation>University Medical Centre Utrecht (UMCU) (Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>PO Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder14339-0">
    <name>Johanna Child Fund (Johanna Kinderfonds) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14339-1">
    <name>Foundation for paediatric rehabilitation (Stichting Bio-Kinderrevalidatie) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">33274262</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dutch Acarbose Intervention Trial (DAISI)</title>
      <scientificTitle/>
      <acronym>DAISI</acronym>
      <studyHypothesis>Approximately 1/3 of persons with impaired glucose tolerance (IGT) develops type 2 diabetes mellitus in 5 - 10 years time. Acarbose is an alpha-glucosidase inhibitor decreasing post-prandial glucose levels, without the risk of hypoglycemia. The prevention of diabetes with acarbose in this study was considered a feasible approach.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Venous plasma glucose level two hours after oral intake (in five minutes) of 75 g glucose dissolved in 300 ml water at study end (ie, after three years). A difference in two hour post-load glucose level between placebo and acarbose group of 0.5 mmol/L was regarded as being clinically relevant.</primaryOutcome>
      <secondaryOutcome>1. Fasting venous glucose level
2. Appearance of type 2 diabetes mellitus and normal glucose tolerance, according to WHO criteria
3. B-cell function and insulin sensitivity as assessed via the method of the hyperglycaemic clamp
4. Level of cardiovascular risk factors: cholesterol, high density lipoprotein (HDL)cholesterol, triglycerides, lipoprotein (a) (later deleted by amendment no. 4), albumin/creatinine ratio in time assessed urine sample</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33274262</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33df032e-443f-4929-b611-f8347f5cbcd6">
	  <name>Department of general practice</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Persons with impaired glucose tolerance on the basis of two oral glucose tolerance tests (World Health Organization [WHO] 1985 criteria).</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>119</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>119</totalTarget>
      <exclusion>1. Not having side effects of acarbose in the qualification period of three months
2. Persons having endocrinological diseases, or having a malignancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes Mellitus type II (DM type II)</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Acarbose used at a fixed dose of 50 mg. The daily maintenance dose was 50 mg three times a day (tid), which was reached as from week 3 after two weeks of up-titration with 50 mg once a day (od) (week 1) and 50 mg twice daily (bid) (week 2).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14369-0</funderId>
      <contactId>Contact52136_14369</contactId>
      <sponsorId>Sponsor50549</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52136_14369">
    <title>Dr</title>
    <forename>Giel</forename>
    <surname>Nijpels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of general practice
EMGO Institute
VU University Medical Center
Van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 4449659</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.nijpels@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50549">
    <organisation>Bayer Medical B.V. (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 80</address>
      <city>Mijdrecht</city>
      <country>Netherlands</country>
      <zip>3640 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491169.2</gridId>
    <rorId>https://ror.org/01442sk86</rorId>
  </sponsor>
  <funder id="Funder14369-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-19T00:00:00.000Z">61223447</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective (sero-)epidemiological study on contact transmission and chemoprophylaxis in leprosy</title>
      <scientificTitle/>
      <acronym>COLEP</acronym>
      <studyHypothesis>Rifampicin is an effective chemoprophylactic intervention method to prevent leprosy among close contacts of leprosy patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure is the number of new leprosy patients emerging from the contact groups. The proportions between the rifampicin and the placebo group will be compared at two-years intervals.</primaryOutcome>
      <secondaryOutcome>Analysis will be carried out in order to define special groups at risk. The results of the serological tests will also be compiled and analysed. The number of leprosy patients found in the referent group will be used to calculate the prevalence rate (at intake) and the incidence rate (during follow-up) in the general population, allowing for calculation of relative risks among the contacts.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61223447</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Bangladesh</country>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dac36d64-78cb-4dbe-a0a8-f82a39ef6744">
	  <name>Erasmus Medical Centre Rotterdam</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 DR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients should give consent for approaching their contacts for the trial.
Inclusion criteria for contacts:
1. Those living in the same house
2. Those living in a house sharing the same kitchen
3. First neighbours
4. Close business or social contacts, including other relatives. To be included into this category one has to be in contact with the patient on a daily base (five or more days a week) and during several hours a day.
5. Second neighbours

All divided into spouse, child, parent, sibling, other relative, relative-in-law, non-relative.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20,000</totalTarget>
      <exclusion>Exclusion criteria for contacts:
1. Any contact who refuses to be included
2. Any contact being pregnant
3. Any contact currently on tuberculosis (TB) or leprosy treatment (however, released from treatment [RFT] patients should be included)
4. Any contact below 5 years of age
5. Any contact suffering from jaundice
6. Any contact living only temporarily in the area
7. Any contact found to suffer from leprosy at the initial survey
8. Any contact already enrolled in the study via the contact</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Leprosy</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Leprosy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All close contacts of 1000 consecutive new leprosy patients in the districts of Nilphamari and Rangpur (Bangladesh) who are recruited for the study are considered for inclusion. A contact group consists of around 20 individuals. 

A single dose of rifampicin or a placebo is given to all included contacts. The rifampicin comes in capsules of 150 mg and the dosage is the same as recommended in the guidelines of the national leprosy control programme of Bangladesh and DBLM. According to bodyweight and age, two to four capsules are taken by the contact under direct supervision of a DBLM staff member. All the contacts of one patient receive medication from the same container.

Dosage of rifampicin according to age and body weight: 
Adult greater than 35 kg: 600 mg
Adult less than 35 kg: 450 mg
Child 10 - 14 years:  450 mg
Child 5 - 9 years: 300 mg</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rifampicin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18332051 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4d2f561d-be32-4879-8e20-f350fa545fff" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18332051"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14302-0</funderId>
      <funderId>Funder14302-1</funderId>
      <contactId>Contact52049_14302</contactId>
      <sponsorId>Sponsor50513</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52049_14302">
    <title>Dr</title>
    <forename>F.J.</forename>
    <surname>Moet</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre Rotterdam
Department of Public Health
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.moet@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50513">
    <organisation>Erasmus Medical Centre (The Netherlands) </organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Public Health 
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder14302-0">
    <name>The Leprosy Mission International (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14302-1">
    <name>American Leprosy Missions (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-16T00:00:00.000Z">28317455</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A controlled trial of the effectiveness of a diabetes education programme in a multi-ethnic community in Glasgow</title>
      <scientificTitle/>
      <acronym>KAP (knowledge-attitude-practice)</acronym>
      <studyHypothesis>Educational intervention could improve the knowledge and attitudes of people from ethnic minority group with diabetes.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Knowledge-attitude-practice.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Greater Glasgow Community/Primary Care local Research Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28317455</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial (block design)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b750205e-fc90-41a4-9e6c-9d8088f1fc96">
	  <name>Educational &amp; Development Centre</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>14496</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All people with diabetes from ethnic minority group aged over 30 years.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>329</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>329</totalTarget>
      <exclusion>1. Disabled
2. Blind
3. Not willing to participate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Educational programme compared to usual care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16709243 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="208cb9ff-5d98-4296-8d6a-2efdcd4239b0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16709243"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14271-0</funderId>
      <funderId>Funder14271-1</funderId>
      <funderId>Funder14271-2</funderId>
      <contactId>Contact52008_14271</contactId>
      <sponsorId>Sponsor50441</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52008_14271">
    <title>Dr</title>
    <forename>Hamid Reza</forename>
    <surname>Baradaran</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Educational &amp; Development Centre
Iran University of Medical Sciences
P.O. Box 14155-5983</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14496</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 8805 2252</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">baradaran@iums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50441">
    <organisation>Iran University of Medical Sciences (Iran) </organisation>
    <website>http://www.iums.ac.ir</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Educational &amp; Development Centre
Iran University of Medical Sciences
P.O. Box 14155-5983</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14496</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 8805 2252</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">baradaran@iuma.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411746.1</gridId>
    <rorId>https://ror.org/03w04rv71</rorId>
  </sponsor>
  <funder id="Funder14271-0">
    <name>Iran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14271-1">
    <name>University of Glasgow (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000853</fundRef>
  </funder>
  <funder id="Funder14271-2">
    <name>NHS Scotland (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-02T00:00:00.000Z">13964268</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>FIC - Training in malaria research in Uganda</title>
      <scientificTitle/>
      <acronym>FIC</acronym>
      <studyHypothesis>The proportion of convulsions terminated by buccal midazolam is higher than the proportion of convulsions terminated by rectal diazepam in children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time taken to terminate convulsion within 10 minutes without re-occurence of the convulsion in an hour.</primaryOutcome>
      <secondaryOutcome>1. Time taken to re-occurence of convulsion after initial control
2. Time taken to terminate the convulsion within 10 minutes
3. Proportion of children who get respiratory depression within one hour after adminstration of the study drug</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approved received from: 
1. The Makerere University Medical School Research and Ethics Review Board (Uganda)
2. National Council of Science and Technology Institutional Review Board (IRB) (Uganda)
3. University of California San Francisco Institutional Review Board (IRB) (USA)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13964268</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double blind clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Uganda</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1fc5c10e-b5eb-4239-9514-054476f4e806">
	  <name>Makerere Univeristy</name>
	  <address/>
	  <city>Kampala</city>
	  <state/>
	  <country>Uganda</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 3 months to 12 years
2. Admission to Acute Care Unit during the study period
3. A child who presents to the Acute Care Unit with convulsions
4. Provision of informed consent to continue participation in the study</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="12.0"/>
      <gender>Both</gender>
      <targetEnrolment>350</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>350</totalTarget>
      <exclusion>1. Documented evidence of having recieved parenteral anticonvulsant in the past 24 hours
2. Cessation of convulsion before adminstration of study drug
3. Parent/caretaker verbally declines to participate in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prolonged convulsions</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Rectal diazepam versus buccal placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Midazolam, diazepam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18166545 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a93498cb-f2b4-4363-9945-a1a79119a78a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18166545"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14195-0</funderId>
      <contactId>Contact51909_14195</contactId>
      <sponsorId>Sponsor50338</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51909_14195">
    <title>Dr</title>
    <forename>Justus</forename>
    <surname>Byarugaba</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Makerere Univeristy
Faculty of Medicine
Department of Pediatrics and Child Health
P.O. Box 7072</address>
      <city>Kampala</city>
      <country>Uganda</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+256 75 696 633</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">byarugabaj@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50338">
    <organisation>Fogarty International Center (FIC) (USA)</organisation>
    <website>http://www.fic.nih.gov/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>National Institutes of Health
Office of Communications
Building 31, Room B2C29
31 Center Drive
MSC 2220</address>
      <city>Bethesda</city>
      <country>United States of America</country>
      <zip>20892-2220</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 301 496 2075</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ficinfo@nih.gov</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453035.4</gridId>
    <rorId>https://ror.org/02xey9a22</rorId>
  </sponsor>
  <funder id="Funder14195-0">
    <name>Fogarty International Centre (FIC) (USA) (grant ref: TW007375)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-11-25T00:00:00.000Z">88861431</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study of safety and immunogenicity of Measles vaccine (Rouvax®) administered by transcutaneous route (France)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 23rd March 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88861431</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC 037</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-23T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5728d984-e44e-428a-9fc3-34ebd890c27f">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy adults between 18 and 22 years of age of haplotype HLA-A201 who have previously been immunised against measles and for whom the anti-measles antibodies are low
2. Female participants must be under contraception</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. Previous infection with measles
2. Contra-indications to the use of Rouvax® vaccine
3. Hypersensitivity to egg proteins
4. Human Immunodeficiency Virus (HIV) seropositive
5. Treatment with corticosteroids or immunosuppressors in 15 days prior to enrolment
6. Exposure of back-skin to sun in 15 days prior to enrolment
7. Dermatological pathology on back
8. Acute and evolutive disease
9. Blood donation in three months prior to enrolment
10. In a period of exclusion following previous clinical trials
11. Having received 3800 or more Euros in preceeding 12 months from participation in clinical trials</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-23T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccine/immunisation</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 1 dose of Rouvax® vaccine administered to the skin of the shoulder after stripping (abrading) the skin
Control: 1 dose of Rouvax® administered by injection</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Measles vaccine (Rouvax®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14243-0</funderId>
      <contactId>Contact51966_14243</contactId>
      <sponsorId>Sponsor50396</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51966_14243">
    <title>Dr</title>
    <forename>Martin</forename>
    <surname>Friede</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4398</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">friedem@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50396">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14243-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-11-17T00:00:00.000Z">28535118</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bowel preparation or not in elective colon surgery</title>
      <scientificTitle/>
      <acronym>Boniec</acronym>
      <studyHypothesis>Postoperative complication rate in the bowel preparation group is the same as in the non-bowel preparation group (null hypothesis).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mortality within 30 days postop
2. Local infectious complications
3. Cardiovascular complications</primaryOutcome>
      <secondaryOutcome>1. Postop bleeding
2. Reoperation
3. General infectious complications
4. Length of postop hospital stay
5. Rehospitalisation within 30 days postop</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28535118</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3734e404-b7bd-4657-9530-36df8cab668b">
	  <name>Kirurg Kliniken</name>
	  <address/>
	  <city>Umeå</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>90185</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient aged 18 - 85 years
2. Elective resection for cancer, adenoma or diverticular disease
3. Survival over 6 months foreseen
4. Written consent after written and spoken information</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1500</totalTarget>
      <exclusion>Bowel preparation given preoperatively from other reasons than surgery.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Elective colon surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Colon surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study compares colon surgery with preoperatively given bowel preparation (standard today) with no given bowel preparation preoperatively.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17514668 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ebef58f9-ba8a-4d24-ad8b-6b6fccf315b6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17514668"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13290-0</funderId>
      <contactId>Contact50898_13290</contactId>
      <sponsorId>Sponsor49286</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50898_13290">
    <title>Prof</title>
    <forename>Erik</forename>
    <surname>Nilsson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kirurg Kliniken
Norrlands Universitetssjukhus</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>90185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">erik.nilsson@surgery.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49286">
    <organisation>Umea University/The Health Research Council of South-East of Sweden (FORSS Sydöstra sjukvårdsregionen) (Sweden)</organisation>
    <website/>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>Norrlands Universitetssjukhus</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>90185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">peter.naredi@surgery.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.12650.30</gridId>
    <rorId>https://ror.org/05kb8h459</rorId>
  </sponsor>
  <funder id="Funder13290-0">
    <name>The Health Research Council of South-East of Sweden (FORSS Sydöstra sjukvårdsregionen) (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-10-21T00:00:00.000Z">75125874</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised phase III clinical trial in patients radically operated for stage III melanoma (American Joint Committee on Cancer [AJCC]): comparison between Interferon (IFN) alpha-2b (sec Eastern Cooperative Oncology Group [ECOG] 1684) versus intensified Interferon alpha-2b</title>
      <scientificTitle/>
      <acronym>IMI - Mel.A.</acronym>
      <studyHypothesis>To verify if intensive intravenously IFN regimen is better than ECOG 1684 IFN regimen in patients with high risk melanoma (Stage III AJCC).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Overall survival</primaryOutcome>
      <secondaryOutcome>1. Toxicity
2. Disease free survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75125874</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d3e559ea-618c-44f1-81da-28a5cd953ff1">
	  <name>Medical Oncology Unit</name>
	  <address/>
	  <city>Venezia</city>
	  <state/>
	  <country>Italy</country>
	  <zip>30100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Primary melanoma of any tumour stage in presence of N1 regional lymph node metastases detected at elective or selective lymph node dissection with clinically not apparent regional lymph node metastases (designed CS1PS2, any TpN1M0)
2. Clinically apparent N1 regional lymph node involvement synchronous with primary melanoma of T1-4 (designed CS2PS2, any TcN1M0)
3. Regional lymph node recurrence at any interval after appropriate surgery for primary melanoma of any depth (designed CS2R, TxrN1M0)
4. ECOG performance status (PS) zero to one
5. Age 18 to 70
6. Absence of active medical or psychiatric troubles requiring medical or pharmacological interventions
7. Absence of thyroid or auto-immune pathology
8. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>328</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>328 patients</totalTarget>
      <exclusion>1. Patients with non-cutaneous primary melanoma
2. Clinical or pathological evidence of not completely resected melanoma or of lymph-node metastases
3. Clinical history of progressed neoplasia, except for the in situ carcinoma of the cervix and of radically treated basal carcinomas
4. Patients requiring a continuous treatment with steroids, non-steroid antiinflammatory drugs or other inhibitors of the prostaglandins synthesis, antihistaminic (cimetidine, ranitidine, famotidine and nazatidine) or other known immunomodulators
5. Patients with history of (ventricular or supraventricular) heart rhythm troubles needing treatment, or congestive heart failure (class New York Heart Association [NYHA] more than two)
6. Patients with organic brain syndrome or significant deterioration of the basal cognitive function or with any psychiatric trouble which may hinder the complete participation in the protocol or which may be exacerbated from the IFN therapy (e.g. depression)
7. Patients previously submitted to adjuvant therapy, chemotherapy, immunotherapy, including any perfusion therapy before surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Melanoma of cutaneous origin with regional lymph-node metastasis radically resected</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Melanoma of cutaneous origin with regional lymph-node metastasis radically resected</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Dose-Dense/Dose-Intense arm: IFN alpha-2b 20 MU/m^2/day intravenously five days a week for four weeks, repeated for four times on weeks nine to 12, 17 to 20, 25 to 28

Standard arm: IFN alpha-2b 20 MU/m^2/day intravenously five days a week for four weeks followed by 10 MU/m^2 subcutaneously three times per week for 48 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Interferon alpha-2b</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16504154 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c43c2fa1-3e8d-4ff7-806f-f4ef988d0687" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-02-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16504154"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14151-0</funderId>
      <contactId>Contact51846_14151</contactId>
      <sponsorId>Sponsor50270</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51846_14151">
    <title>Dr</title>
    <forename>Adriano</forename>
    <surname>Paccagnella</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Oncology Unit
SS Giovanni e Paolo Hospital</address>
      <city>Venezia</city>
      <country>Italy</country>
      <zip>30100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">adriano.paccagnella@ulss12.ve.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50270">
    <organisation>Italian Melanoma Intergroup - IMI (Italy)</organisation>
    <website>http://www.imi-online.it</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Istituto Oncologico Romagnolo
Corso Mazzini 65</address>
      <city>Forlì</city>
      <country>Italy</country>
      <zip>47100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)543 35929</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cor.epiclin@unipd.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14151-0">
    <name>Non-profit trial, partially supported by Italian Melanoma Intergroup (IMI)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-17T00:00:00.000Z">31625370</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of POstoperative Nausea and Vomiting with metoclopramide and dexamethasone</title>
      <scientificTitle/>
      <acronym>MultiPONV</acronym>
      <studyHypothesis>A prophylactic treatment of postoperative nausea and vomiting consisting of an optimal dosage of metoclopramide combined with dexamethasone increases effectiveness and lowers side effects.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Occurrence of nausea and/or vomiting within 24 hours after the end of surgery.</primaryOutcome>
      <secondaryOutcome>1. Occurrence of post-operative nausea (PON) and vomiting (POV) separately
2. Frequency and severity of PON and POV
3. Time to first PONV event
4. Need of rescue medication
5. Frequency of hypotension and arrhythmia after intra-operative administration of the study drugs
6. Frequency and severity of adverse effects within 24 hours after the end of surgery: 
6.1. Headache
6.2. Dizziness
6.3. Drowsiness
6.4. Dry mouth
6.5. Itching
6.6. Flush
6.7. Urticaria
6.8. Restlessness
6.9. Extrapyramidal symptoms
6.10. Dyskinesia
6.11. Central-anticholinergic syndrome
6.12. Bradycardia/tachycardia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31625370</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8133f48d-1691-4391-8970-2dcb75ee7ae4">
	  <name>Liebigstr. 20</name>
	  <address/>
	  <city>Leipzig</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-04103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age greater than 18 years
2. Patient receives balanced anaesthesia (with intubation) or spinal, peridural, or combined spinal epidural anaesthesia for any of the following surgeries: 
2.1. Hysterectomy
2.2. Cholecystectomy
2.3. Hernia repair
2.4. Otorhinolaryngological surgery
2.5. Thyroid surgery
2.6. Total endoprothesis of the hip or knee
2.7. Arthroscopy
3. Patient is able to answer questions regarding symptoms (taking his/her physical, emotional and mental constitution, understanding and compliance into consideration)
4. Informed consent in writing</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>3000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>3000</totalTarget>
      <exclusion>1. Anaesthesiological risk level of American Society of Anaesthesiologists (ASA) IV
2. Presence of at least one of the following cardiac risk factors: 
2.1. Unstable angina pectoris
2.2. Heart failure with New York Heart Association (NYHA) greater than or equal to III and/or left ventricular ejection fraction (LVEF) less than 40%
2.3. Atrioventricular block grade II or III
3. Current treatment with any of the following: 
3.1. Study medication
3.2. Other anti-emetic drugs except ranitidine
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.4. Monoamine oxidase (MAO) inhibitors
3.5. Tricyclic antidepressants
3.6. Antiarrhythmics class I or III
4. Disposition of the patient to malignant hyperthermia, or known occurrence thereof
5. History of any of the following diseases: 
5.1. Parkinson's disease and other extrapyramidal-motoric impairment
5.2. Hepatic insufficiency (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] greater than 2 x upper normal value [UNV])
5.3. Renal insufficiency (Creatinine greater than 2 x UNV)
5.4. Phaeochromocytoma
5.5. Mechanical ileus
5.6. Epilepsy
6. Known anaphylaxis following any of the study drugs
7. Pregnancy or breast feeding
8. Participation in another therapeutic trial
9. Planned or foreseeable post-operative application of propofol
10. Planned or foreseeable post-operative artificial respiration
11. Planned or foreseeable leaving of a stomach tube post-operatively</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postoperative nausea and/or vomiting following inhalational or regional anaesthesia.</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Postoperative nausea and vomiting</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients were randomised to receive either of 0, 10, 25 or 50 mg metoclopramide in addition to 8 mg dexamethasone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Metoclopramide, dexamethasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16861255 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0723b4a0-ad4b-4e2c-9bbc-c94db2aa928f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16861255"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13519-0</funderId>
      <funderId>Funder13519-1</funderId>
      <contactId>Contact51177_13519</contactId>
      <sponsorId>Sponsor49576</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51177_13519">
    <title>Prof</title>
    <forename>Derk</forename>
    <surname>Olthoff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Liebigstr. 20</address>
      <city>Leipzig</city>
      <country>Germany</country>
      <zip>D-04103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)341 9717701</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">olthoff@medizin.uni-leipzig.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49576">
    <organisation>University of Leipzig (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ritterstr. 26</address>
      <city>Leipzig</city>
      <country>Germany</country>
      <zip>D-04109</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)341 9730100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kanzler@uni-leipzig.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9647.c</gridId>
    <rorId>https://ror.org/03s7gtk40</rorId>
  </sponsor>
  <funder id="Funder13519-0">
    <name>Self-funded by the Department of Anaesthesiology and Intensive Care Medicine and by the Committee of Clinical Innovation of the University of Leipzig (Germany).</name>
    <fundRef/>
  </funder>
  <funder id="Funder13519-1">
    <name>Supply of the study drugs free of charge by the manufacturers.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-20T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">58354123</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of cryoanalgesia on pain perception during infiltration of local anaesthetic agents: a randomised double blind controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does cryoanalgesia used prior to injection of local anaesthetic agent, reduce pain perception during inflitration of the agents?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Level of pain perception during infiltration of local anaesthetic agents and the operative procedure</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58354123</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0515154546</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3987f7f0-117f-4013-84d4-eb02aa9749b8">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Harrow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>HA1 3UJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients coming for hernia repairs under local anaesthetic in 'One-Stop Hernia Clinic' at ACAD will be requested to enter into trial on the day of arrival. Patient will be give complete information regarding the trial and will be explained that they are free no to enter if the so wish. Approximately 50 patients in each group.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Signs and Symptoms: Pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients from one-stop hernia clinic will be given the research protocol information sheet on arrival (i.e. one hour prior to surgery). Surgeons will explain the research and the operation and obtain an informed consent, for both the operation and entry into the trial. Surgeons will answer any and every patient query regarding the trial and the operation. Patients will have the right to withdraw from the trial at any point without explanation. Patients will be randomised alternately into:
1. The control group 
2. The trial group</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17567343 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e8bc8ef4-b09f-4005-b663-9b86969043ac" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17567343"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14092-0</funderId>
      <contactId>Contact51716_14092</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51716_14092">
    <title>Mr</title>
    <forename>Raj</forename>
    <surname>Bhutiani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
North West London Hospitals NHS Trust
Northwick Park Hospital
Watford Road</address>
      <city>Harrow</city>
      <country>United Kingdom</country>
      <zip>HA1 3UJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14092-0">
    <name>North West London Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-09-28T00:00:00.000Z">38797445</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Early goal directed therapy following major surgery reduces complications and duration of hospital stay: a randomised, controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>That post-operative goal directed therapy reduces the incidence of complications following major general surgery</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of post-operative complications.</primaryOutcome>
      <secondaryOutcome>Mortality and duration of hospital stay.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38797445</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="20558d9b-bfd6-4d94-a86f-af0fc96fdc6e">
	  <name>Intensive Care Unit</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SW170QT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients aged 18 years or older presenting for major surgery expected to last more than one and a half hours were eligible for inclusion if one or more of the following criteria were satisfied before surgery:
1. Severe cardiac or respiratory illness resulting in severe functional limitation
2. Extensive surgery planned for carcinoma involving bowel anastamosis
3. Acute massive blood loss (greater than 2.5 l)
4. Aged over 70 years with moderate functional limitation of one or more organ systems
5. Septicaemia (positive blood cultures or septic focus)
6. Respiratory failure (partial pressure of oxygen in arterial blood [PaO2] less than 8 kPa on Fraction of inspired Oxygen [FiO2] greater than 0.4, i.e., PaO2 : FiO2 ratio less than 20 kPa or ventilation greater than 48 hours)
7. Acute abdominal catastrophe (e.g., pancreatitis, perforated viscous, gastro-intestinal bleed)
8. Acute renal failure (urea greater than or equal to 20 mmol/l, creatinine greater than 60 µmol/l)
9. Surgery for abdominal aortic aneurysm</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Refusal of consent
2. Pregnancy
3. Acute myocardial ischaemia prior to enrolment
4. Patients receiving palliative treatment only
5. Disseminated malignancy
6. Patients unlikely to survive more than 6 hours
7. Patients requiring intervention outside intensive care unit (ICU) within the first 6 hours following surgery
8. Patients on lithium therapy
9. Weight less than 40 kg</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major general surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Goal directed therapy protocol to achieve oxygen delivery index of 600 ml/min/m^2 compared to protocol designed to reflect standard care.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16356219 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1ef479b5-ef23-407a-badd-ff9402b688b7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16356219"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13596-0</funderId>
      <contactId>Contact51263_13596</contactId>
      <sponsorId>Sponsor49663</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51263_13596">
    <title>Dr</title>
    <forename>Rupert</forename>
    <surname>Pearse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Intensive Care Unit
1st Floor St James' Wing
St George's Hospital</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW170QT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)7718 910 440</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rupert.pearse@doctors.net.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49663">
    <organisation>St Georges Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Blackshaw Road</address>
      <city>London</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>SW17 0QT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.464688.0</gridId>
    <rorId>https://ror.org/0001ke483</rorId>
  </sponsor>
  <funder id="Funder13596-0">
    <name>The Intensive Care Research Fund managed by the St Georges Hospital charitable funds trustees (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-08-11T00:00:00.000Z">61546997</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial of a Lung-Open Ventilation Strategy in acute lung injury</title>
      <scientificTitle/>
      <acronym>LOVS</acronym>
      <studyHypothesis>The Lung Open Ventilation strategy may reduce mortality, other organ dysfunction, and the duration of mechanical ventilation, intensive care, and hospital stay.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Hospital Mortality</primaryOutcome>
      <secondaryOutcome>1. Mortality attributed to respiratory failure
2. Duration of respiratory failure and duration of mechanical failure
3. Evaluation of respiratory function during mechanical ventilation
4. Incidence of barotrauma
5. Non-respiratory organ dysfunction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Hamilton Health Sciences/McMaster University Research Ethics Board, 15/06/2004</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61546997</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00182195</clinicalTrialsGovNumber>
      <protocolSerialNumber>MCT-38141</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4fd5ebd5-b858-4f99-8a6a-8a33351f12c2">
	  <name>Clinical Epidemiology &amp; Biostatistics</name>
	  <address/>
	  <city>Hamilton, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>L8N 3Z5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Persons of either sex 18 years and older.
1. Invasive mechanical ventilation
2. Acute respiratory insufficiency (within past 28 days)
3. Bilateral infiltrates on frontal chest radiograph
4. Hypoxemia, defined as paO2/FiO2 less than or equal to 250, on any amount of Positive End-Expiratory Pressure (PEEP)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>980</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>980</totalTarget>
      <exclusion>1. Primary cause of respiratory failure is cardiac
2. Anticipated duration of mechanical ventilation &lt;48 hours, as judged by the intensivist
3. Inability to wean from other experimental ventilation strategies
4. Severe chronic respiratory disease
5. Neuromuscular disease that will result in prolonged need for mechanical ventilation
6. Conditions where hypercapnia-induced intracranial hypertension should be avoided
7. Morbid obesity (&gt;1 kg per cm body weight)
8. Pregnancy
9. Very unlikely to survive in the judgment of the investigator, and luck of commitment to life support
10. Malignancy or underlying irreversible condition with 6 month mortality greater than or equal to 50%
11. Greater than 48 hours elapsed since first eligible in study hospital
12. Current participation in competing trial
13. Lack of physician, patient or proxy consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Critically Ill Patients with Acute Lung Injury (ALI)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Acute lung injury (ALI)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control Ventilation Strategy (assist control; low tidal volume; low airway pressures; standard PEEP)
Experimental Lung Open Ventilation Strategy (pressure control; low tidal volumes; low airway pressures; high PEEP; recruitment maneuvers).

For further information, please contact Dr Meade at the address listed below or Dr Thomas Stewart at University of Toronto (tstewart@mtsinai.on.ca).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18270352 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4f995594-35de-4b90-a484-bf5d95991904" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-02-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18270352"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13359-0</funderId>
      <contactId>Contact50982_13359</contactId>
      <sponsorId>Sponsor49374</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50982_13359">
    <title>Dr</title>
    <forename>Maureen Ora</forename>
    <surname>Meade</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Epidemiology &amp; Biostatistics
McMaster University
Health Sciences Centre
Room 2C10
1200 Main Street West</address>
      <city>Hamilton, Ontario</city>
      <country>Canada</country>
      <zip>L8N 3Z5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 905 525 9140 (22900)</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">meadema@hhsc.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49374">
    <organisation>McMaster University (Canada)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1200 Main Street West</address>
      <city>Hamilton, Ontario</city>
      <country>Canada</country>
      <zip>L8N 3Z5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 905 525 9140</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">browna@mcmaster.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.25073.33</gridId>
    <rorId>https://ror.org/02fa3aq29</rorId>
  </sponsor>
  <funder id="Funder13359-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-38141)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-07-05T00:00:00.000Z">34957881</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparative evaluation of efficacy and safety of ophthalmic viscosurgical devices in phacoemulsification</title>
      <scientificTitle/>
      <acronym>Ophthalmic viscosurgical devices</acronym>
      <studyHypothesis>To compare the efficacy and safety of three ophthalmic viscosurgical devices that are routinely used in phacoemulsification.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The safety and efficacy of the three viscosurgical devices namely Viscoat®, Healon GV® and Healon 5® in performing phacoemulsification is comparable.</primaryOutcome>
      <secondaryOutcome>Viscoat® can result in a mild transient rise in the intraocular pressure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34957881</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-27T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c8ba12ec-bfbd-42f2-8ea6-b921dc9e6e11">
	  <name>R. P. Centre</name>
	  <address/>
	  <city>New Delhi</city>
	  <state/>
	  <country>India</country>
	  <zip>110029</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. More than 40 years of age
2. Senile cataract
3. Nucleus hardness of grade 3/4
4. Not having any evidence of subluxation or pseudoexfoliation 
5. Not having any other associated ocular pathology</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>56</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>56</totalTarget>
      <exclusion>Pre-existing glaucoma and intraoperative events like manual dilatation of pupil, posterior capsular rent and placement of intraocular lens (IOL) in the sulcus</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-27T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Senile Cataract</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Cataract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparing three viscosurgical devices namely Viscoat®, Healon GV® and Healon 5® in performing phacoemulsification.</description>
	<interventionType>Device</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16018819 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="07c75413-c31a-4ab6-a998-89645d3ccb29" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16018819"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13167-0</funderId>
      <contactId>Contact50732_13167</contactId>
      <sponsorId>Sponsor49118</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50732_13167">
    <title>Prof</title>
    <forename>Rasik</forename>
    <surname>Vajpayee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>R. P. Centre
AIIMS
Ansari Nagar</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49118">
    <organisation>All India Institute of Medical Sciences (AIIMS) (India) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>R. P. Centre
Ansari Nagar</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413618.9</gridId>
    <rorId>https://ror.org/02dwcqs71</rorId>
  </sponsor>
  <funder id="Funder13167-0">
    <name>All India Institute of Medical Sciences (AIIMS) (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-07-04T00:00:00.000Z">19227688</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Folate Activity Cognition Trial</title>
      <scientificTitle>The effects of physical activity and vitamin B supplementation on cognitive functioning and psychosocial health of older persons with mild cognitive impairment</scientificTitle>
      <acronym>FACT</acronym>
      <studyHypothesis>The aim of the study is to examine the effects of a walking programme and/or Folic Acid/B12/B6 supplementation on cognitive functioning and psychosocial health of older persons with mild cognitive impairment (MCI).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cognitive functioning.</primaryOutcome>
      <secondaryOutcome>1. Psychosocial health status
2. Physical activity
3. Physical fitness
4. Serum homocysteine levels</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the VU University Medical Center Medical Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19227688</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3cd1a040-b74b-47f7-91e4-7b529f5a9bd2">
	  <name>van der Boechorststraat 7</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. People aged 70 years or older 
2. MCI according to the criteria of Petersen:
2.1. Memory complaint
2.2. Objective memory impairment
2.3. Normal general cognitive function
2.4. Intact activities of daily living
2.5. Not demented
3. Recruited from the community</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>185</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>185</totalTarget>
      <exclusion>1. Diseases interfering with cognition 
2. Unable to participate in moderate-intensity physical activity</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild cognitive impairment (MCI)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Mild cognitive impairment (MCI)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Twice weekly brisk walking in a group at moderate intensity and/or daily supplementation with Folic Acid, vitamin B12 and B6.

Non-supplement groups receive a placebo supplement; non-walking groups will do stretching and relaxation exercises.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Folic Acid, vitamin B12 and B6 supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/16375760 Protocol
2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18308888 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9fab1da8-1f70-4514-8343-e5fd3e2faac6" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2005-12-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16375760"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="91b1d0dd-4142-44e0-abd9-7f6b92bec2b7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18308888"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13114-0</funderId>
      <funderId>Funder13114-1</funderId>
      <funderId>Funder13114-2</funderId>
      <funderId>Funder13114-3</funderId>
      <funderId>Funder13114-4</funderId>
      <contactId>Contact50653_13114</contactId>
      <sponsorId>Sponsor49037</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50653_13114">
    <title>Dr</title>
    <forename>Marijke Jeanette Maidy</forename>
    <surname>Chin A Paw</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 4448203</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.chinapaw@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49037">
    <organisation>Research Center on Physical Activity, Work and Health (The Netherlands)</organisation>
    <website>http://www.bodyatwork.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>TNO-VUmc  - Body@Work
van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 8206</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.vanderleden@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13114-0">
    <name>Body@Work (The Netherlands) - Research Center Physical Activity, Work and Health</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-1">
    <name>The Netherlands Organisation for Applied Scientific Research (TNO) (The Netherlands) -VU University Medical Center (VUMC)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-2">
    <name>Fund for the Heart (Fonds voor het Hart) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-3">
    <name>Viatris B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-4">
    <name>Municipality of Alkmaar (Gemeente Alkmaar) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-06-15T00:00:00.000Z">41383109</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Scottish Childhood Obesity Treatment Trial</title>
      <scientificTitle/>
      <acronym>SCOTT</acronym>
      <studyHypothesis>To test whether a novel (intensive and behavioural) dietetic intervention for childhood obesity was more successful than standard care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body mass index (BMI) standard deviation score.

Outcomes measured at baseline, +6 months after start of intervention and +12 months after start of intervention.</primaryOutcome>
      <secondaryOutcome>1. Objectively measured habitual physical activity and sedentary behaviour (accelerometry)
2. Waist circumference standard deviation score
3. Quality of life

Outcomes measured at baseline, +6 months after start of intervention and +12 months after start of intervention.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41383109</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cdfce78c-332e-44b1-9f3c-bd56b94e5164">
	  <name>Reader in Paediatric Energy Metabolism</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G3 8SJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Obese (body mass index [BMI] greater than 98th percentile) children of primary school age (5 - 11 years at baseline), referred for treatment for their obesity.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="5.0"/>
      <upperAgeLimit unit="Years" value="11.0"/>
      <gender>Both</gender>
      <targetEnrolment>134</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>134</totalTarget>
      <exclusion>1. Non obese
2. Family apparently not willing to attempt lifestyle changes
3. Having special educational needs
4. Receiving treatment for obesity elsewhere</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 
Intensive behavioural approach to treatment (eight appointments over six months; 5 - 6 hours patient/family contact time).

Control: 
Standard dietetic care (1 - 1.5 hours patient/family contact time over six months).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18310175 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="377f8a90-d896-4db8-b913-3fb67838ba21" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18310175"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13024-0</funderId>
      <contactId>Contact50554_13024</contactId>
      <sponsorId>Sponsor48933</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50554_13024">
    <title>Dr</title>
    <forename>John J</forename>
    <surname>Reilly</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Reader in Paediatric Energy Metabolism
University of Glasgow Division of Developmental Medicine
1st Floor Tower Block QMH
Yorkhill Hospitals</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G3 8SJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jjr2y@clinmed.gla.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48933">
    <organisation>Yorkhill Hospitals NHS Trust (UK)</organisation>
    <website>http://www.nhsggc.org.uk/content/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Yorkhill</address>
      <city>Glasgow</city>
      <state>Scotland</state>
      <country>United Kingdom</country>
      <zip>G3 8SJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Morlet.Meinertz@yorkhill.scot.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13024-0">
    <name>Chief Scientist Office of the Scottish Executive Health Department (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">73698240</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre field trial of ofloxacin-containing Multidrug Therapy (MDT) in leprosy (Philippines)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73698240</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>920335</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Philippines</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4160aded-c599-4285-8bb9-b16a8607ac94">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients suspected of leprosy without previous treatments with MDT or ofloxacin in dermatological consultation and referred to the Leprosy Unit.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. Patients with provincial addresses, temporary addresses and temporary works
2. Patients not residing in targeted areas for the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Leprosy</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Leprosy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Therapeutic efficacy of new MDT regimen containing Ofloxacin, in comparison with the standard World Health Organization (WHO)/MDT regimen among paucibacillary (PB) and multibacillary (MB) leprosy patients.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ofloxacin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12973-0</funderId>
      <contactId>Contact50496_12973</contactId>
      <sponsorId>Sponsor48874</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50496_12973">
    <title>Dr</title>
    <forename>V.E.</forename>
    <surname>Pannikar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pannikerv@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48874">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12973-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">88133880</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase I clinical trial to evaluate the safety and immunogenicity of aluminium hydroxide precipitated autoclaved Leishmania major (Alum-ALM) + Bacillus Calmette-Guerin (BCG) combined with sodium stibo-gluconate (SSG) compared with SSG alone in the treatment of post kala azar dermal leishmaniasis (Sudan)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88133880</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A30468</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sudan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f6f2e05f-735a-405d-b022-707dceaf82d6">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males and females 7 - 60 years
2. Skin rash of greater than six months duration following a history of successful treatment for Visceral Leishmaniasis (VL)
3. Absence of other skin conditions
4. Positive Direct Agglutination Rest (DAT) or rk39
5. Willing for hospitalisation at Khartoum for 90 days
6. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Pregnant or lactating women
2. Concurrent/chronic illness
3. Known allergy to vaccine components
4. Other allergies requiring steroids and Levamisole
5. Known immunological deficiency-including human immunodeficiency virus (HIV)
6. Concurrent participation in any other drug or vaccine trial
7. Known or planned vaccination within one month prior to study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dermal leishmaniasis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Dermal leishmaniasis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Alum-ALM and BCG combined with sodium stibo-gluconate (SSG)
Control group: Sodium stibo-gluconate (SSG)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>Aluminium hydroxide precipitated autoclaved Leishmania major (Alum-ALM) + Bacillus Calmette-Guerin (BCG) + sodium stibo-gluconate (SSG)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12976-0</funderId>
      <contactId>Contact50499_12976</contactId>
      <sponsorId>Sponsor48877</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50499_12976">
    <title>Dr</title>
    <forename>S</forename>
    <surname>Naozin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">naozins@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48877">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12976-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">48141450</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of World Health Organisation (WHO) cardiovascular disease (CVD)-risk management package - scenario one (Sri Lanka)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48141450</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC050</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-07T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sri Lanka</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5fd0eb71-2960-48c5-a0d9-c4cd6a21fff6">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 30 - 70 years
2. Currently not under treatment for hypertension
3. Systolic blood pressure between 140 and 179 mmHg measured twice with a 5 to 10 minute interval
4. Informed consent given</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. Pregnancy
2. Trauma (injury) as presenting complaint
3. Renal diseases: nephropathy, renal artery stenosis
4. Endocrinological (hormonal) disorders: phaechromocytoma, Cushing syndrome, Conn syndrome, acromegaly
5. Coarctation of the aorta
6. Use of steroids and/or non-steroidal anti-inflammatories (NSAIs)
7. All acute conditions presenting with bleeding, pain, diarrhoea, vomiting, breathing disorders and circulatory disorders
8. Inability to comply with the follow-up requirements
9. Inability to provide informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-07T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>20 primary health care facilities.
10 facilities to apply the study protocol based on Scenario One of the WHO CVD-Risk Management Package (intervention sites).
Other 10 to continue with conventional treatment or usual care (control sites).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12983-0</funderId>
      <contactId>Contact50506_12983</contactId>
      <sponsorId>Sponsor48884</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50506_12983">
    <title>Dr</title>
    <forename>S</forename>
    <surname>Mendis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mendiss@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48884">
    <organisation>The Department of Cardiovascular Diseases (CVD)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12983-0">
    <name>The Department of Cardiovascular Diseases (CVD)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">13670619</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparative study of the bactericidal and sterilising activity of three fluoroquinolones: gatifloxacin, moxifloxacin and ofloxacin substituted for ethambutol in the two month initial phase of the standard anti-tuberculosis treatment regimen also containing rifampicin, isoniazid and pyrazinamide (South Africa)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13670619</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC078</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-25T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9eb2f0ba-8eb1-4516-924d-aaec5b05457c">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male/female of 18-65 years
2. Weight 38-80 kg
3. Recently microscopically diagnosed pulmonary TB
4. Findings in medical history and physical examination not exceeding grade 2
5. Voluntarily signed informed consent
6. Confirmed negative pregnancy test at the screening visit
7. Willing to use effective contraceptive methods during treatment
8. Normal lab values not exceeding grade 2, except haemoglobin &lt;6.5 g/dl and potassium &lt;3.0 mEq/l (&gt;grade 1)
9. Consent for a pre-screening biological test to exclude possible Multi Drug Resistant (MDR) TB and Negative MDR TB screen test will be a check if pre-screening biological test is done</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="65.0"/>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. History of TB within the last 3 years
2. Concomitant infection requiring additional anti-infectious treatment (especially anti-retroviral medication [ARV])
3. Human immunodeficiency virus (HIV) infected patients at World Health Organisation (WHO) stage 4
4. Diabetes mellitus or non insulin dependent diabetes mellitus requiring treatment
5. Drug and alcohol abuse
6. History of drug hypersensitivity and/or active allergic disease
7. Impaired renal, hepatic or gastric function that may interfere with drug absorption, distribution, metabolism or elimination</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-25T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis (TB)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control
Regimen 1: Standard TB treatment (isoniazid, rifampicin, pyrazinamide and ethambutol)

Interventions
Regimen 2: Isoniazid, rifampicin, pyrazinamide and gatifloxacin
Regimen 3: Isoniazid, rifampicin, pyrazinamide and ofloxacin
Regimen 4: Isoniazid, rifampicin, pyrazinamide and moxifloxacin</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Gatifloxacin, moxifloxacin and ofloxacin, ethambutol, rifampicin, isoniazid and pyrazinamide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12986-0</funderId>
      <contactId>Contact50511_12986</contactId>
      <sponsorId>Sponsor48888</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50511_12986">
    <title>Dr</title>
    <forename>T</forename>
    <surname>Kanyok</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kanyokt@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48888">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12986-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-20T00:00:00.000Z">56720616</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Glucose-insulin-potassium infusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction</title>
      <scientificTitle/>
      <acronym>Glucose-Insulin-Potassium Study (GIPS)</acronym>
      <studyHypothesis>In this study we considered the question of whether adjunction of glucose-insulin-potassium (GIK) infusion to primary coronary transluminal angioplasty (PTCA) is effective in patients with an acute myocardial infarction (MI).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>30-day mortality</primaryOutcome>
      <secondaryOutcome>Recurrent infarction, repeat coronary angioplasty, and the composite incidence of death, recurrent infarction, or repeat coronary angioplasty.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN56720616</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>99.028</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4028f48b-ff9a-48f4-8bb9-279c40bbe0ac">
	  <name>Hanzeplein 1</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>30.001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All consecutive patients with symptoms consistent with acute MI of &gt;30 min duration, presenting within 24 hours after the onset of symptoms and with an ST-segment elevation of more than 1 mm (0.1 mV) in two or more contiguous leads on the electrocardiogram, or new onset left bundle branch block, were evaluated for inclusion in this single-center study. Patients presented at our center and patients referred for treatment of high-risk myocardial infarction (MI) from nine referring hospitals without angioplasty facilities were included.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>940</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>940</totalTarget>
      <exclusion>Patients were excluded when pre-treated with thrombolysis or when an illness associated with a marked restricted life expectancy was present.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>ST elevation myocardial infarction (mi)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Acute myocardial infarction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After admission, patients were randomly assigned to either glucose-insulin-potassium (GIK) infusion or no infusion. In patients randomized to GIK, a continuous infusion of 80 mmol potassium chloride in 500 ml 20% glucose with a rate of 3 ml/kg body weight/hour over an 8- to 12-hour period in a peripheral venous line was given, as soon as possible. A continuous infusion of short-acting insulin (50 U Actrapid) in 50 ml 0.9% sodiumchloride was started. Baseline insulin-infusion dose and hourly adjustments of the insulin dose were based on an algorithm to obtain blood-glucose levels between 7.0 and 11.0 mmol/l.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>glucose-insulin-potassium</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15932638 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0b4ff9e7-aa06-4e1a-86f4-5f65db4964a6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-06-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15932638"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13099-0</funderId>
      <contactId>Contact50636_13099</contactId>
      <sponsorId>Sponsor49020</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50636_13099">
    <title>Prof</title>
    <forename>Felix</forename>
    <surname>Zijlstra</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>30.001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)503612355</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.zijlstra@thorax.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49020">
    <organisation>Netherlands Heart Foundation (Netherlands)</organisation>
    <website>http://www.hartstichting.nl/go/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Bordewijklaan 3</address>
      <city>The Hague</city>
      <country>Netherlands</country>
      <zip>300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)703155555</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@hartstichting.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453051.6</gridId>
    <rorId>https://ror.org/05nxhgm70</rorId>
  </sponsor>
  <funder id="Funder13099-0">
    <name>Netherlands Heart Foundation (99.028)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-05-16T00:00:00.000Z">74123635</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>TTT plus intravitreous triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Preservation of visual acuity</primaryOutcome>
      <secondaryOutcome>Closure of CNV, OCT characteristics</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74123635</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Chile</country>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="71d49342-40fa-4991-b23e-59e0d9725f3c">
	  <name>Exequiel Fernández nº 920</name>
	  <address/>
	  <city>Santiago</city>
	  <state/>
	  <country>Chile</country>
	  <zip/>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Age-Related Macular Degeneration (ARMD) not available for current therapies</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Age-Related Macular Degeneration (ARMD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triamcinolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16309554 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ab1f915e-6d6b-4c40-bd5a-28e03b62b859" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-11-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16309554"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13065-0</funderId>
      <contactId>Contact50598_13065</contactId>
      <sponsorId>Sponsor48981</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50598_13065">
    <title>Dr</title>
    <forename>Ricardo</forename>
    <surname>Agurto-Rivera</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Exequiel Fernández nº 920
Casa F
Ñuñoa</address>
      <city>Santiago</city>
      <country>Chile</country>
      <zip/>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+56 8 5021968</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ricardo_agurto@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48981">
    <organisation>Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Vicente García Torres Nº 46
Barrio San Lucas
Del Coyoacán</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>04030</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 10841400</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">retinamex@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.464508.b</gridId>
    <rorId>https://ror.org/03sgfhr82</rorId>
  </sponsor>
  <funder id="Funder13065-0">
    <name>Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-05-16T00:00:00.000Z">18216584</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A preference trial with rizatriptan 10 mg and ibuprofen 400 mg in migraine patients in the general practice</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Patients prefer rizatriptan over ibuprofen for the acute treatment of migraine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Direction and strength of patient preference on a 10 cm scale ranging from -5 (strong preference for treatment 1) to +5 (strong preference for treatment 2) where 0 indicates no preference.</primaryOutcome>
      <secondaryOutcome>1. Pain free rate at 2 hours postdose
2. Migraine disability assessment (MIDAS) score at visit 1</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local Medical Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18216584</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NTR33</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, double dummy, crossover study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-09T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="27ce756e-0451-4ad2-8806-e6c84d21179c">
	  <name>Leiden University Medical Center</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. At least 18 years of age at visit 1
2. Current history of migraine with or without aura according to the International Headache Society (IHS) criteria
3. Experienced an average of at least one migraine attack per month for six months prior to entry to the study
4. Naïve to the use of 5HT1 agonists and ergotamine
5. Willing and able to understand and complete questionnaires
6. Willing and able to give informed consent prior to entry into the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>35</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>35</totalTarget>
      <exclusion>1. A history suggestive of ischaemic heart disease (IHD) (e.g. angina pectoris) or any atherosclerotic disease which places them at increased risk of coronary ischaemia
2. A history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA)
3. A history of hypertension or a current blood pressure above 160/95 mmHg (measured three times)
4. A history of basilar, hemiplegic or ophtalmoplegic migraine
5. Impaired hepatic or renal function
6. A history of gastrointestinal disease
7. A history of asthma
8. Have a known or suspected hypersensitivity to, intolerance of, or contraindications to any component of the study medication
9. Currently use propanolol as a prophylactic agent
10. Currently use monoamine oxidase (MAO) inhibitors
11. Currently abuse alcohol, analgesics or psychotropic drugs
12. A history of hypertension
13. Any severe concurrent medical condition, which may affect the interpretation in a clinical trial
14. Females who are pregnant or breastfeeding, and females of childbearing potential who are not using a medically acceptable form of contraception
15. Have participated in a clinical trial within the previous month or are currently participating in any other clinical research study or clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-09T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Migraine</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Thirty-five triptan naive patients treat three attacks within each crossover period with either:
1. Rizatriptan 10 mg
2. Ibuprofen 400 mg

Preference is measured after the second period on a 10 cm scale.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rizatriptan, ibuprofen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13094-0</funderId>
      <funderId>Funder13094-1</funderId>
      <contactId>Contact50632_13094</contactId>
      <sponsorId>Sponsor49015</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50632_13094">
    <title>Dr</title>
    <forename>N.J.</forename>
    <surname>Wiendels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center
Department of Neurology, K5Q-106
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 526 1730</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">N.J.Wiendels@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49015">
    <organisation>Merck Sharp and Dohme BV (MSD) (The Netherlands)</organisation>
    <website>http://www.msd.nl/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 581</address>
      <city>Haarlem</city>
      <country>Netherlands</country>
      <zip>2003 PC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)23 515 3153</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">msdbvnl@merck.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420097.8</gridId>
    <rorId>https://ror.org/05y28vr04</rorId>
  </sponsor>
  <funder id="Funder13094-0">
    <name>Merck Sharp and Dohme BV (MSD) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13094-1">
    <name>Booth Healthcare International (The Netherlands) - now Reckittbenckiser</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-10T00:00:00.000Z">14751911</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee: a randomised controlled study</title>
      <scientificTitle/>
      <acronym>Knee study</acronym>
      <studyHypothesis>The study was designed to investigate the analgesic effects and mechanisms of acetaminophen (paracetamol) in symptomatic osteoarthritis (OA) of the knee.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The functional status of the knee joint was assessed by the Western Ontario McMaster Universities Osteoarthritis (WOMAC) questionnaire in German. Visits and measurements were scheduled upon entry (T0), month 1 (T1) and month 3 (T3).</primaryOutcome>
      <secondaryOutcome>The intensity of joint pain was evaluated by 100-mm visual analogue scale (VAS) at rest. Visits and measurements were scheduled upon entry (T0), month 1 (T1) and month 3 (T3).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local ethical committee (Kantonale Ethikkommission, Spezialisierte Unterkommission fur Spezialfa cher) (ref: 343)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14751911</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f1f0ea77-ae50-4e48-8d57-d18ca02c8d8c">
	  <name>Department of Rheumatology and Institute of Physical Medicine</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>8091</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients and healthy subjects: 20 patients fulfilled the American College of Rheumatology criteria for knee OA accompanied with joint pain (visual analogue scale [VAS] ≥60) were recruited to the study. For control, blood from 20 age and gender-matched healthy subjects was obtained from a local blood bank, the Blutspenderdienst Zürich. All patients signed the informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Secondary OA as a consequence of inflammation, gout, pseudogout or tumour
2. Kidney insufficiency 
3. OA-influencing concomitant diseases
4. Drug medication with opioids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After washout of earlier OA medications, patients were randomly allocated into two groups treated with either acetaminophen up to 4 g per day (n = 10, age 60-77 years) or rofecoxib 25 mg per day (n = 10, age 48-80 years) for 3 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Acetaminophen (paracetamol), rofecoxib</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16449370 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="60e83253-e59a-48c1-841c-129ea23c16aa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16449370"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13063-0</funderId>
      <funderId>Funder13063-1</funderId>
      <contactId>Contact50596_13063</contactId>
      <sponsorId>Sponsor48979</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50596_13063">
    <title>Dr</title>
    <forename>Haiko</forename>
    <surname>Sprott</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology and Institute of Physical Medicine
University Hospital Zurich
Gloriastrasse 25</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>8091</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)44 2558679</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">haiko.sprott@usz.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48979">
    <organisation>Merck Sharp and Dohme (MSD) (Switzerland)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Schaffhauserstrasse 136</address>
      <city>Glattbrugg</city>
      <country>Switzerland</country>
      <zip>8152</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)1 8287111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">claude_fischlewitz@merck.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.474492.8</gridId>
    <rorId>https://ror.org/009nc9s30</rorId>
  </sponsor>
  <funder id="Funder13063-0">
    <name>Merck Sharp and Dohme (MSD) (Switzerland) - gave a Medical School Grant in 2001 to perform the study, and provided the drug Vioxx (rofecoxib). The acetaminophen drugs and the other research costs were paid for from the grant.</name>
    <fundRef/>
  </funder>
  <funder id="Funder13063-1">
    <name>University Hospital Zurich (Switzerland) - provided the infrastructure</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-09T00:00:00.000Z">65784760</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The N-methyl-D-aspartate (NMDA)-antagonist memantine affects training induced motor cortex plasticity: a study using transcranial magnetic stimulation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Training of a repetitive synchronised movement of two limb muscles leads to short-term plastic changes in the primary motor cortex, which can be assessed by transcranial magnetic stimulation (TMS) mapping.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The differential effects of different treatment regimens.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65784760</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d41b3459-55cf-4d45-beb2-2e1c3b347b0f">
	  <name>Department of Neurology</name>
	  <address/>
	  <city>Bochum</city>
	  <state/>
	  <country>Germany</country>
	  <zip>44789</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy subjects (adults, either sex)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Left-handedness
2. Neurological disorders
3. Intake of central acting drugs</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Training induced motor cortex plasticity</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Memantine versus placebo either given as a single dose or daily over 8 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Memantine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15890074 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2579bdb5-216d-400c-b1d8-645495a47e5b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15890074"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13058-0</funderId>
      <funderId>Funder13058-1</funderId>
      <contactId>Contact50591_13058</contactId>
      <sponsorId>Sponsor48974</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50591_13058">
    <title>Prof</title>
    <forename>Martin</forename>
    <surname>Tegenthoff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Neurology
BG-Kliniken Bergmannsheil
Buerkle-de-la-Camp-Platz 1</address>
      <city>Bochum</city>
      <country>Germany</country>
      <zip>44789</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48974">
    <organisation>BG-Kliniken Bergmannsheil (Germany) - Department of Neurology</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Buerkle-de-la-Camp-Platz 1</address>
      <city>Bochum</city>
      <country>Germany</country>
      <zip>44789</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412471.5</gridId>
    <rorId>https://ror.org/04j9bvy88</rorId>
  </sponsor>
  <funder id="Funder13058-0">
    <name>BG-Kliniken Bergmannsheil (Germany) - Department of Neurology; main funders</name>
    <fundRef/>
  </funder>
  <funder id="Funder13058-1">
    <name>Merz Pharmaceuticals GmbH (Germany) - funded the measurement of the memantine serum levels</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-05-09T00:00:00.000Z">68505294</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of moderate red wine consumption on antioxidant and redox-sensitive immunological parameters in healthy volunteers</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Moderate consumption of red wine shows antioxidant activity in vivo and modulates functions of the specific and unspecific immune response. The effects of native and dealcoholised red wine are compared to control intervention (short term: water; dietary intervention: no study drink).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Concentration of total phenolic compounds in plasma (folin assay)
2. Deoxyribonucleic acid (DNA) strand breaks in peripheral leukocytes (single cell gel electrophoresis)
3. Antioxidant capacity in plasma (trolox equivalent antioxidant capacity)
4. Apoptosis of PHA activated T lymphocytes (annexin-V binding test)
5. Phagocytosis in monocytes and granulocytes (Phagotest® test kit)
6. Respiratory burst in monocytes and granulocytes (Bursttest® test kit)</primaryOutcome>
      <secondaryOutcome>1. Vitamin C concentration in plasma a-tocopherol concentration in serum (dietary intervention trial only)
2. Concentration of uric acid, albumin and bilirubin in plasma</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ethics committee of the University of Bonn.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68505294</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="57757722-075d-4002-9711-7e89d8e3182c">
	  <name>Institute for Molecular Biotechnology</name>
	  <address/>
	  <city>Aachen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>52074</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy, normal-weight male and female subjects between 18 and 50 years of age.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>105</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>105</totalTarget>
      <exclusion>1. Pregnancy and lactation: women not taking oral contraceptives underwent a pregnancy test to exclude an unknown pregnancy before starting the intervention
2. Known diseases of the liver and pancreas or dysfunctions of the gastro-intestinal tract associated with maldigestion or malabsorption
3. Hypertension
4. Dysfunctions of the lipid metabolism
5. Hyperuricaemia/gout
6. Kidney dysfunctions
7. Autoimmune diseases
8. Diabetes mellitus type I or type II
9. Acute infectious diseases
10. Eating disorders
11. Allergy to hen's eggs (albumen used as finings in red wine)
12. Alcohol abuse (more than 40 g/day) or previous addiction to alcohol
13. Drug abuse
14. Tobacco smoking during the last 6 months prior to the study
15. Regular intake of pharmaceuticals, which influence the immune system and/or the antioxidant capacity in plasma (anti-inflammatory drugs including cortisol containing medications, immune stimulants) as well as intake of drugs which might cause adverse affects by interacts with alcohol
16. Intake of nutritional supplements e.g. multivitamins, supplements containing vitamin A, C and/or vitamin E, fish oil or red wine preparations, bioactive concentrates
17. Excessive exercising (competitive athletes) defined as greater than 10 hours strenous exercise per week
18. Limited contractual capability
19. Every other state opposed to participation in the study stated by the medical supervisor
20. Participation in any other clinical trial (ongoing or completed less than 30 days prior to the present study)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Oxidative stress in healthy subjects</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. One single dose (one glass) of red wine, dealcoholised red wine or water in a fasting state (Single dose analysis) OR
2. One glass of red wine, dealcoholised red wine or no special drink (controls) daily after dinner for a period of 6 weeks (dietary intervention trial)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16287499 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c18facfa-511b-4f88-a3c0-8b7e75ee98b1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-11-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16287499"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13022-0</funderId>
      <funderId>Funder13022-1</funderId>
      <funderId>Funder13022-2</funderId>
      <funderId>Funder13022-3</funderId>
      <contactId>Contact50552_13022</contactId>
      <sponsorId>Sponsor48931</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50552_13022">
    <title>Prof</title>
    <forename>Roland</forename>
    <surname>Goerlich</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Molecular Biotechnology
RWTH Aachen University
Worringerweg 1</address>
      <city>Aachen</city>
      <country>Germany</country>
      <zip>52074</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)241 8026627</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">goerlich@molbiotech.rwth-aachen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48931">
    <organisation>Institute for Molecular Biotechnology (Germany)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>RWTH Aachen University
Worringerweg 1</address>
      <city>Aachen</city>
      <country>Germany</country>
      <zip>52074</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder13022-0">
    <name>German Wine Academy (Deutsche Weinakademie) (Germany) - Funding</name>
    <fundRef/>
  </funder>
  <funder id="Funder13022-1">
    <name>Landesgraduiertenfoerderung Nordrheinwestfalen (Germany) - Scholarship</name>
    <fundRef/>
  </funder>
  <funder id="Funder13022-2">
    <name>Friedrich-Ebert-Stiftung (Germany) - Scholarship</name>
    <fundRef/>
  </funder>
  <funder id="Funder13022-3">
    <name>Staatliche Weinbaudomaene Marienthal (Germany) - Wine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-05-06T00:00:00.000Z">34467885</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Using the Internet to Improve Hypertension Care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Access to the website would decrease patient satisfaction with hypertension care</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Satisfaction with hypertension care</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34467885</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>R43HL074458-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0200a319-6d26-45e1-a44c-e4deb128f9bc">
	  <name>Jefferson Medical College</name>
	  <address/>
	  <city>Philadelphia</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>19107</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adults with self-reported hypertension.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: A patient activation website that provides computer-tailored hypertension feedback. The website asks questions and provides feedback that highlights areas where their care adheres to guidelines and areas where their care does not, and encourages patients to ask questions during doctor visits that would lead to changes in their hypertension care. The feedback is based on standard guidelines for the treatment of hypertension and the feedback suggests specific questions that patients should ask during doctor visits, in order to receive higher quality care.

Control: A delayed treatment control. Control subjects got access to the website after completing the follow-up measures.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder13052-0</funderId>
      <contactId>Contact50584_13052</contactId>
      <sponsorId>Sponsor48965</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50584_13052">
    <title>Dr</title>
    <forename>Christopher</forename>
    <surname>Sciamanna</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Jefferson Medical College
Department of Health Policy
1015 Walnut Street, Suite 115</address>
      <city>Philadelphia</city>
      <country>United States of America</country>
      <zip>19107</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48965">
    <organisation>The National Heart, Lung, and Blood Institute (USA) </organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>NHLBI Health Information Center
P.O. Box 30105</address>
      <city>Bethesda</city>
      <country>United States of America</country>
      <zip>20824-0105</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.279885.9</gridId>
    <rorId>https://ror.org/012pb6c26</rorId>
  </sponsor>
  <funder id="Funder13052-0">
    <name>The National Heart, Lung, and Blood Institute (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-03T00:00:00.000Z">74938765</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Increasing weight-bearing physical activity and calcium-rich foods to promote bone mass gains among 9-11 year old girls: the Cal Girls study</title>
      <scientificTitle/>
      <acronym>Cal Girls</acronym>
      <studyHypothesis>It was hypothesised that the behavioural intervention would result in increases in dietary Calcium (Ca) intake and weight-bearing physical activity (PA), and in the rate of bone mass accrual. Innovative aspects of the present study included:
1. Its focus on changing eating and PA behaviors to increase bone mass growth
2. Its focus on pre-adolescent girls, a group at risk for declines in Ca intake and PA levels as they develop into adolescence
3. Its unique collaboration with a community-based organisation (the Girl Scouts of America) as a channel to implement a health behaviour intervention</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change in areal bone mineral content (aBMC) was the primary outcome variable for the study because it best reflects bone mass change in developing children.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was reviewed and approved by the University of Minnesota Research Participants Internal Review Board.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74938765</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>R01 HD 037743</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d6f180e3-eefc-41eb-923f-0c19594eefe4">
	  <name>Division of Epidemiology</name>
	  <address/>
	  <city>Minneapolis</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>55454</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>30 5th-grade Girl Scout troops from the Minneapolis and St Paul metropolitan area were recruited to take part in the study through mailed fliers to troop leaders and troop leader meeting announcements. Troop eligibility criteria were:
1. Troop size greater than or equal to 8 girls
2. Parental consent and girl assent from each troop member to participate in troop meetings with intervention program activities
3. Troop plans to remain together at minimum two more years</inclusion>
      <ageRange>Child</ageRange>
      <gender>Female</gender>
      <targetEnrolment>322</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>322</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoporosis prevention</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoporosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Thirty 5th-grade Girl Scout troops were recruited and randomised to a two-year behavioural intervention program (n = 15 troops) or to a no-treatment control group (n = 15 troops). The behavioural program was implemented during 5th and 6th grades by trained troop leaders as part of the regular troop meetings. The intervention program was based on Social Cognitive Theory and consisted of ten 90-minute activity-based sessions during each of the two years. It focused on the development of behavioural skills to choose Ca-rich foods and to engage in weight-bearing physical activity. Behavioural goals for the intervention were to
increase daily dietary Ca intake to 1300 mg/day (increase of 4 daily servings of Ca rich foods; about 800 Ca mg/day) and to increase weight-bearing physical activity to 120 minutes per week. A continuously available, interactive web-based program, and a one-week summer camp between 5th and 6th grade years, were implemented as components of the intervention program. Parents were also targeted through the web-based program.

Control troops did not receive any program and conducted their usual troop meeting activities during the two-year intervention period.

Evaluation was conducted with individual girls and a parent at clinic visits at baseline prior to randomisation, at one-year follow-up, and at the end of the study (two year follow-up).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16029507 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f6593532-6cf3-463e-ab23-2da52ddb2666" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16029507"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13042-0</funderId>
      <contactId>Contact50573_13042</contactId>
      <sponsorId>Sponsor48953</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50573_13042">
    <title>Prof</title>
    <forename>Simone</forename>
    <surname>French</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Epidemiology
&amp; Community Health
1300 S 2nd St, #300</address>
      <city>Minneapolis</city>
      <country>United States of America</country>
      <zip>55454</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 612 626 8495</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">french@epi.umn.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48953">
    <organisation>University of Minnesota (USA)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Division of Epidemiology
&amp; Community Health
1300 S 2nd St, #300</address>
      <city>Minneapolis</city>
      <country>United States of America</country>
      <zip>55454</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 612 624 1818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">french@epi.umn.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.17635.36</gridId>
    <rorId>https://ror.org/017zqws13</rorId>
  </sponsor>
  <funder id="Funder13042-0">
    <name>National Insititutes of Health (NIH) (USA) (ref: R01 HD 037743)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-04-20T00:00:00.000Z">46561076</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of racemic epinephrine versus salbutamol for treatment of respiratory distress in bronchiolitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Aerosolised racemic epinephrine given to hospitalised children under two years of age with bronchiolitis is more effective than aerosolised salbutomol in relieving respiratory distress.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Wheezing and retractions measured by the Respiratory Distress Assessment Instrument each day during hospitalisation.</primaryOutcome>
      <secondaryOutcome>1. Length of stay
2. RSV antigen detection test
3. Feeding pattern
4. Adverse events
5. Parental report of feeding and respiratory status one week after discharge</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the Ethics Review Board at both participating institutions.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46561076</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="41006c83-d0b9-421b-b37c-45974e5ef0d1">
	  <name>5850 University Avenue</name>
	  <address/>
	  <city>Halifax, Nova Scotia</city>
	  <state/>
	  <country>Canada</country>
	  <zip>B3K 6R8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Children less than two years of age with first episode wheezing.</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="2.0"/>
      <gender>Both</gender>
      <targetEnrolment>62</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>62</totalTarget>
      <exclusion>Children were not eligible for enrollment if they:
1. Had a previous diagnosis of asthma
2. Were critically ill
3. Had chronic pulmonary or cardiac disease

Other exclusion criteria included: 
4. Allergy to sodium metabisulfite
5. Presence of tachycardia exceeding 200 beats per minute
6. Use of glucocorticoids
7. Sympathomimetic amines or monoamine oxidase inhibitor therapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bronchiolitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Bronchiolitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Racemic epinephrine or salbutamol.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Racemic epinephrine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15876347 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="29bd801c-8692-4bb9-9a6a-d9c1da545ed7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15876347"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13009-0</funderId>
      <funderId>Funder13009-1</funderId>
      <contactId>Contact50536_13009</contactId>
      <sponsorId>Sponsor48914</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50536_13009">
    <title>Dr</title>
    <forename>Joanne</forename>
    <surname>Langley</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>5850 University Avenue</address>
      <city>Halifax, Nova Scotia</city>
      <country>Canada</country>
      <zip>B3K 6R8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48914">
    <organisation>Lung Association of Nova Scotia (Canada)</organisation>
    <website>http://www.ns.lung.ca/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>17 Alma Crescent</address>
      <city>Halifax, Nova Scotia</city>
      <country>Canada</country>
      <zip>B3N 3E6</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder13009-0">
    <name>Lung Association of Nova Scotia (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13009-1">
    <name>IWK Health Center Research Office (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-04-19T00:00:00.000Z">77370654</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of the efficacy of pimecrolimus 1% cream and hydrocortisone 1% cream in facial seborrheic dermatitis: a single-blind randomized clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pimecrolimus 1% cream improves facial seborrheic dermatitis better than hydrocortisone 1% cream</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical response (erythema, pruritis, scaling) at 2, 4 and 6 weeks after treatment
2. Patient's general perception about treatment result 
3. Adverse events in each treatment group</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77370654</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0bd15087-5885-4149-860d-a9d8b21126d8">
	  <name>79 Taleghani Avenue</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>14166</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with facial seborrheic dermatitis older than 8 years.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Presence of active malignancy on the facial lesion
2. Presence of any kind of active viral skin disease on the facial lesion
3. Use of oral steroids in the past two weeks
4. Use of psoralen plus ultraviolet A (PUVA), ultraviolet B (UVB), ultraviolet A (UVA), azathioprine or cyclosporin in past month
5. Application of any topical treatment in past week 
6. Use of any systemic antibiotics or antifungals in past 2 weeks 
7. Attending in any other research study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seborrheic dermatitis</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Dermatitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: pimecrolimus 1% cream applied twice daily for 2 weeks
Group 2: hydrocortisone acetate 1% cream applied twice daily for 2 weeks</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pimecrolimus, hydrocortisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16924062 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5cc13c41-6e12-4f5e-87eb-fd16d546d581" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16924062"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12862-0</funderId>
      <contactId>Contact50356_12862</contactId>
      <sponsorId>Sponsor48725</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50356_12862">
    <title>Dr</title>
    <forename>Alireza</forename>
    <surname>Firooz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>79 Taleghani Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14166</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 21 8978190</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">firozali@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48725">
    <organisation>Tehran University of Medical Sciences (Iran) - Center for Research and Training in Skin Diseases and Leprosy </organisation>
    <website>http://www.tums.ac.ir/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>79 Taleghani Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14166</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder12862-0">
    <name>Tehran University of Medical Sciences (Iran) - Center for Research and Training in Skin Diseases and Leprosy</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-04-19T00:00:00.000Z">41671411</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Decreased salivary flow rate as a dipsogenic factor in haemodialysis patients: a pilocarpine clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We conducted a 3-month prospective observational study followed by a trial of pilocarpine - a parasympathomimetic agent shown to effectively increase salivary flow in radiation-induced xerostomia or Sjögren syndrome (27 - 30) - to determine whether the reduction of salivary flow contributes to exaggerated thirst and excess interdialytic weight gain (IDWG) in haemodialysis (HD) patients, and whether pilocarpine can alleviate it.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes were:
1. Changes in the visual analogue scale (VAS) scores of xerostomia, thirst, and stress of fluid restriction
2. Unstimulated salivary flow rate (UWS)
3. Mean IDWG2days and IDWG3days in each intervention period</primaryOutcome>
      <secondaryOutcome>The secondary outcomes were:
1. Changes in mean blood pressure
2. Adverse events
3. Blood test results</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by ethics committees of National Cheng Kung University Hospital and Kuo&#146;s General Hospital, Tainan, Taiwan, and adhered to the Declaration of Helsinki.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41671411</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bf4c118e-034c-4044-847e-81dfe98b8c66">
	  <name>138 Shing-Li Road</name>
	  <address/>
	  <city>Tainan</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>70428</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>In the observational study, we collected prospective data for 3 consecutive months (December 2002 to February 2003) from 90 participants recruited from a pool of 217 patients undergoing HD at the outpatient dialysis unit of the Kuo's General Hospital. Inclusion criteria included: 
1. Maintenance HD three times weekly for at least 6 months
2. Over 18 years of age
3. Daily urine output less than 200 ml
4. Stable clinical condition with stable dry weight and hematocrit

The inclusion and exclusion criteria for the intervention study (March to October 2003), were the same as those for the observation study except that: 
5. Only hyperdipsic patients (IDWG % greater than 2%/day) were included
6. Patients using the xerogenic mediations were included if these drugs could be stopped at least 14 days before entering and throughout the interventional study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Haemodynamic instability preventing sufficient ultrafiltration
2. Hospitalisation within the preceding 3 months
3. Dementia or terminal diseases
4. Those not feasible to investigate for logistic reasons
5. Depression or anxiety (which cause xerostomia possibly due to the dysfunction of both brain and salivary glands)
6. Using xerogenic mediations (including anticholinergies, antidepressants, antipsychotics, antihistamines, antiparkinsonian agents, and diuretics)
7. Unwilling to participate in this study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Haemodialysis (HD) patient with large weight gain (&gt;2%/day)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Haemodialysis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>5 mg pilocarpine OPD solution (1% pilocarpine HCl ophthalmic solution, Shionogi &amp; Co., Taipei, Taiwan) was used. The placebo was constructed using normal saline and Mill-Q water with 3:7 mixing. The sodium concentration of the two solutions was identical, with both administered in fixed doses (10 drops four times/day, 30 minutes before each meal and at bed time). Ten drops of pilocarpine is equivalent to 5 mg.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pilocarpine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12962-0</funderId>
      <contactId>Contact50485_12962</contactId>
      <sponsorId>Sponsor48861</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50485_12962">
    <title>Prof</title>
    <forename>Junne-Ming</forename>
    <surname>Sung</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>138 Shing-Li Road</address>
      <city>Tainan</city>
      <country>Taiwan</country>
      <zip>70428</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 6 2353535 ext.2591</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jmsung@mail.ncku.edu.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48861">
    <organisation>National Cheng Kung University (Taiwan)</organisation>
    <website>http://www.ncku.edu.tw/en/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>138 Shing-Li Road</address>
      <city>Tainan</city>
      <country>Taiwan</country>
      <zip>70428</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.64523.36</gridId>
    <rorId>https://ror.org/01b8kcc49</rorId>
  </sponsor>
  <funder id="Funder12962-0">
    <name>Cheng Kung University Hospital Research Committee (Taiwan) - research grants (ref: NCKUH-2003-05 and NCKUH-2004-63)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-04-08T00:00:00.000Z">41221647</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Chiropractic Manipulation in Adolescent Idiopathic Scoliosis: a pilot study</title>
      <scientificTitle/>
      <acronym>MSU-AIS</acronym>
      <studyHypothesis>A large scale, multi-disciplinary, collaborative clinical trial is needed to explore the effectiveness of chiropractic manipulation of patients with Adolescent Idiopathic Scoliosis (AIS). But prior to conducting such a trial, we needed to perform a pilot randomised controlled trial to explore issues of safety, patient recruitment and compliance, treatment standardisation, sham treatment refinement, inter-professional cooperation, quality assurance, outcome measure selection and statistical analysis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was Cobb, and the psychosocial measure was Scoliosis Quality of Life Index.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Institutional Review Board of Borgess Medical Center, Kalamazoo approved the study protocol.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41221647</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d48a198f-d7e7-4319-93b7-398b8508011d">
	  <name>1000 Oakland Drive</name>
	  <address/>
	  <city>Kalamazoo</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>49008</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 10 - 16 years
2. Diagnosis of Adolescent Idiopathic Scoliosis
3. Spinal curvature on Posterior/Anterior (P/A) radiographs of between 20 and 30 degrees measured by the Cobb method in non-braced individuals and 30 to 40 degrees in braced individuals
4. Palpatory evidence of subluxation (manipulative lesion) on chiropractic screening examination
5. No contraindications to spinal manipulative therapy
6. Signed informed consent by parent/guardian
7. Signed child assent form
8. Availability for follow-up evaluation</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="10.0"/>
      <upperAgeLimit unit="Years" value="16.0"/>
      <gender>Both</gender>
      <targetEnrolment>6</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>6</totalTarget>
      <exclusion>1. Age less than 10 or greater than 16 years
2. Diagnosis other than AIS following clinical, radiographic and advanced imaging assessment
3. Contraindications to manipulation
4. Congenital or acquired structural spinal abnormalities
5. Leg length inequality greater than 3/8 inch
6. Pregnancy
7. Pain as a primary clinical feature
8. Mentally incapacitated patient
9. Planning to move/unwilling to return for follow-up
10. Previous back surgery
11. Significant trauma
12. Obesity impairing ability to manipulate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Adolescent Idiopathic Scoliosis (AIS)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Scoliosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were treated for six months by:
1. Standard medical care (observation or brace treatment)
2. Standard medical care plus chiropractic manipulation
3. Standard medical care plus sham manipulation</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16923185 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="889c14a0-70f9-4de2-9d1e-90d3ac956903" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16923185"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12980-0</funderId>
      <funderId>Funder12980-1</funderId>
      <funderId>Funder12980-2</funderId>
      <funderId>Funder12980-3</funderId>
      <contactId>Contact50503_12980</contactId>
      <sponsorId>Sponsor48881</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50503_12980">
    <title>Dr</title>
    <forename>Dale</forename>
    <surname>Rowe</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1000 Oakland Drive</address>
      <city>Kalamazoo</city>
      <country>United States of America</country>
      <zip>49008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48881">
    <organisation>Michigan State University (USA) - Kalamazoo Center for Medical Studies</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1000 Oakland Drive</address>
      <city>Kalamazoo</city>
      <country>United States of America</country>
      <zip>49008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17088.36</gridId>
    <rorId>https://ror.org/05hs6h993</rorId>
  </sponsor>
  <funder id="Funder12980-0">
    <name>Michigan State University (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12980-1">
    <name>Kalamazoo Center for Medical Studies, Kalamazoo, Michigan (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12980-2">
    <name>American Chiropractic Scoliosis Foundation, Fort Collins, Colorado (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12980-3">
    <name>Canadian Memorial Chiropractic College, Toronto (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-03T00:00:00.000Z" version="27">
    <isrctn dateAssigned="2005-04-01T00:00:00.000Z">27140757</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, controlled trial in primary care of a nicotine replacement therapy (NRT) assisted cessation intervention amongst adult smokers with established vascular disease to confirm effectiveness, safety and genetic influences</title>
      <scientificTitle/>
      <acronym>RESCINDING</acronym>
      <studyHypothesis>Not provided at time of registration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27140757</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>TRIAL TERMINATED BEFORE RECRUITMENT started due to lack of funding</reasonAbandoned>
      <overallStartDate>2005-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="19ac8b6b-8d83-4122-b1de-8d1a3a60ecd9">
	  <name>General Practice Research Group</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX2 2BE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All smokers (self-report ≥10 cigarettes per day) aged 18 years and over who wish to stop with (at least) one of the following diagnoses:
1. Ischaemic Heart Disease:
i. Stable Angina, clinically or exercise electrocardiogram (ECG) diagnosed
ii. Myocardial infarction more than 2 months previously with recovery uncomplicated by any rhythm disturbances other than atrial fibrillation
2. Cerebrovascular disease: No exclusions
3. Peripheral vascular disease: No exclusions</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>2400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2400</totalTarget>
      <exclusion>1. Patients the GP, for whatever reason, does not wish to include
2. Known skin hypersensitivity to nicotine, plasters or widespread active eczema/psoriasis or other skin conditions that would restrict patch application
3. Pregnant or breast feeding women or those who are not using reliable contraceptive methods
4. Phaeochromocytoma/Hyperthyroidism and severe renal and/or hepatic impairment
5. Severe (life threatening) arrhythmia
6. Command of English (+/- interpreter) or impairment of faculties does not allow informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Nicotine replacement therapy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Nicotine replacement therapy in the form of patches versus placebo</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12860-0</funderId>
      <contactId>Contact50351_12860</contactId>
      <sponsorId>Sponsor48721</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50351_12860">
    <title>Dr</title>
    <forename>Paul</forename>
    <surname>Aveyard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>General Practice Research Group 
Department of Clinical Pharmacology
Radcliffe Infirmary
Woodstock Road</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX2 2BE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 228484</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.aveyard@clinpharm.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48721">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Offices
Wellington Square</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX1 2JD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 270000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research.services@admin.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder12860-0">
    <name>Medical Research Council (MRC) (Grant number: G0200247)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-03-23T00:00:00.000Z">04517206</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A multicentre, parallel group, randomised, double blind study to investigate the efficacy of fluticasone 100 mcg metered dose inhaler (MDI) twice a day (bd) versus placebo MDI bd both via Babyhaler® spacer in 1 to 5 year old children with asthma or asthma-like symptoms during a 6 month study period</title>
      <scientificTitle/>
      <acronym>ASTERISK</acronym>
      <studyHypothesis>To compare the efficacy of fluticasone propionate (FP) with placebo (PBO) using daily record card symptoms (shortness of breath, cough, wheezing, rescue medication use).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Symptom score (cough, wheeze, shortness of breath during night and day) as measured by a symptom diary card.</primaryOutcome>
      <secondaryOutcome>1. Symptom-free days and nights
2. Use of rescue medication
3. Lung function as measured by the interrupter technique and forced oscillation technique</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04517206</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FLU 9705</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0151e149-93d2-4002-b623-d85257fef5c4">
	  <name>Dept. General Practice</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9713 AV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 1 to 5 years with recurrent respiratory symptoms for which the GP considered prescribing inhaled corticosteroids
2. During the 2-week run-in period, children are eligible if they have symptoms on at least 7 days</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="1.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>96</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>96 children (140 were screened, from whom 96 were randomised)</totalTarget>
      <exclusion>1. Use of oral steroids within 8 weeks prior to the study
2. Use of inhaled steroids within 4 weeks prior to the study
3. Other respiratory disease
4. Inability of parents to fill in diaries
5. Incapable of using the inhaler device in a proper way
6. Participation in other trials</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Recurrent respiratory symptoms in children</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>6 months treatment with
1. Fluticasone propionate 50 mcg 2 puffs MDI bd via Babyhaler®, or
2. Placebo 2 puffs MDI bd via Babyhaler® and salbutamol 200 mcg MDI via Babyhaler® as rescue medication</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluticasone, salbutamol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12878-0</funderId>
      <funderId>Funder12878-1</funderId>
      <contactId>Contact50384_12878</contactId>
      <sponsorId>Sponsor48753</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50384_12878">
    <title>Prof</title>
    <forename>Thys</forename>
    <surname>van der Molen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. General Practice
University Medical Center Groningen
A. Deusinglaan 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9713 AV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48753">
    <organisation>GlaxoSmithKline (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Huis ter Heideweg 62</address>
      <city>Zeist</city>
      <country>Netherlands</country>
      <zip>3705 LZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491225.9</gridId>
    <rorId>https://ror.org/05atcw115</rorId>
  </sponsor>
  <funder id="Funder12878-0">
    <name>GlaxoSmithKline (The Netherlands) (ref: flu9705)</name>
    <fundRef>http://dx.doi.org/10.13039/100004330</fundRef>
  </funder>
  <funder id="Funder12878-1">
    <name>Stichting Astma Bestrijding (The Netherlands) (ref: 2000/006)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-21T00:00:00.000Z">18873428</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of bimatoprost and latanoprost on ocular hemodynamics in normal tension glaucoma: a randomised trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>It is hypothesised that locally applied prostaglandins improve ocular haemodynamics in normal tension glaucoma patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Ocular perfusion is assessed by Doppler imaging. Primary endpoints are the peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the short posterior ciliary artery.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints are:
1. The PSV and EDV in:
1.1. The long posterior ciliary artery,
1.2. The central retinal artery, and 
1.3. The ophthalmic artery
2. Resistivity index, pulsatility index and time average velocity (maximum and mean) in all four vessels 
3. Intraocular pressure</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was performed in accordance to institutional, national, and international guidelines and was approved by the local ethics committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18873428</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1723427327/3</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3cb5a302-8fb0-49bc-b310-c93eb73605a5">
	  <name>Martinistr. 52</name>
	  <address/>
	  <city>Hamburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>20246</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Progressive normal tension glaucoma patients. Progression was defined as progressive excavation of the optic disc (funduscopic and controlled by the Heidelberg retina tomography [HRT]) and/or progressive visual field loss in the Humphrey perimeter over the last 6 - 12 months.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Treated open angle glaucoma
2. Intraocular pressure greater than 21
3. Non-compliance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Normal tension glaucoma</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of latanoprost or bimatoprost eye drops.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bimatoprost, latanoprost</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15811188 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8d195645-9313-4d38-b1fd-57a3fa18ce47" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-04-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15811188"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12925-0</funderId>
      <contactId>Contact50443_12925</contactId>
      <sponsorId>Sponsor48818</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50443_12925">
    <title>Dr</title>
    <forename>Oliver</forename>
    <surname>Zeitz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martinistr. 52</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>20246</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48818">
    <organisation>University Medical Center Hamburg-Eppendorf (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Martinistr. 52</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>D-20246</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.13648.38</gridId>
    <rorId>https://ror.org/01zgy1s35</rorId>
  </sponsor>
  <funder id="Funder12925-0">
    <name>University Medical Center Hamburg-Eppendorf (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-08T00:00:00.000Z">54513166</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Glucosamine in osteoarthritis: long-term effectiveness</title>
      <scientificTitle/>
      <acronym>GOAL</acronym>
      <studyHypothesis>Pharmacological treatment for osteoarthritis (OA) can be divided into two groups: symptom-modifying drugs and disease-modifying drugs. Symptom-modifying drugs are currently the prescription of choice for patients with OA, as disease-modifying drugs are not yet available in usual care. However, there has recently been a lot of debate about glucosamine sulphate (GS), a biological agent that is thought to have both symptom-modifying and disease-modifying properties. This assumption has yet to be proved. This blind randomised clinical trial examines the long-term symptom-modifying and disease-modifying effectiveness of GS in patients with hip OA.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measures, which are joint space narrowing (JSN), and change in the pain and function score of the Western Ontario McMaster Universities Osteoarthritis index (WOMAC), are determined at baseline and after two years of follow-up during the final assessment. Intermediate measures at three-month intervals throughout the trial are used to study secondary outcome measures.</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures are changes in WOMAC stiffness score, quality of life, medical consumption, side effects and differences in biomarker CTX-II.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Trial approved by the Medical Ethics Committee at the Erasmus MC - University Medical Centre Rotterdam.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54513166</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, blinded, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5a475361-d50d-4a03-aee5-62b3191eff72">
	  <name>Department of General Practice, room Ff320</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients are eligible for participation when they meet one of the American College of Rheumatology (ACR) criteria for osteoarthritis of the hip.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>222</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>222</totalTarget>
      <exclusion>1. Patients that have already undergone hip replacement surgery
2. Patients on the waiting list for hip replacement surgery
3. Patients that have a Kellgren-Lawrence score of 4
4. Patients with renal or hepatic disease or diabetes mellitus or a disabling co-morbidity</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis (OA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomised to either 1500 mg of oral glucosamine sulphate or a placebo daily for the duration of two years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Glucosamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/15850497 Study protocol
2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18283204 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9304a290-2364-49a5-b443-8853b5f5d57c" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2005-04-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15850497"/>
	<description>Study protocol</description>
	<productionNotes/>
      </output>
      <output id="0324ec09-ebaa-4024-af47-a5818eec5220" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-02-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18283204"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12852-0</funderId>
      <contactId>Contact50340_12852</contactId>
      <sponsorId>Sponsor48711</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50340_12852">
    <title>Dr</title>
    <forename>Sita M.A.</forename>
    <surname>Bierma-Zeinstra</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of General Practice, room Ff320
Erasmus MC
PO Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 408 7633</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.bierma-zeinstra@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48711">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Board of Directors
PO Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 2578</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.festen@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder12852-0">
    <name>Erasmus Medical Centre (The Netherlands) - Breedtestrategie</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-07T00:00:00.000Z">38432711</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind randomised placebo controlled trial to compare two doses of a mineral supplement and a herbomineral combination in alleviating the symptoms of osteoarthritis of the knee</title>
      <scientificTitle/>
      <acronym>HerbomineralOA</acronym>
      <studyHypothesis>It was proposed that a natural mineral supplement, which has been shown to attenuate the degradation of human cartilage caused by the cytokine, interleukin-1 (IL-1), and catabolic pathways like nitric oxide production, would provide relief of the symptoms of osteoarthritis (OA) of the knee. The study examined two doses of this mineral supplement, as well as the combination of the low dose with a botanical extract, cat's claw, which had previously been reported to be effective in treating OA. These three groups were compared to a placebo treated group and treatment was for an 8 week period.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Western Ontario McMaster Arthritis Index (WOMAC) A, B, C and total scores (scores are for pain, stiffness, function).</primaryOutcome>
      <secondaryOutcome>1. Visual Analogue Score (VAS) for pain
2. Consumption of rescue medication (paracetamol)
3. Recovery (physician and patients' assessments)
4. Tolerability
5. Safety variables
6. Vitals (pulse rate, temperature, blood pressure, respiration rate) measured at baseline and weeks 1, 2, 4, 6 and 8
7. Laboratory investigations - complete blood count, serum glutamate pyruvate transaminase (SGPT), serum creatinine, erythrocyte sedimentation rate (ESR) at screening and week 8, adverse event monitoring at week 1, 2 4, 6, 8.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Ethics Committee of K.J. Somaiya Medical College &amp; Hospital, Mumbai (India) and was in compliance with the Helsinki Declaration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38432711</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>3062/RF</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11ef9433-d674-486b-92f5-55fcd67a92d2">
	  <name>118, Morya House</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>4000 053</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ambulatory adults of either sex of greater than 20 years of age
2. OA of the knee diagnosed as per radiologic examination and the American Rheumatology Association (ARA) functional classification (II or III) or Kellgren-Lawrence Classification of grade II or grade III
3. Functional assessments of overall pain of at least 50 mm on a 100 mm Visual Analogue Scale</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>107</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>107</totalTarget>
      <exclusion>1. Osteoarthritis of grade I or grade IV
2. ARA functional class I or IV
3. Any arthritis other than OA
4. Arthroscopy of either knee for the past year
5. Intraarticular steroids for the last 3 months or hyaluronic acid in the last 9 months
6. Pregnant or lactating women
7. Evidence of severe renal, haematologic disease or severe cardiac insufficiency as revealed by laboratory investigations and other tests
8. Unwilling to come to regular follow up visits for the duration of the study
9. Moderate to severe peripheral neuropathy
10. Any condition that the investigator feels does not allow participation in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA) of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis (OA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group A: Mineral supplement SierraSil (high dose 750 mg/capsule, 4 capsules a day)
Group B: Mineral supplement SierraSil (low dose 500 mg/capsule, 4 capsules a day)
Group C: Herbomineral supplement (low dose SierraSil 500 mg, 4 times a day, plus cat's claw extract, vincaria, 25 mg/capsule, 4 times a day)
Group D: Placebo (750 mg/capsule, 4 times a day)
Rescue Medication: Paracetamol</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mineral supplement (SierraSil), herbomineral supplement (SierraSil, cat's claw extract and vincaria)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16242032 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3aacdf77-b787-4c58-9b53-e5381fb05b86" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-10-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16242032"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12901-0</funderId>
      <contactId>Contact50411_12901</contactId>
      <sponsorId>Sponsor48780</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50411_12901">
    <title>Mr</title>
    <forename>Jayesh</forename>
    <surname>Chaudhary</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>118, Morya House
Off Link Road
Anheri-west</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>4000 053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)22 267 33092</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vedic@ayuherbal.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48780">
    <organisation>Vedic Lifesciences (India)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>118, Morya House
Off Link Road
Andheri-west</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>4000 053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)22 267 33092</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vedic@ayuherbal.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.497496.1</gridId>
    <rorId>https://ror.org/00xd7fg81</rorId>
  </sponsor>
  <funder id="Funder12901-0">
    <name>Sierra Mountain Minerals, Inc. (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-02T00:00:00.000Z">97552320</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of timing of cord clamping on postnatal packed red blood cells value and clinical outcome in term newborns: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine the effect of timing of umbilical cord clamping on neonatal venous haematocrit, clinical outcome and maternal postpartum haemorrhage.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Venous haematocrit six hours after birth.</primaryOutcome>
      <secondaryOutcome>1. Neonatal haematocrit at 24 - 48 hours of age
2. Plasma bilirubin level at 24 - 48 hours of age
3. Early neonatal morbidity (tachypnea, respiratory grunting, respiratory distress, jaundice, seizures, sepsis, necrotising enterocolitis, neonatal death)
4. Admission to Neonatal Intensive Care Unit
5. Length of newborn hospital stay
6. Any neonatal disease that occurs between birth and one month of age
7. Weight and type of feeding at one month of age
8. Postpartum maternal blood loss volume 
9. Maternal haematocrit level at 24 hours postpartum</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The trial was approved by the ethics committees of both hospitals (Hospital Italiano de Buenos Aires protocol number: 681/2002).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97552320</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-11-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-04-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Argentina</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e3033eac-b57f-49a3-a76a-7ea1023aa308">
	  <name>Pueyrredón 985</name>
	  <address/>
	  <city>Rosario</city>
	  <state/>
	  <country>Argentina</country>
	  <zip>2000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women were eligible if they had uneventful cephalic vaginal or cesarean section delivery with the following characteristics: 
1. Singleton pregnancy at term
2. No evidence of clinical disease (diabetes, preeclampsia, hypertension) or any other complications
3. No evidence of congenital malformations or intrauterine growth restriction (estimated foetal weight less than 10th percentile)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>276</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>276</totalTarget>
      <exclusion>Does not comply with above inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-11-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-04-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Timing of cord clamping on newborns at term</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Timing of cord clamping</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Early cord clamping within the first 15 seconds of life
2. Cord clamping at first minute of life
3. Cord clamping at third minute of life</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16567393 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d7fcbdff-4dc7-476a-b90e-98c0783b2bac" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16567393"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12899-0</funderId>
      <contactId>Contact50407_12899</contactId>
      <sponsorId>Sponsor48776</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50407_12899">
    <title>Dr</title>
    <forename>Guillermo</forename>
    <surname>Carroli</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Pueyrredón 985</address>
      <city>Rosario</city>
      <country>Argentina</country>
      <zip>2000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+54 (0)341 447 2625</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gcarroli@crep.com.ar</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48776">
    <organisation>United Nations Children's Fund (UNICEF) (Argentina) </organisation>
    <website>http://www.unicef.org/argentina/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Junin 1940</address>
      <city>Buenos  Aires</city>
      <country>Argentina</country>
      <zip>C 1113AAX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+54 (0)11 5093 7100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mthourte@unicef.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420318.c</gridId>
    <rorId>https://ror.org/02dg0pv02</rorId>
  </sponsor>
  <funder id="Funder12899-0">
    <name>United Nations Children's Fund (UNICEF) (Argentina)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-02-23T00:00:00.000Z">30487061</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of combination versus single antipyretic treatment in febrile children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Our study hypothesis is that combined antipyretic therapy (a single dose of 10 mg/kg ibuprofen followed by a single dose of 15 mg/kg of acetaminophen after 4 hours) is more effective than ibuprofen (10 mg/kg) followed by placebo, in reducing the temperature of children with high fever.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint of this study is the proportion of children in each group, with body temperature of 37.8°C or less at time 6 hours.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints include the proportion of children in each group, with body temperarures of 37.8°C and below, at times 7 and 8 hours, and the change in hourly temperature from baseline, at times 4, 5, 6, 7, 8 hours.
 The proportion of patients in each group with any immediate adverse effect (within 24 hours from administration) that may be related to either drug, such as gastrointestinal bleed, hypothermia or others.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN30487061</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-11-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lebanon</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e93e3694-8f88-4dbd-a43d-ac5843956771">
	  <name>American University of Beirut Medical Center</name>
	  <address/>
	  <city>Beirut</city>
	  <state/>
	  <country>Lebanon</country>
	  <zip>113-6044/C8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 6 months and 14 years
2. Rectal temperature greater than or equal to 38.8°C
3. Consent of treating physician
4. Consent of parent(s) and child if old enough to give consent (greater than 7 years)
5. No antipyretic intake for 8 hours prior to enrolment</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="14.0"/>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Presence of concurrent hepatic or renal disease
2. Chronic and/or serious disease such as malignancy, septic shock, malabsorption syndromes etc.
3. Any condition that may interfere with the absorption of the investigational drugs such as gastritis, diarrhoea, ileus etc.
4. Hypersensitivity to acetaminophen or ibuprofen
5. Bleeding disorder or tendency
6. Asthma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-11-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fever</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Fever</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Experimental group: A single dose (10 mg/kg) of Ibuprofen at zero time, followed by a single dose (15 mg/kg) of Acetaminophen at time = 4 hours
2. Control group: A single dose (10 mg/kg) of Ibuprofen at time zero, followed by a single dose (15 mg/kg) of Placebo at time = 4 hours
3. Rectal temperature recordings at baseline and at time = 4, 5, 6, 7 and 8 hours</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16515705 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a6fdc44a-2e43-4b76-8faa-62a17d5ac82f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-03-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16515705"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12898-0</funderId>
      <contactId>Contact50406_12898</contactId>
      <sponsorId>Sponsor48775</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50406_12898">
    <title>Dr</title>
    <forename>Mona</forename>
    <surname>Nabulsi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>American University of Beirut Medical Center</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>113-6044/C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)3 628528</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mn04@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48775">
    <organisation>American University of Beirut (Lebanon)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Faculty of Medicine, Medical Practice Plan
Riyad El-Solh</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>11-02-36</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)1 350000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">resdean@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.22903.3a</gridId>
    <rorId>https://ror.org/04pznsd21</rorId>
  </sponsor>
  <funder id="Funder12898-0">
    <name>American University of Beirut (Lebanon) - Medical Practice Plan of the Faculty of Medicine (ref: DCR 114170-034120)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-02-15T00:00:00.000Z">48076318</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to evaluate the effectiveness of a pharmacist's telephone reminders in reducing mortality in patients receiving polypharmacy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To investigate the effects of compliance and periodic telephone counselling by a pharmacist on mortality in patients receiving polypharmacy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time from randomisation to death from any cause.</primaryOutcome>
      <secondaryOutcome>1. Changes in the rate of admission to hospital
2. Number of emergency room visits
3. Hospital stay in the two years before and after the screening visit
4. Changes in compliance</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 22/10/2007: 
Ethics approval received from the Chinese University of Hong Kong clinical research ethics committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48076318</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HSRC/HCPF226103</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0c4a876c-a93f-4ae5-91f5-3b23b03a23f5">
	  <name>Dept of Medicine and Therapeutics</name>
	  <address/>
	  <city>-</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients receiving polypharmacy defined as five or more chronic medications who were found to be non-compliant upon first assessment by pharmacist</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>502</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Added as of 22/10/2007: 502 recruited</totalTarget>
      <exclusion>1. Speak non-Cantonese dialects or a different language 
2. Conditions that prevented effective communication (for example, patients who are deaf, mute, or have dementia or other psychological disorders)
3. Live in nursing homes with supervised treatment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Compliance to polypharmacy</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Compliance to polypharmacy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomised to the intervention group received a 10 - 15 minute telephone call from the pharmacist for education and counselling between clinic visits for 2 years. Patients in the control group did not receive any telephone reminders.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16916809 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2108e074-2afc-465a-9d04-df6bb071d317" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16916809"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12766-0</funderId>
      <contactId>Contact50223_12766</contactId>
      <sponsorId>Sponsor48591</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50223_12766">
    <title>Prof</title>
    <forename>Juliana CN</forename>
    <surname>Chan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Medicine and Therapeutics
Chinese University of Hong Kong
The Prince of Wales Hospital
Shatin</address>
      <city>-</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+852 (0)2632 3138</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jchan@cuhk.edu.hk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48591">
    <organisation>Hong Kong Health Services Research Fund (Hong Kong)</organisation>
    <website>http://www.fhb.gov.hk/index.html</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Health Welfare and Food Bureau
Government Secretariat, HKSAR
20th floor Murray Building
Garden Road</address>
      <city>-</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+852 (0)2973 8288</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hsrf@hwfb.gov.hk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453538.c</gridId>
    <rorId>https://ror.org/03qh32912</rorId>
  </sponsor>
  <funder id="Funder12766-0">
    <name>Hong Kong SAR Government Health Services Research Committee (Hong Kong)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-02-09T00:00:00.000Z">26222607</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of hydroxyethyl starch (HES) 130/0.4 versus glucose solution in haemodilution therapy of idiopathic sudden hearing loss: a dose-finding, double-blind multicentre trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Objective: Obtain first data on HES 130/0.4 (hydroxyethyl starch) as monotherapy in patients with acute idiopathic sudden sensorineural hearing loss (ISSNHL).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Absolute hearing gain (AHG) in decibel at Day 7, calculated as mean audiometric hearing threshold (MAHT) at baseline minus MAHT at Day 7, whereby MAHT was the arithmetic mean of the hearing thresholds in dB at the main speech frequencies of 0.5, 1, 2, 3, and 4 kilohertz</primaryOutcome>
      <secondaryOutcome>Efficacy:
1. AHG at other timepoints (i.e. Days 3, 14, and 90)
2. AHG based on geometric MAHT
3. Hearing gain based on the Schwab/Ewert formula i.e. the arithmetic mean of the delogarithmed pure tone thresholds
4. AHG based on arithmetic and geometric MAHT calculated only on speech frequencies with an initial hearing loss of 20 dB or more
5. Outcome categorised in complete/partial/no recovery or deterioration
6. Changes of subjective hearing, vertigo, and tinnitus

Safety:
1. Adverse events
2. Laboratory parameters (haematology, haemostasis, clinical chemistry, urinalysis)
3. Vital signs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26222607</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HS-13-26-EU</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7847e82b-5c31-46b1-84c9-d3aa04e7456a">
	  <name>HNO-Klinik Krankenhaus Dresden-Friedrichstadt</name>
	  <address/>
	  <city>Dresden</city>
	  <state/>
	  <country>Germany</country>
	  <zip>01067</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>210 inpatients with first-time idiopathic sudden sensorineural hearing loss (ISSNHL) of 20 dB or more at two or more frequencies and 95 dB or less at all of the speech frequencies (0.5, 1.0, 2.0, 3.0, 4.0 kHz) with respect to the other (normal) ear for up to 7 days.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>210</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>210</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sudden hearing loss</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Sudden hearing loss</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Infusion of 750 ml per day with HES 45 g per day (group H), 30 g per day (M), 15 g per day (L), or glucose 5% (G) acting as 'placebo' control over 6 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydroxyethyl starch</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12880-0</funderId>
      <contactId>Contact50386_12880</contactId>
      <sponsorId>Sponsor48755</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50386_12880">
    <title>Prof</title>
    <forename>Eckart</forename>
    <surname>Klemm</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>HNO-Klinik Krankenhaus Dresden-Friedrichstadt
Friedrichstr. 41</address>
      <city>Dresden</city>
      <country>Germany</country>
      <zip>01067</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)351 480 1220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Raehder-Co@khdf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48755">
    <organisation>Fresenius Kabi Deutschland GmbH (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Else Kröner Str. 1</address>
      <city>Bad Homburg v.d.H</city>
      <country>Germany</country>
      <zip>61352</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)6172 686 7324</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Daniela.Baus@fresenius-kabi.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.462236.7</gridId>
    <rorId>https://ror.org/01v376g59</rorId>
  </sponsor>
  <funder id="Funder12880-0">
    <name>Fresenius Kabi Deutschland GmbH (Germany) (ref: HS-13-26-EU)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-02-09T00:00:00.000Z">45687883</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective multicentre double blind placebo controlled trial to evaluate the effectiveness of patent foramen ovale (PFO) closure with the STARFlex® septal repair implant to resolve refractory migraine headache</title>
      <scientificTitle/>
      <acronym>MIST - Migraine Intervention with STARFlex® Technology</acronym>
      <studyHypothesis>To investigate the effect of PFO closure with the STARFlex® Septal Repair Implant System in a selected refractory migraine with aura population on the resolution of migraine attacks.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of migraine headache during the 90 days analysis period following the healing phase.</primaryOutcome>
      <secondaryOutcome>1. Incidence of migraine during the healing phase (the first 90 days post procedure)
2. Change in the severity of migraine attacks, based on MIDAS (Migraine Disability Assessment) and HIT-6 (Headache Impact Test) scores
3. Change in the frequency of migraine attacks other than elimination of attacks
4. Change in characteristics of migraine (with or without aura and change thereon)
5. Change in severity, frequency and character of migraine relative to effective closure rate or presence of residual leak
6. Change in quality of life based on SF36-v2 QOL survey

The secondary endpoints of safety are:
 7. Device success, defined as successful delivery of one or more STARFlex® device(s) to the site during the index procedure without a procedural complication, deployment of the device at the intended site, and removal of the delivery system
8. Procedural success, defined as device success without the occurrence of procedural complications prior to discharge, including device embolisation, cerebral or pulmonary embolism, cardiac perforation, and infective endocarditis

The secondary endpoints of failure are: 
9. Incidence of major adverse events from the STARFlex® Septal Repair Implant
10. Incidence of major vascular access complications related to the index procedure, including access site haematoma &gt;5 cm, false aneurysm, AV fistula, retroperitoneal bleed, peripheral ischaemia/nerve injury, procedure related transfusion, and the need for vascular surgical repair or ultrasound compression
11. Incidence of adverse drug reactions to medications used in the index procedure
12. Incidence of adverse drug reactions to procedure specific medications required during the follow phase
13. Major bleeding, defined as the occurrence of intracranial, intraocular, or retroperitoneal hemorrhage or any hemorrhage requiring a blood transfusion during the index hospitalisation, or during the follow-up time period
14. Death (due to any cause) during the first 30 days following treatment
15. Death caused directly by a malfunction of the implant after the first 30 days
16. Incidence of other major adverse events


The tertiary endpoints of efficacy are: 
17. Relationship between PFO and associated atrial septal aneurysm and frequency of migraine
18. Relationship between patient sex and change in migraine frequency, or severity
19. Effective closure rate, defined as procedural success with either grade 0 (none) or 1 (trace) residual shunt as measured by TTE at 180&#150;210 days post-procedure</secondaryOutcome>
      <trialWebsite>http://www.migraine-mist.org/index.asp</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>MREC approved 04/11/2004</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45687883</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MIST01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective, multicentre, double blind, placebo controlled parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="63f2fd68-39e0-465a-be24-16bf8dc19809">
	  <name>King's Healthcare</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE5 9RS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with refractory migraine

Inclusion criteria:
1. The patient is greater than or equal to 18 years of age and less than or equal to 60 years of age
2. Patients must meet the definition of 'with aura'
3. Patients with a history of migraine onset prior to age 50
4. Patients must meet the definition of refractory migraine
5. Patients must have a positive contrast valsalva bubble trial by TTE, demonstrating grade 2 or 3 right to left shunting. An atrial septal aneurysm may or may not be identified.
6. Patients must be available for follow-up in accordance with the protocol 
7. The patient is able to provide a signed informed consent form signed at three stages to participate.  Informed consent from guardians is not acceptable. 
8. Patients critical cardiac structures are not expected to come in contact with the device (e.g. AV valves and pulmonary veins). It is recommended that the device be approximately 1 mm from these structures. 
9. Patients must agree not to get pregnant during the trial


Post-randomisation - Device Patients Only:
10. The vascular access from the femoral vein is expected to accommodate the 11F delivery system
 11. The size of the PFO (measured by indentation with a soft balloon) must demonstrate the defect to be amenable to selection of a STARFlex® Septal Repair Implant as described in the Instructions for Use</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150 - first patient was enrolled 24/11/04, last patient 31/05/05</totalTarget>
      <exclusion>1. Patients are less than 18, or greater than 60, years of age
2. Failure to meet the definition of migraine 'with aura'
3. Failure to meet the definition of refractory migraine
4. A contrast valsalva bubble study demonstrates no or trivial shunting from right to left through a PFO
5. Any cardiovascular condition, including those requiring chronic medications that would interfere with the conduct or assessment of outcome of the trial, or that would increase patient risk relative to undergoing the procedure or with the ability to deliver and deploy the STARFlex® Septal Repair System
6. Inability of the patient to personally give and sign the informed consent
7. A large, redundant atrial septal aneurysm which cannot, in the judgment of the investigator, be covered by the STARFlex® Septal Repair System without (1) causing the device to interfere with other intracardiac structures, or (2) prohibiting the ability of the operator to adequately deploy the distal/proximal arms in the left/right atrium prior to final placement on the septum. 
8. Patients with an elongated waist (long tunnel), any other reason requiring Transseptal puncture for device placement
9. Other cardiac defects, whether or not repaired, including:  Atrial septal defect; Ventricular septal defect; Coarctation of the aorta; Patent ductus arteriosus; or Mitral or aortic stenosis. 
10. Thrombus in or occlusion of the venous lumen between the femoral vein access site (or superior access site, if used) and the right atrium
11. A previously implanted atrial septal device
12. Echocardiography evidence of an intra-atrial or ventricular thrombus
13. History of drug abuse
14. Known active endocarditis or documented bacteraemia
15. Elevated serum creatinine such that the use of contrast dye during the implant procedure would expose the patient to unnecessary risks of additional renal dysfunction
16. Active infections requiring current antibiotic therapy (if temporary illness, patients may enroll after discontinuation of antibiotics, once asymptomatic for 4 weeks)
17. Patients who are pregnant, nursing, or planning pregnancy over the duration of the patient&#146;s participation in the study
18. A known sensitivity to medications used in general anaesthesia
19. A known contraindication to aspirin or clopidogrel
20. Sensitivity to contrast media, which cannot be adequately pre-medicated
21. A platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, or a WBC of &lt;3,000 cells/mm3, or a known disorder of platelet function 

22. Any patient with a known coagulopathy for which they are currently being treated medically with anticoagulants
23. Patients with any neurological disorder or disease that would interfere with proper assessment and or conduct of the trial

24. Patients unable to perform a satisfactory valsalva manoeuvre 
25. Patients in whom transoesophageal echocardiography is contraindicated
26. Active peptic ulcer or upper gastrointestinal bleeding within the prior 6 months
27. Concurrent medical condition with a life expectancy of less than 12 months
28. Currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints.  [NOTE: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.]
29. The presence of a permanent pacemaker
30. The presence of an inferior vena cava filter 
31. Haemodynamic conditions generally contraindicating closure of a PFO or any other right to left decompressive shunt.  (i.e., normal RV function and PVR &gt;10 indexed Wood units if RV pressure &lt;1/2 systemic pressure or, PVR &gt;8 indexed Wood units if RV pressure &gt;1/2 systemic pressure)
32. If echocardiography suggests moderate or greater tricuspid regurgitation
33. Suspected/recognised cirrhosis or portal hypertension or known pulmonary arterio-venous malformations
34. Any PFO that requires closure for reasons unrelated to the migraine history (e.g., orthodeoxia, stroke, TIA, decompression illness)
35. Patients known to be headache medication over users 
36. Patients diagnosed with chronic daily headache
37. Patients with a documented medical history of oesophageal stricture, diverticulae, symptomatic hiatus hernia, oesophagitis or oesophageal varices
38. If in the investigator&#146;s opinion, the patient is unsuitable to be entered in the trial for any other reason</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>PFO/Migraine</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Double blinded study randomising migraine patients with PFOs to either PFO closure with the STARFlex® implant or a control arm who received a sham procedure, assessments of PFO were made using trans oesophageal echo and trans thoracic echo.  Baseline headache data has been obtained for both groups and has been followed up with 6 months of post-procedure headache diary data and physicians' assessments of migraine profile for both implant and placebo groups.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18316488 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9729252c-3969-4e18-aada-c2c8d8d0dba5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18316488"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12801-0</funderId>
      <contactId>Contact50270_12801</contactId>
      <sponsorId>Sponsor48641</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50270_12801">
    <title>Dr</title>
    <forename>Andy</forename>
    <surname>Dowson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>King's Healthcare
Neuroscience Centre
King's College Hospital
Demmark Hill</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE5 9RS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48641">
    <organisation>NMT Medical Inc. (USA) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>27 Wormwood St</address>
      <city>Boston</city>
      <country>United States of America</country>
      <zip>MA 02210</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12801-0">
    <name>NMT Medical Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-02-01T00:00:00.000Z">23032971</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomised controlled study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of this study was to examine the efficacy of the antihistamine desloratadine at different time points during the day and to evaluate whether the time of dosing of desloratadine has any impact on the treatment efficacy in seasonal allergic rhinitis (SAR).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The mean change from baseline for the AM last hour total symptom score (TSS) over the 2 weeks treatment period.</primaryOutcome>
      <secondaryOutcome>1. Interference with sleep and interference with daily activity 
2. The number of hours spent outdoors</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol and the patient informed consent form were approved by Ethics Committees and Health Authorities in each of the participating countries.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23032971</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P02278</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-02T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Denmark</country>
	<country>Finland</country>
	<country>Iceland</country>
	<country>Norway</country>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d4f6369-6c76-4028-8678-98c6efdfe9f8">
	  <name>Dept. of Otolaryngology</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>0027</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients 18 years or above with a minimum of two years history of SAR confirmed by either a positive skin prick test or a positive serologic allergen test to the relevant seasonal allergen
2. Clinically symptomatic with SAR at baseline/inclusion with a minimum total nasal symptom score (rhinorrhoea, congestion, itching and sneezing) of at least 6 and rhinorrhoea being minimum 2 (moderate)
3. Willingness to adhere to dosing and visit schedule
4. Females of childbearing potential have to use medically accepted methods of birth control 
5. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>663</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>663</totalTarget>
      <exclusion>1. Pulmonary disease, perennial rhinitis, sinusitis, rhinitis medicamentosa, pollen desensitisation during the last 6 months
2. Respiratory tract infection within the last two weeks
3. Structural nasal abnormalities (including polyps)
4. Use of oral, nasal, ocular decongestants, corticosteroids in any form (except mild dermatological group I corticosteroids allowed in only small areas), other antihistamines (oral or topical), any investigational drug during the last 30 days
5. Pregnant or nursing females</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-02T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal allergic rhinitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Allergic rhinitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised into one of two treatment groups with dosing of 5 mg desloratadine tablets either in the morning between 07 - 09 (AM-group) or evening between 19 - 21 (PM-group) in a 1:1 ratio.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Desloratadine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15686600 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="52c055c7-bc9d-4d18-b649-08422ff26b61" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-02-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15686600"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12873-0</funderId>
      <contactId>Contact50374_12873</contactId>
      <sponsorId>Sponsor48743</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50374_12873">
    <title>Prof</title>
    <forename>Rolf</forename>
    <surname>Haye</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. of Otolaryngology
Rikshospitalet</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0027</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48743">
    <organisation>Schering-Plough AS (Norway)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Ankerv. 209</address>
      <city>Eiksmarka</city>
      <country>Norway</country>
      <zip>1359</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.488502.3</gridId>
    <rorId>https://ror.org/0118bra88</rorId>
  </sponsor>
  <funder id="Funder12873-0">
    <name>Schering-Plough in the Nordic countries</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-01-25T00:00:00.000Z">64733264</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase III study of neoadjuvant bicalutamide in patients with intermediate risk prostate cancer undergoing radiation therapy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64733264</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>99-07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7f2adff-1a6b-4e5e-b953-2235e6a7b1db">
	  <name>610 University Avenue</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 2M9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. T1/T2a prostate cancer with:
1.1. Gleason 7, prostate specific antigen (PSA) less than 20 ng/ml
1.2. Gleason less than 7, PSA 10 - 20 ng/ml
2. T2b prostate cancer with:
2.1. PSA less than 20 ng/ml
2.2. Gleason less than or equal to 7</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Localised prostate cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Bicalutamide 150 mg daily for 3 months before and 2 months during radiation therapy versus no hormonal therapy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bicalutamide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12782-0</funderId>
      <funderId>Funder12782-1</funderId>
      <contactId>Contact50246_12782</contactId>
      <sponsorId>Sponsor48617</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50246_12782">
    <title>Dr</title>
    <forename>Padraig</forename>
    <surname>Warde</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>610 University Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2M9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 946 2122</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">padraig.warde@rmp.uhn.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48617">
    <organisation>Princess Margaret Hospital (Canada) - Department of Radiation Oncology </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>610 University Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2M9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.415224.4</gridId>
    <rorId>https://ror.org/03zayce58</rorId>
  </sponsor>
  <funder id="Funder12782-0">
    <name>Princess Margaret Hospital (Canada) - internal genitourinary (GU) group funds</name>
    <fundRef/>
  </funder>
  <funder id="Funder12782-1">
    <name>AstraZeneca (Canada) - small unrestricted grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-12-08T00:00:00.000Z">32740751</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical trial on enzymatic agent Salizolis</title>
      <scientificTitle/>
      <acronym>SALIZOLIS</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32740751</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lithuania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="652f90c8-eabc-468e-b9da-f57953e0ef30">
	  <name>Kaunas Medical University Hospital</name>
	  <address/>
	  <city>Kaunas</city>
	  <state/>
	  <country>Lithuania</country>
	  <zip>50009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with acute and chronic wounds containing necrotic tissue (thermal and chemical burns, frostbites, trophic ulcers, injuries of truncal and limb, injuries of wrist and hand, injuries of tarsus and foot, varicosis of lower limbs with ulcers and inflammation, foot ulcers, pressure sores, infections on dermal and hypodermal tissue and other purulent inflammations).

Inclusion criteria:
1. Older than 18 years</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Children under the age of 18
2. Pregnant women
3. Soldiers of active service
4. Incurable patients
5. Patients with mental disorder
6. Patients dependent on drugs and alcohol
7. Subjects incapable of giving consent
8. Subjects disagree with participation in clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Wounds</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Acute and chronic wounds</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The randomised and controlled, single blind and parallel group study will be carried out on two groups. Each group consists of 15 patients.
Patients of group A are being treated according to the current standards of therapy. The wounds will be self-purged out of necrotic tissues.
Patients of group B are being treated according to the new regimen under investigation - enzymatic agent Salizolis. Necrotic tissue of the wounds will be purged out by enzymatic agent.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Salizolis</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12795-0</funderId>
      <contactId>Contact50263_12795</contactId>
      <sponsorId>Sponsor48634</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50263_12795">
    <title>Dr</title>
    <forename>Rimdeika</forename>
    <surname>Rytis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kaunas Medical University Hospital
Department of Surgery
Division of Plastic Surgery and Burns
Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+370 37 326083</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rimdeika@kmu.lt</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48634">
    <organisation>JSC Biocentras (Lithuania)</organisation>
    <website>http://www.biocentras.lt/about_en.html</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Graiciuno str. 10</address>
      <city>Vilnius</city>
      <country>Lithuania</country>
      <zip>02241</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+370 5 2661313</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">biocentras@biocentras.lt</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.426447.7</gridId>
    <rorId>https://ror.org/005gk6w44</rorId>
  </sponsor>
  <funder id="Funder12795-0">
    <name>Sixth framework programme horizontal research activities involving small and medium sized enterprises (SMEs) co-operative research project - Ultimate Pressure Dressing System for the Management of Venous Ulcers (European Union)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">84553798</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Ketamine on post-operative intraocular inflammation following cataract surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does ketamine reduce post-operative cystoid  macula oedema in patients who undergo cataract surgery?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To define population for definitive randomised prospective trial on effects of ketamine on cystoid macula oedema in patients undergoing cataract surgery</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84553798</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0207129695</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, parallel group, double blind, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a55ba400-97eb-48b2-84ce-0e22836c1d7c">
	  <name>St Pauls Eye Unit</name>
	  <address/>
	  <city>Liverpool</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>L7 8XP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>33</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Pilot study; 3 groups of 11.</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Cataract</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group A receive ketamine under general anaesthetic
Group B receive general anaesthetic without ketamine
Group C receive local anaesthetic without ketamine</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>ketamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17653058 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="319f197d-89d0-48fe-bb35-a14d5828d175" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17653058"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12612-0</funderId>
      <contactId>Contact50132_12612</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50132_12612">
    <title>Mr</title>
    <forename>S B</forename>
    <surname>Kaye</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St Pauls Eye Unit
8Z Link
Royal Liverpool University Hospital
Prescot Street</address>
      <city>Liverpool</city>
      <country>United Kingdom</country>
      <zip>L7 8XP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)151 706 2134</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Stephen.kaye@rlbuht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12612-0">
    <name>Royal Liverpool and Broadgreen University Hospitals Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">45665423</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of a personalised letter on response rates to a postal questionnaire: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does a personalised addressed letter compared with a standard letter increase response rate to a postal questionnaire on service quality sent to people referred to an exercise referral scheme?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The number of completed questionnaires returned after completing all methods of follow-up.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval for the study was received in advance from the local research ethics committee and the research governance committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45665423</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0311114507</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a19060e4-63ad-4a03-b4a2-e8ba17bc50c3">
	  <name>Bolton Primary Care Trust</name>
	  <address/>
	  <city>Bolton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BL1 1PP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>People living in the community of Bolton who had been referred to the exercise referral scheme over a three year period.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>627</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>627</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Exercise referral</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A two-group randomised trial of a personalised letter versus a standard letter.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15537429 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="354b295e-9cb3-4562-92d8-c70d6d07ddf2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-10T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15537429"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12710-0</funderId>
      <contactId>Contact49985_12710</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact49985_12710">
    <title>Dr</title>
    <forename>R A</forename>
    <surname>Harrison</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bolton Primary Care Trust
St Peter's House
Silverwell Street</address>
      <city>Bolton</city>
      <country>United Kingdom</country>
      <zip>BL1 1PP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1204 907728</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Roger.Harrison@bolton.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12710-0">
    <name>Bolton Primary Care Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">69248640</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does prophylactic N acetylcysteine decrease the incidence of contrast nephropathy in patients undergoing endovascular abdominal aortic aneurysm (AAA) repair?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is peri-operative oral N acetylcysteine nephroprotective in patients undergoing endovascular abdominal aortic aneurysm repair?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN69248640</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0544139644</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4683ab13-eb7f-43de-9942-115596f31709">
	  <name>Cambridge Vascular Unit</name>
	  <address/>
	  <city>Cambridge</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB2 2QQ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Abdominal aortic aneurysm (AAA) repair</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Abdominal aortic aneurysm (AAA) repair</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participation offered to all patients undergoing endovascular abdominal aortic aneurysm repair in the Cambridge Vascular Unit, Addenbrooke's Hospital. Consenting patients will be randomised to receive either intra venous saline hydration (current practice) or intravenous saline hydration and oral N acetyl-cysteine (600 mg twice a day (bd) orally (PO) on the day before the procedure; and 600 mg bd PO on the day of the procedure, one dose before, and one dose after the procedure).  Evidence of renal injury will be monitored post-procedure by assay of serum creatinine levels, and also by measuring urinary low molecular weight proteins such as N acetyl beta glucosaminidase (NAG) a subclinical marker of renal injury, and albumin and creatinine.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17042662 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fd5a6aa1-f301-4583-9ea3-b0b60af0167f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17042662"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12734-0</funderId>
      <contactId>Contact50087_12734</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50087_12734">
    <title>Mr</title>
    <forename>J</forename>
    <surname>Boyle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cambridge Vascular Unit
Dept. of General Surgery
Box 201
Addenbrooke's Hospital</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB2 2QQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1223 217246</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jonathan.boyle@addenbrookes.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12734-0">
    <name>Cambridge Consortium - Addenbrooke's (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">40732847</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of 4% articaine and bupivacaine/lignocaine for sub-tenon anaesthesia in phacoemulsification cataract surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess if articaine 4% is a suitable and SAFE agent for use in sub-tenon anaesthesia of the eye (for cataract surgery).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The aim of the trial is to examine the possibility that the success rate of sub-tenon anaesthesia can be improved by using 4% articaine rather than the presently used combination of lignocaine/bupivacaine. Sub-tenon's anaesthesia has distinct advantages over 'sharp needle' technique, chiefly being globe perforation but currently, acceptance of this technique is hampered by poor success rate. If the success rate of sub-tenons anaesthesia could be enhanced by 4% articaine then it would become a widely used technique. 

Study endpoints: Collating data and to see if 4% articaine is safe and effective compared to existing lignocaine/bupivacaine anaesthetic agent.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40732847</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0203132063</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="00e187b4-232c-4cb3-8bd5-da6a75c3632f">
	  <name>Royal Devon &amp; Exeter Hospital (Wonford)</name>
	  <address/>
	  <city>Exeter</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>EX2 5DW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patient will be selected at random from the waiting list. Letters will be sent out to the patient along with appointment letter. They will be contacted a day prior to surgery and their willingness to participate ascertained on the day of surgery.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>65</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>65</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Previous intra-ocular surgery
3. Pupil diameter less than 5 mm when fully dilated
4. Pregnant females or of child bearing potential
5. Those known to have reduced plasma chlolinesterase levels
6. Patient unwilling to participate in the study
7. A history of allergy to amide-type anaesthetics
8. Subjects of non-therapeutic research</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cataract surgery</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Cataract surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomly allocated to one of two groups using sealed, numbered envelopes and computer randomisation. Group A will receive sub-tenon's anaesthesia using 4% articaine and group B will receive a mixture of equal volume of 0.5% bupivicaine and 2% lignocaine. Ocular movements will be scored for each direction of gaze in the superior, inferior, medial and lateral directions with a maximum score for each direction of 3 points and a possible total maximum of 12 points. Patients will be considered to be ready for surgery when the ocular scores are 5 or less. Table showing scoring system for ocular movements. Full Movement 3/ Moderate Movement 2/ Flicker of movement 1/ No movement 0. In addition formal ocular motility testing will be undertaken at the orthoptics department immediately before and after surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Articaine, bupivacaine/lignocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18211939 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="abea4235-4148-4836-976d-f02b64fc757d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18211939"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12595-0</funderId>
      <contactId>Contact50149_12595</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50149_12595">
    <title>Mr</title>
    <forename>Vasant</forename>
    <surname>Raman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Devon &amp; Exeter Hospital (Wonford)
Barrack Road</address>
      <city>Exeter</city>
      <country>United Kingdom</country>
      <zip>EX2 5DW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1392 406033</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Vasant317@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12595-0">
    <name>Royal Devon and Exeter NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-08-09T00:00:00.000Z">73254583</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Glutamine-Enriched Enteral Feeding in very low birth weight infants</title>
      <scientificTitle/>
      <acronym>GEEF study</acronym>
      <studyHypothesis>Very Low Birth Weight (VLBW) infants may be susceptible to glutamine depletion as nutritional supply of glutamine is limited in the first weeks after birth. Glutamine depletion has negative effects on functional integrity of the gut and leads to immunosuppression. This double-blind randomised controlled trial is designed to investigate the effect of glutamine-enriched enteral nutrition on feeding tolerance, infectious morbidity and short-term outcome in VLBW infants. Furthermore, an attempt is made to elucidate the role of glutamine in postnatal adaptation of the gut and modulation of the immune response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to full enteral feeding, defined as a feeding volume greater than or equal to 120 mL/kg/day.</primaryOutcome>
      <secondaryOutcome>1. Feeding tolerance:
1.1. Age at finishing parenteral nutrition
1.2. Days of no enteral feeding during study period  
1.3. Necrotising enterocolitis 
2. Infectious morbidity:
2.1. Serious infections  
2.2. Number of infectious episodes  
2.3. Cultured micro-organisms 
3. Short-term outcomes:
3.1. Weight z scores at birth, day 30 and at discharge
3.2. Patent ductus arteriosus  
3.3. Ventilatory support  
3.4. Use of oxygen at postmenstrual age of 36 weeks
3.5. Intraventricular hemorrhage
3.6. Retinopathy of prematurity
3.7. Death  
3.8. Age at discharge from NICU and at discharge home 
4. Intestinal permeability, determined during the 30 day study period
5. Faecal flora, determined during the 30 day study period
6. Plasma Th1/Th2 cytokine concentrations, determined during the 30 day study period
7. Plasma amino acid profiles, determined during the 30 day study period</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The National Central Committee on research involving human subjects and the Medical Ethical Review Board of our hospital approved the study protocol.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73254583</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NTR205</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group, double blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-09-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-19T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="39db807d-8bc2-4935-9e3c-7dbc121c1e3a">
	  <name>Vrije University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Infants with a gestational age less than 32 weeks and/or a birth weight less than 1500 g 
2. Admitted to the level III Neonatal Intensive Care Unit (NICU) of the Vrije University Medical Centre (VUMC)
3. Written informed consent obtained from all parents</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>107</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>107</totalTarget>
      <exclusion>1. Major chromosomal or congenital anomalies
2. Death less than 48 hours after birth
3. Transfer to another hospital less than 48 hours after birth 
4. Admission from an extraregional hospital</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-09-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-19T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Very low birth weight infants</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Very low birth weight infants</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Enteral glutamine supplementation in a dose of 0.3 g/kg/day between days three and 30 of life versus isonitrogenous placebo supplementation (alanine).</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Enteral glutamine supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/15341667 Protocol
2005 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/15941893
2005 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/15990633
2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16931609
2007 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17499398
2007 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17984413</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="22ae7c70-dcdc-4fdc-964d-cc2fa6ccdcd3" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15341667"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="0e2d0257-4506-4e8a-ab8b-2f9ba9f80d20" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15941893"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="584b352d-3f8f-4b1d-924b-7c097468d4ee" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15990633"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="be8e6540-b23e-4265-87e0-e233b4229ee2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16931609"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="413a6d3e-2685-47f8-a875-aaf5ff748c35" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17499398"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="f6648dff-c982-45f5-9121-7aecdc2a522d" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17984413"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11283-0</funderId>
      <contactId>Contact41734_11283</contactId>
      <sponsorId>Sponsor39479</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41734_11283">
    <title>Prof</title>
    <forename>Willem</forename>
    <surname>Fetter</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije University Medical Centre
De Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2413</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.fetter@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39479">
    <organisation>Vrije University Medical Centre (VUMC) (The Netherlands) </organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>De Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2413</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.fetter@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder11283-0">
    <name>Nutricia Nederland B.V. (The Netherlands) - provided neonatal glutamine and placebo supplementation</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2004-02-06T00:00:00.000Z">27290841</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and efficacy of the combination of chloroquine and methylene blue in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso</title>
      <scientificTitle/>
      <acronym>BlueCQ2</acronym>
      <studyHypothesis>Safe, effective and affordable drug combinations against falciparum malaria are urgently needed for the poor populations in malaria endemic countries. Methylene blue (MB) combined with chloroquine (CQ) has been considered as one promising new regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of severe haemolysis or other serious adverse events (SAEs).</primaryOutcome>
      <secondaryOutcome>Efficacy outcomes were defined according to the WHO 2003 classification system.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the Ethics Committee of the Medical Faculty of Heidelberg University and the local Ethics Committee in Burkina Faso.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27290841</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="401f8608-7a43-454f-995e-50f1a17410d1">
	  <name>Department of Tropical Hygiene and Public Health</name>
	  <address/>
	  <city>Heidelberg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-69120</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children (6 - 59 months) with uncomplicated falciparum malaria
2. Greater than or equal to 2000 Plasmodium falciparum
3. Burkinabe nationality</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>225</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>225</totalTarget>
      <exclusion>1. Complicated or severe malaria (repeated vomiting, seizures or other neurological impairment)
2. Anaemia (haemoglobin less than 8 g/dl or haematocrit less than 24%) 
3. Any other apparent significant disease (e.g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Uncomplicated falciparum malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Arm A (N = 45): 25 mg/kg oral chloroquine within 3 days
Arm B (N = 180): 25 mg/kg oral chloroquine and 15 mg/kg methylene blue within 3 days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Chloroquine, methylene</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16179085 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="52c68beb-6de0-46a5-b7b9-87cdca080278" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-22T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16179085"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5735-0</funderId>
      <contactId>Contact7168_5735</contactId>
      <sponsorId>Sponsor5331</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7168_5735">
    <title>Dr</title>
    <forename>Olaf</forename>
    <surname>Müller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Tropical Hygiene and Public Health
University of Heidelberg</address>
      <city>Heidelberg</city>
      <country>Germany</country>
      <zip>D-69120</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)6221 56 5035</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Olaf.Mueller@urz.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5331">
    <organisation>DSM Fine Chemicals (Austria)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr. Wolfgang Schiek
St. Peter-Str. 25
PO Box 933</address>
      <city>Linz</city>
      <country>Austria</country>
      <zip>A-4021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0)732 6916 2150</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wolfgang.schiek@dsm.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.451620.4</gridId>
    <rorId>https://ror.org/01j7tpx52</rorId>
  </sponsor>
  <funder id="Funder5735-0">
    <name>DSM Fine Chemicals (Austria) - Dream Award</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">77561786</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A preventative programme for victims of violent crime</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We tested the efficacy of two brief interventions, education and psychological debriefing, designed to prevent adverse psychological reactions to criminal victimisation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>PTSD and depression are the primary outcome measures.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77561786</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NMH2</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1994-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1997-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="39beb544-996e-4bfc-8499-a3e0d57f83a3">
	  <name>Subdepartment of Clinical Health Psychology</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 6BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Individuals who had been the victims of a violent crime within the past month. Subjects were recruited from police and hospital sources and interviewed in their own homes.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>157</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>157</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1994-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1997-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mental and behavioural disorders: Depression, anxiety, neuroses</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>2161 were contacted and 243 replied, of whom 157 were eligible and were randomly assigned either to an education condition, to a psychological debriefing plus education condition, or to an assessment only condition. Education involved providing information about normal post-traumatic reactions. Debriefing involved in-depth probing about events, thoughts and feelings experienced during the crime. 138 participants were followed up at 6 months, and 92 at 11 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1999 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10473306 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4b2acd46-518c-4e56-9f36-073277db2ca3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1999-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/10473306"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5827-0</funderId>
      <contactId>Contact7256_5827</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7256_5827">
    <title>Prof</title>
    <forename>Chris</forename>
    <surname>Brewin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Subdepartment of Clinical Health Psychology
University College London
Gower Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 6BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7679 5927</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.brewin@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5827-0">
    <name>NHS Mental Health National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">85788243</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Chemonucleolysis or manipulation for lumbar disc herniation?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The purpose of this study is to compare the effects of two treatment modalities available for lumbar disc herniation. The principle aim of the project is to ascertain which, if either, treatment is superior in terms of reducing symptoms/disability, and the relative cost effectiveness/patient satisfaction. The treatments to be studied are chemonucleolysis and osteopathic manipulation.  Despite the choice of a well defined low back pathology for this trial, it may be that some 'types' of patient respond better to one or other of the treatments; strenuous attempts will be made to identify any such categories. The benefits to the NHS will be the determination of the more cost-effective treatment for this condition. Should the result favour manipulation, there will be the potential for reduction both of therapeutic costs and of orthopaedic waiting lists.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Symptoms/disability and the relative cost effectiveness/patient satisfaction.
2. Pain (back and leg) and disability</primaryOutcome>
      <secondaryOutcome>Therapeutic failure</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85788243</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ND0020 T367  Burton R&amp;D</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1994-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="81bca07f-48f8-4e47-ad93-5aec54b048e1">
	  <name>Spinal Research Unit</name>
	  <address/>
	  <city>Huddersfield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>HD1 2SP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with lumbar disc herniation</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1994-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lumbar disc herniation</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Spinal conditions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Chemonucleolysis
2. Osteopathic manipulation</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2000 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10905437 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4b9f986a-f8ca-4d4f-8a62-c24a1c0b1c5d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2000-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/10905437"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5875-0</funderId>
      <contactId>Contact7582_5875</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7582_5875">
    <title>Prof</title>
    <forename>Kim</forename>
    <surname>Burton</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Spinal Research Unit
30 Queen Street</address>
      <city>Huddersfield</city>
      <country>United Kingdom</country>
      <zip>HD1 2SP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1484 535200</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kim@spineresearch.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5875-0">
    <name>NHS Executive Northern and Yorkshire (UK)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>